

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
18 December 2003 (18.12.2003)

PCT

(10) International Publication Number
WO 03/104462 A2

(51) International Patent Classification⁷: C12N 15/67,
15/82, 15/54, 15/55, 15/90, 9/10, 9/16, C12Q 1/68, A01H
5/00

(21) International Application Number: PCT/CA03/00822

(22) International Filing Date: 6 June 2003 (06.06.2003)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
60/387,088 6 June 2002 (06.06.2002) US

(71) Applicant (for all designated States except US): **HER
MAJESTY THE QUEEN IN RIGHT OF CANADA** as
represented by **THE MINISTER OF AGRICULTURE
AND AGRI-FOOD** [CA/CA]; Saskatoon Research Cen-
tre, 107 Science Place, Saskatoon, Saskatchewan S7N 0X2
(CA).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **HANNOUFA,**

Abdelali [CA/CA]; 350 Costigan Crescent, Saskatoon,
Saskatchewan S7J 4M7 (CA). **LYDIATE, Derek, J.**
[GB/CA]; 101 Albert Avenue, Saskatoon, Saskatchewan
S7N 1E6 (CA). **GAO, Ming-Jun** [CA/CA]; 1802
Grosvenor Avenue, Saskatoon, Saskatchewan S7H 2T4
(CA).


(74) Agents: **SECHLEY, Konrad** et al.; Gowling Lafleur Hen-
derson LLP, 160 Elgin Street, Suite 2600, Ottawa, Ontario
K1P 1C3 (CA).

(81) Designated States (national): AE, AG, AL, AM, AT, AU,
AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU,
CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,
GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,
LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW,
MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD,
SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US,
UZ, VC, VN, YU, ZA, ZM, ZW.


(84) Designated States (regional): ARIPO patent (GH, GM,
KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW),

[Continued on next page]


(54) Title: REGULATION OF GENE EXPRESSION USING CHROMATIN REMODELLING FACTORS



A



B



C

(57) Abstract: The invention provides a method to regulate expression of a gene of interest in a plant comprising, introducing into the plant a first nucleotide sequence comprising, the gene of interest operatively linked to a first regulatory region, and an operator sequence capable of binding a fusion protein, and a second nucleotide sequence comprising a second regulatory region in operative association with a nucleotide sequence encoding the fusion protein. The fusion protein comprising, a DNA binding protein, or a portion thereof, capable of binding the operator sequence, and a recruitment factor protein, or a portion thereof, capable of binding a chromatin remodelling protein. In this manner, expression of the second nucleotide sequence produces the fusion protein that regulates expression of the gene of interest.

BEST AVAILABLE COPY

BEST AVAILABLE COPY

WO 03/104462 A2



Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM),
European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE,
ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO,
SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM,
GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

Published:

— *without international search report and to be republished upon receipt of that report*

REGULATION OF GENE EXPRESSION USING CHROMATIN REMODELLING FACTORS

The present invention relates to the regulation of gene expression. More
5 particularly, the present invention relates to the control of gene expression of one or
more nucleotide sequences of interest in transgenic plants using chromatin
remodelling factors.

10 BACKGROUND OF THE INVENTION

Transgenic plants have been an integral component of advances made in
agricultural biotechnology. They are necessary tools for the production of plants
exhibiting desirable traits (e.g. herbicide and insect resistance, drought and cold
15 tolerance), or producing products of nutritional or pharmaceutical importance. As the
applications of transgenic plants become ever more sophisticated, it is becoming
increasingly necessary to develop strategies to fine-tune the expression of introduced
genes. The ability to tightly regulate the expression of transgenes is important to
address many safety, regulatory and practical issues. To this end, it is necessary to
20 develop tools and strategies to regulate the expression of transgenes in a predictable
manner.

Several strategies have so far been employed to control plant gene/transgene
expression. These include the use of regulated promoters, such as inducible or
25 developmental promoters, whereby the expression of genes of interest is driven by
promoters responsive to various regulatory factors (Gatz, 1997). Other strategies
involve co-suppression (Eisner et al., 1998) or anti-sense technology (Kohno-Murase
et al., 1994), whereby plants are transformed with genes, or fragments thereof, that are
homologous to genes either in the sense or antisense orientations. Chimeric RNA-
30 DNA oligonucleotides have also been used to block the expression of target genes in
plants (Beetham et al., 1999; Zhu et al., 1999).

Posttranslational modifications of histones in chromatin are important mechanisms in the regulation of gene expression. Protein-protein interactions between histones H3, H4, H2A and H2B form an octomeric core which is wrapped with DNA. N-terminal tails of histones protrude from the octamer and are subject to posttranslational modification involving acetylation and deacetylation of conserved lysine residues. A nucleosome comprises 26 lysine residues that may be subject to acetylation. Acetylation of core histones, including H4 and H3 via histone acetyltransferase (HAT), is correlated with transcriptionally active chromatin of eukaryotic cells. Acetylation is thought to weaken the interactions of histones with DNA and induce alterations in nucleosome structure. These alterations enhance the accessibility of promoters to components of the transcription machinery, and increase transcription. HATs have been identified in yeast, insects, plants and mammals (e.g. Kolle et al. 1998), and are typically components of multiprotein complexes including components of RNA polymerase II complex, TFIID, TFIIC and recruitment factors (e.g. see Lusser et al. 2001 for review).

Histone deacetylation, via histone deacetylase (HD, HDA, HDAC), is thought to lead to a less accessible chromatin conformation, resulting in the repression of transcription (e.g. Pazin and Kadonaga, 1997; Struhl, 1998; Lusser et al., 2001). The role of the yeast histone deacetylase, RPD3, in transcriptional repression was first discovered through a genetic screen for transcriptional repressors in *S. cerevisiae* (Vidal and Gaber, 1991). Since then, a number of yeast and mammalian HDAC genes have been cloned (Rundlett et al., 1996; Emiliani et al., 1998; Hassig et al., 1998; Verdel and Khochbin, 1999). Most eukaryotic histone deacetylases show some sequence homology to yeast *RPD3*, suggesting that these proteins are all members derived from a single gene family (Khochbin and Wolffe, 1997; Verdel and Khochbin, 1999). In yeast and mammalian cells, the RPD3/HDACs mediate transcriptional repression by interacting with specific DNA-binding proteins or associated corepressors and by recruitment to target promoters (Kadosh and Struhl, 1997; Hassig et al., 1997; Nagy et al., 1997; Gelmetti et al., 1998). Recently, a second family of histone deacetylases, HDA19 and related proteins, were identified in yeast and mammalian cells (Rundlett et al., 1996; Fischle et al., 1999; Verdel and Khochbin, 1999). The deacetylase domain of HDA19-related proteins is homologous to but significantly different from that of RPD3 (Fischle et al., 1999; Verdel and

Khochbin, 1999). These proteins also appear to be functionally different from RPD-like proteins in yeast cells (Rundlett et al., 1996). WO 97/35990 discloses mammalian-derived histone deacetylase (HDx) gene sequences, gene products, and uses for these sequences and products. The down regulation of gene expression in plants using histone deacetylase, fused to a DNA binding domain that targeted the fusion protein to a specific gene, has been demonstrated (Wu et al., 2000a; Wu et al., 2000b).

The present invention embraces the use of fusion proteins comprising a DNA binding domain fused to a recruitment factor, that is capable of recruiting chromatin remodelling proteins such as HDAC and HAT, to specific DNA sites to regulate expression of a gene of interest. Also disclosed is the use of fusion proteins comprising a DNA binding portion fused to histone acetyltransferase (HAT) to regulate transcription of a gene of interest.

It is an object of the invention to overcome disadvantages of the prior art.

The above object is met by the combinations of features of the main claims, the sub-claims disclose further advantageous embodiments of the invention.

SUMMARY OF THE INVENTION

The present invention relates to the regulation of gene expression. More particularly, the present invention relates to the control of gene expression of one or more nucleotide sequences of interest in transgenic plants using chromatin remodelling factors.

According to an aspect of an embodiment of the present invention, there is provided a method to regulate the expression of a gene of interest in a plant comprising:

- i) introducing to the plant:
 - 1) a first nucleotide sequence comprising,
 - a) the gene of interest operatively linked to a first regulatory region,
 - b) an operator sequence capable of binding a fusion protein, and;

2) a second nucleotide sequence comprising a second regulatory region in operative association with a nucleotide sequence encoding a fusion protein, the fusion protein comprising,

- a) a DNA binding protein, or a portion of a DNA binding protein capable of binding the operator sequence, and;
- b) a recruitment factor protein, or a portion thereof, capable of binding a chromatin remodelling protein,

ii) growing the plant, wherein expression of the second nucleotide sequence produces the fusion protein and regulates expression of the gene of interest.

The present invention also embraces the methods as defined above, wherein the first and second regulatory regions are either the same or different and are selected from the group consisting of a constitutive promoter, an inducible promoter, a tissue specific promoter, and a developmental promoter.

The present invention also relates to a method of enhancing the expression of a gene of interest or enhancing the transcription of a gene of interest in a plant comprising:

i) introducing to the plant:

1) a first nucleotide sequence comprising,

- a) the gene of interest operatively linked to a first regulatory region, and;
- b) an operator sequence that interacts with a fusion protein;

2) a second nucleotide sequence comprising a second regulatory region in operative association with a nucleotide sequence encoding a fusion protein comprising,

- a) a DNA binding protein, or a portion thereof, capable of binding the operator sequence, and;
- b) a histone acetyltransferase (HAT) protein, or portion thereof, capable of increasing histone acetylation;

ii) growing the plant, wherein expression of the second nucleotide sequence produces the fusion protein and increases transcription of the gene of interest.

The present invention pertains to a method of regulating the expression of a gene of interest or enhancing the transcription of a gene of interest in a plant comprising:

i) introducing to the plant:

5 1) a first nucleotide sequence comprising,

a) the gene of interest operatively linked to a first regulatory region,
and;

b) an operator sequence that interacts with a fusion protein;

10 2) a second nucleotide sequence comprising a second regulatory region in operative association with a nucleotide sequence encoding a fusion protein comprising,

a) a DNA binding protein, or a portion thereof, capable of binding the operator sequence, and;

15 b) a chromatin remodelling factor, or portion thereof, capable of increasing histone acetylation;

ii) growing the plant, wherein expression of the second nucleotide sequence produces the fusion protein and regulates the transcription of the gene of interest.

20 The present invention also embraces the methods as defined above, wherein the first and second regulatory regions are either the same or different and are selected from the group consisting of a constitutive promoter, an inducible promoter, a tissue specific promoter, and a developmental promoter.

25 The first and second nucleotide sequences may be placed within the same or within different vectors, genetic constructs, or nucleic acid molecules. Preferably, the first nucleotide sequence and the second nucleotide sequence are chromosomally integrated into a plant or plant cell. The two nucleotide sequences may be integrated into two different genetic loci of a plant or plant cell, or the two nucleotide sequences may be integrated into a singular genetic locus of a plant or plant cell. However, the
30 second nucleotide sequence may be integrated into the DNA of the plant or it may be present as an extra-chromosomal element, for example, but not wishing to be limiting a plasmid.

Also, according to the present invention there is provided a method for selectively controlling the transcription of a gene of interest, comprising:

- i) producing a first plant comprising a first genetic construct, the first genetic construct comprising a first regulatory region operatively linked to the gene of interest and at least one operator sequence capable of binding a fusion protein;
- ii) producing a second plant comprising a second genetic construct, the second genetic construct comprising a second regulatory region in operative association with a nucleic sequence encoding the fusion protein, the fusion protein comprising,
 - a) a DNA binding protein, or a portion thereof, capable of binding the operator sequence, and;
 - b) a recruitment factor protein, or a portion thereof, capable of binding a chromatin remodelling protein;
- iii) crossing the first plant and the second plant to obtain progeny comprising both the first genetic construct and the second genetic construct, the progeny characterized in that the expression of the fusion protein regulates expression of the gene of interest.

The present invention also embraces the methods as defined above, wherein the first and second regulatory regions are either the same or different and are selected from the group consisting of a constitutive promoter, an inducible promoter, a tissue specific promoter, and a developmental promoter.

The present invention also pertains to the method as just defined, wherein the nucleic acid sequence encoding the fusion protein is optimised for expression in a plant, and that the nucleotide sequence encodes a nuclear localization signal.

Also, according to the present invention there is provided a method for selectively controlling the transcription of a gene of interest, comprising:

- i) producing a first plant comprising a first genetic construct, the first genetic construct comprising a first regulatory region operatively linked to the gene of interest and at least one operator sequence capable of binding a fusion protein;

ii) producing a second plant comprising a second genetic construct, the second genetic construct comprising a second regulatory region in operative association with a nucleic sequence encoding the fusion protein comprising,

a) a DNA binding protein, or a portion thereof, capable of binding the operator sequence, and;

b) a HAT protein, or portion thereof, capable of histone acetylation in plants;

iii) crossing the first plant and the second plant to obtain progeny comprising both the first genetic construct and the second genetic construct and characterized in that the expression of the fusion protein up-regulates the expression of the gene of interest.

The present invention also provides the method as just defined, wherein, the nucleic acid sequence encoding the fusion protein is optimised for expression in the plant, and that the nucleic acid sequence encodes a nuclear localization signal.

The present invention also embraces the methods as defined above, wherein the first and second regulatory regions are either the same or different and are selected from the group consisting of a constitutive promoter, an inducible promoter, a tissue specific promoter, and a developmental promoter.

Furthermore, this invention provides a method to regulate expression of an endogenous nucleic acid sequence of interest in a plant comprising:

i) introducing into the plant a nucleotide sequence comprising, a regulatory region, operatively linked with a nucleotide sequence encoding a fusion protein, the fusion protein comprising,

a) a DNA binding protein, or a portion thereof, capable of binding a segment of a DNA sequence of the endogenous nucleotide sequence of interest;

b) a recruitment factor protein, or a portion thereof, capable of binding a chromatin remodelling protein; and

ii) growing the plant, wherein expression of the nucleotide sequence produces the fusion protein that regulates expression of the endogenous nucleic acid sequence of interest.

The present invention also includes a method to regulate expression of an endogenous nucleic acid sequence of interest in a plant comprising:

- i) introducing into the plant a nucleotide sequence comprising a regulatory region, operatively linked with a nucleotide sequence encoding a recruitment factor protein, the recruitment factor protein capable of binding an endogenous DNA binding protein, the endogenous DNA binding protein characterized in binding a segment of a DNA sequence of the endogenous nucleotide sequence of interest, and;
- ii) growing the plant, wherein expression of the nucleotide sequence produces the recruitment factor thereby regulating expression of the endogenous nucleic acid sequence of interest.

This summary of the invention does not necessarily describe all necessary features of the invention but that the invention may also reside in a sub-combination of the described features.

BRIEF DESCRIPTION OF THE DRAWINGS

These and other features of the invention will become more apparent from the following description in which reference is made to the appended drawings wherein:

- 5 **FIGURE 1** shows the nucleotide and deduced amino acid sequences of wild type ROS and a modified ROS of *Agrobacterium tumefaciens*. **Figure 1(A)** shows the amino acid sequence alignment of known ROS repressors (wild-type ROS, SEQ ID NO:1; ROSR, SEQ ID NO:63; ROSAR, SEQ ID NO: 64; MucR, SEQ ID NO: 65), and a synthetic ROS (SEQ ID NO: 4). The amino acid sequence 'PKKKRKV' (SEQ ID NO: 6) at the carboxy end of synthetic ROS
- 10 is one of several nuclear localization signals. **Figure 1(B)** shows the nucleotide sequence of a synthetic ROS (SEQ ID NO:2) that had been optimised for plant codon usage containing a nuclear localization signal peptide (in italics). Optional restriction sites at the 5' end of the sequence are underlined. **Figure 1(C)** shows the consensus nucleotide (SEQ ID NO:3) and predicted amino acid (SEQ ID NO:4) sequence, of a composite ROS sequence comprising all possible nucleotide sequences that encode wild type ROS repressor, and the wild type ROS amino acid sequence. The amino acid sequence 'PKKKRKV' (SEQ ID NO:6) at the carboxy end represents a
- 15 nuclear localization signal. Amino acids in bold identify the zinc finger motif. Nucleotide codes are as follows: N= A or C or T or G; R= A or G; Y= C or T; M= A or C; K= T or G; S= C or G; W= A or T; H= A or T or C; B= T or C or G; D= A or T or G; V= A or C or G. **Figure 1(D)** shows the nucleotide sequence of the operator sequences of the virC/virD (SEQ ID NO:27) and ipt (SEQ ID NO:8) genes. **Figure 1(E)** shows a consensus operator sequence (SEQ ID NO:5) derived from the virC/virD (SEQ ID NOs:66-67) and ipt (SEQ ID NOs:68-69) operator sequences. This sequence comprises 10 amino acids, however, only the first 9 amino acids are required for binding ROS.
- 20
- 25
- 30 **FIGURE 2-4** shows in a diagrammatic form several variations of regulating gene expression using the methods of the present invention.

FIGURE 5 shows schematic representations of nucleotide constructs that place the expression of a gene of interest under the control a regulatory region, in this

case a CaMV35S regulatory region, modified to contain a ROS operator site. **Figure 5(A)** shows the nucleotide construct p74-315 in which a CaMV35S regulatory region, modified to contain a ROS operator site downstream of the TATA box, is operatively linked to a gene of interest (β -glucuronidase; GUS). **Figure 5(B)** shows the nucleotide construct p74-316 in which a CaMV35S regulatory region is modified to contain a ROS operator site upstream of the TATA box is operatively linked to the protein encoding region of GUS. **Figure 5(C)** shows the nucleotide construct p74-309 in which a CaMV35S regulatory region modified to contain ROS operator sites upstream and downstream of the TATA box is transcriptionally fused (i.e. operatively linked) to the protein encoding region of GUS. **Figure 5(D)** shows construct p74-118 comprising a 35S regulatory region with three ROS operator sites downstream from the TATA box. The 35S regulatory region is operatively linked to the gene of interest (GUS).

FIGURE 6 shows a schematic representation of a nucleotide construct that places the expression of a gene of interest gene under the control of a regulatory region, in this case, the tms2 regulatory region that has been modified to contain ROS operator sites. **Figure 6(A)** shows the nucleotide construct p76-507 in which a tms2 regulatory region is operatively linked to a gene of interest (in this case encoding β -glucuronidase, GUS). **Figure 6(B)** shows the nucleotide construct p76-508 in which a tms2 regulatory region modified to contain two tandemly repeated ROS operator sites downstream of the TATA box is transcriptionally fused (i.e. operatively linked) to the protein coding region of GUS.

FIGURE 7 shows a schematic representation of a nucleotide construct that places the expression of a gene of interest under the control of a regulatory region, in this case actin 2 regulatory region, that has been modified to contain ROS operator sites. **Figure 7(A)** shows the nucleotide construct p75-101 in which an actin2 regulatory region is operatively linked to a gene of interest (the β -glucuronidase (GUS) reporter gene). **Figure 7(B)** shows the nucleotide construct p74-501 in which an actin2 regulatory region modified to contain two tandemly repeated ROS operator sites upstream of the TATA box is transcriptionally fused (operatively linked) to the a gene of interest (GUS).

FIGURE 8 shows Southern analysis of transgenic *Arabidopsis* plants. **Figure 8(A)** shows Southern analysis of a plant comprising a first genetic construct, p74-309 (35S-operator sequence-GUS; see Figure 5(C) for map). DNA was digested with *Cla*I or *Xho*I and the blot was probed with the ORF of the GUS gene. **Figure 8(B)** shows Southern analysis of a plant comprising a second genetic construct p75-101 (see Figure 7A). *Hind*III digests were probed with NPTII.

FIGURE 9 shows expression of a gene of interest in plants. Upper panel shows expression of GUS under the control of 35S (pBI121; 35S:GUS). Middle panel shows GUS expression under the control of actin2 comprising ROS operator sequences (p74-501; see Figure 7(B) for construct). Lower panel shows the lack of GUS activity in a non-transformed control.

FIGURE 10 shows alignments of bnKCP1 and sequence comparison of kinase inducible domains (KIDs) in bnKCP1 and CREB family members. **Figure 10(A)** shows alignment of the deduced amino acid sequences of bnKCP1 (SEQ ID NO:71), atKCP (SEQ ID NO:72), atKCL1 (SEQ ID NO:73) and atKCL2 (SEQ ID NO:74) proteins. Serine (S)-rich residues and the conserved region (GKSKS domain) among the four sequences are single underlined and double underlined, respectively. The putative nuclear localization signal (NLS) and the phosphorylation site of protein kinase A are indicated by asterisks and diamonds, respectively. **Figure 10(B)** shows alignment of the amino acid sequences of bnKCP1 (SEQ ID NO:75), hydra CREB (hyCREB) (SEQ ID NO:77), canfa CREM (cCREM) (SEQ ID NO:80), and mammalian ATF-1 (SEQ ID NO:76), CREB (SEQ ID NO:78) and CREM (SEQ ID NO:79). Diamonds indicate the conserved phosphorylation site of protein kinase A. **Figure 10(C)** shows a phylogenetic tree of the KIDs sequences using the NTI Vector program.

FIGURE 11 shows structural features of bnKCP1. **Figure 11(A)** shows schematic representation of entire bnKCP1 protein. Numbers above or under the boxes refer to positions of amino acid residues. S-rich (34-58), GKSKS (88-143) and

KID (161-215) domains or motifs are shown in dotted boxes, the nuclear localization signal (NLS) in black box, and the three acidic motifs (I, II, III) in gray boxes. Figure 11(B) shows secondary structure features and hydrophilicity of bnKCP1 analyzed using DNASTar Protean program.

FIGURE 12 shows Southern blot analysis of Brassica genomic DNA. Total genomic DNA (10 µg/lane) from *Brassica napus* cv Westar was digested with restriction enzymes *EcoRI* (EI), *XbaI* (X), *HindIII* (H), *PstI* (P), *EcoRV* (EV) and *KpnI* (K). The entire ORF of *bnKCP1* was used as a probe.

FIGURE 13 shows *in vitro* interaction of wild type and mutant bnKCP1 proteins with the GST-HDA19 and GST-Gcn5 fusion proteins. Figure 13(A) shows a schematic representation of the bnKCP1 and its deletion mutants obtained by deletion of C-terminal regions of bnKCP1. Figure 13(B) shows binding activities of bnKCP1 and its mutants with GST-HDA19, GST-Gcn5 and GST alone (negative control), respectively, as indicated. The wild type bnKCP1, mutants bnKCP1¹⁻¹⁶⁰ and bnKCP1¹⁻⁸⁰, luciferase (as positive control) and negative control (no template) were produced using *in vitro* transcription/translation reactions. The translation products were incubated with GST fusion proteins or GST and their binding activities were examined as described in Example 4. Figure 13(C) shows activation of lacZ reporter gene by bnKCP1 and its deletion mutants, ΔbnKCP1¹⁻¹⁶⁰ and ΔbnKCP1¹⁻⁸⁰, in yeast cells. MaV203 yeast cells carrying plasmid pDBLeu-HDA19 and the reporter gene were transfected with the plasmid pPC86-bnKCP1, pPC86-bnKCP1¹⁻¹⁶⁰, pPC86-bnKCP1¹⁻⁸⁰ or pPC86 vector only. Yeast strains A and B were used as negative and positive controls, respectively. The β-galactosidase activity was assayed using chlorophenol red-β-D-galactopyranoside (CPRG) and was expressed as a percentage of activity conveyed by bnKCP1.

FIGURE 14 shows the effect of S¹⁸⁸ on the interaction between bnKCP1 and GST-HDA19 fusion protein. A glycine residue (G¹⁸⁸) was introduced by site-directed mutagenesis to replace S¹⁸⁸. The binding activities of wild-type bnKCP1 and the mutant ΔbnKCP1G¹⁸⁸ with GST-HDA19 or GST alone (negative control) were examined with GST pulldown affinity assay as

described in Example 4. Figure 14A shows the introduction of G188 into the KID of bnKCP1. Figure 14B shows in vitro protein interaction of bnKCP1 and the mutant Δ bnKCP1G¹⁸⁸ with GST-HDA19 or GST alone.

5 **FIGURE 15** shows expression patterns of *bnKCP1* mRNA in different tissues. Total RNA (20 μ g/lane) was isolated from leaves with petioles, flowers, roots, stems and immature siliques.

10 **FIGURE 16** shows expression of *bnKCP1* gene in response to low temperature, LaCl₃ and inomycin treatments. Total RNA (20 μ g/lane) was isolated from leaf blades of four-leaf stage *Brassica napus* cv Westar seedlings after exposure to different stress conditions and analyzed by northern blotting using the *bnKCP1* ORF as probe. **Figure 16(A)** shows *bnKCP1* transcript accumulation in leaves and stems of seedlings exposed to cold (4°C). **Figure**
15 **16(B)** shows expression pattern of *bnKCP1* gene after treatment with LaCl₃ and inomycin.

FIGURE 17 shows transactivation of the *lacZ* gene by bnKCP1 in yeast. The *lacZ* gene was driven by a promoter containing GAL4 DNA binding sites and integrated into the genome of yeast MaV203. **Figure 17(A)** is a schematic representation of the bnKCP1 and its deletion mutants. **Figure 17(B)** Yeast cells carrying the reporter gene were transfected with the effector plasmids pDBLeu-bnKCP1, pDBLeu-bnKCP1¹⁻¹⁶⁰, pDBLeu-bnKCP1¹⁻⁸⁰, and pDBLeu-bnKCP1⁸¹⁻²¹⁵ or the pDBLeu vector only. Yeast strains A and B (GibcoL
20 BRL, Life Technologies) were used as negative and positive controls, respectively. The β -galactosidase activity was assayed using CPRG (chlorophenol red- β -D-galactopyranoside) and was expressed as a percentage of activity conveyed by the positive control (strain C). Bars indicate the standard error of three replicates.

30

FIGURE 18 shows the nuclear localization of GUS-bnKCP1 protein in onion cells. **Figure 18(A)** is a schematic diagram of the GUS-bnKCP1 fusion construct containing the CaMV 35S promoter. The *bnKCP1* was fused in-frame to the GUS reporter gene. **Figure 18(B)** shows transient expression of GUS-

bnKCP1 fusion protein (top) and GUS alone (bottom) in onion cells. Onion tissues were simultaneously analysed using histochemical GUS assay (left) and nucleus-specific staining with DAPI (right) as described in Example 4.

5 **FIGURE 19** shows a diagrammatic representation of a strategy for preparing fusions between a recruitment factor involved in chromatin remodelling and a DNA binding protein. In the non-limiting example shown in this figure, the recruitment factor is KID (see Example 4), and the DNA binding protein is a zinc finger.

10

FIGURE 20 shows alignment of the deduced products of *BnSCL1* (SEQ ID NO:81), *AtSCL15* (accession number Z99708) (SEQ ID NO:82) and *LsSCL* (accession number AF273333) (SEQ ID NO:83). Identical and conserved amino acids in the three proteins are shown as white letters on a black background and black letter on a gray background, respectively. Amino acids with weak similarity are indicated as white letters on a gray background. Amino acids with no similarity are shown as black letters on a white background. The putative nuclear localization signals and LXXLL motif are indicated by asterisks and dots, respectively. The VHIID motif, two leucine heptad regions (LHRI and LHRII), PFYRE and SAW motif are underlined as indicated.

15

20

FIGURE 21 shows a phylogenetic tree of the GRAS family sequences made by the NTI Vector program in *Brassica napus*, *Arabidopsis thaliana*, *Hordeum vulgare*, *Zea mays*, *Lycopersicon esculentum*, *Pisum sativum* and *Oryza sativa*. The *BnSCL1* is underlined.

25

FIGURE 22 shows DNA gel blot analysis of *BnSCL1* gene. Total genomic DNA (10 µg/lane) from *Brassica napus* was digested with restriction enzymes *EcoRI* (EI), *XbaI* (X), *HindIII* (H), *PstI* (P), *EcoRV* (EV) and *KpnI* (K), and hybridized with the entire ORF of *BnSCL1* under high stringency conditions.

30

FIGURE 23 shows *in vitro* interaction of wild type and mutant *BnSCL1* proteins with the GST-HDA19 fusion protein. **Figure 23(A)** is a schematic representation of the *BnSCL1* and its deletion mutants obtained by the deletion of its C-terminal regions.

Figure 23(B) shows the binding activities of BnSCL1 and its mutants with GST-HDA19.

The wild type BnSCL1, mutants Δ BnSCL1¹⁻³⁵⁸, Δ BnSCL1¹⁻²⁶¹, Δ BnSCL1¹⁻²¹⁷ and Δ BnSCL1¹⁻¹⁴⁵, luciferase (positive control) and negative control (no template) were produced using *in vitro* transcription/translation reactions. The translation products were incubated with GST fusion proteins or GST alone (data not shown) and their binding activities were examined as described in Example 5. Arrow point to band representing the *in vitro* translated Δ BnSCL1¹⁻¹⁴⁵ protein that did not bind to the recombinant protein.

FIGURE 24 shows *in vivo* interaction of wild type and mutant BnSCL1 proteins. **Figure**

24(A) is a schematic representation of the BnSCL1 and its deletion mutants. **Figure 24(B)** shows the activation of *lacZ* reporter gene by BnSCL1 and its deletion mutants in yeast cells. MaV203 yeast cells carrying plasmid pDBLeu-HDA19 and the *lacZ* reporter gene were transfected with the plasmid pPC86-BnSCL1, pPC86-BnSCL1¹⁻³⁵⁸, pPC86-BnSCL1¹⁻²⁶¹, pPC86-BnSCL1¹⁻²¹⁷, pPC86-BnSCL1¹⁻¹⁴⁵, pPC86-BnSCL1¹⁴⁶⁻³⁵⁸, pPC86-BnSCL1²¹⁸⁻⁴³⁸ or pPC86 vector only. The negative control yeast strain A, and the positive controls yeast strains B and C (GIBCOL BRL, Life Technologies) were also used. The β -Galactosidase activity was assayed using CPRG (chlorophenol red- β -D-galactopyranoside) and was expressed as a percentage of activity conveyed by yeast strain C. Bars indicate the standard error of three replicates.

FIGURE 25 shows transactivation of the *lacZ* gene by BnSCL1 protein in yeast. **Figure**

25(A) is a schematic representation of the BnSCL1 and its deletion mutants. **Figure 25(B)** shows the activation of *lacZ* reporter gene by BnSCL1 and its deletion mutants in yeast cells. The *lacZ* reporter gene was driven by a promoter containing GAL4 DNA binding sites and integrated into the genome of yeast MaV203 cell. Yeast cells carrying the reporter gene were transfected with the effector plasmids pDBLeu-BnSCL1, pDBLeu-BnSCL1¹⁻³⁵⁸, pDBLeu-BnSCL1¹⁻²⁶¹, pDBLeu-BnSCL1¹⁻²¹⁷, pDBLeu-BnSCL1¹⁻¹⁴⁵, pDBLeu-BnSCL1¹⁴⁶⁻³⁵⁸, pDBLeu-BnSCL1²¹⁸⁻⁴³⁸ or pDBLeu vector only. Yeast strains A, B, C and D (GIBCOL BRL, Life Technologies) were used as controls as described in Example 5. The β -Galactosidase activity was assayed using CPRG and was expressed as a percentage

of activity conveyed by the wild type BnSCL1 protein. Bars indicate the standard error of three replicates.

FIGURE 26 shows expression patterns of *BnSCL1* mRNA in different tissues. **Figure 26(A)** is a RNA gel blot analysis of total RNA (20 µg/lane) isolated from leaves, flowers, roots, stems and siliques, electrophoresed through a 1.2% agarose gel containing formaldehyde and probed with the ORF of *BnSCL1* as described in Example 5. EtBr stained total RNA is shown to indicate even loading. **Figure 26(B)** is a quantitative one-step RT-PCR analysis of total RNA extracted from leaves, flowers, roots, stems, siliques and shoots. Quantitative RT-PCR products were electrophoresed through a 1% agarose gel and hybridized with ³²P-labelled 5'-end fragment (435 bp) of *BnSCL1* ORF. A 960 bp fragment of the *Brassica napus actin* gene co-amplified with *BnSCL1* was used as an internal standard as described in Example 5.

FIGURE 27 shows expression of *BnSCL1* gene in four-leaf stage *Brassica napus* seedlings in the presence or absence of 2,4-D. Total RNA was isolated from the fourth leaves after the indicated period of the first foliar application of 1 mM 2,4-D and subjected to quantitative one-step RT-PCR. The RT-PCR products were analyzed by Southern blotting using the *BnSCL1* ORF as probe (left) and the blotting results were shown graphically relative to the level of internal standard *Actin* (arbitrary value of 100)(right).

FIGURE 28 shows kinetics of *BnSCL1* mRNA accumulation in response to auxin in the presence and absence of histone deacetylase inhibitor sodium butyrate. Nine-day-old light-grown seedlings were treated with 10 mM sodium butyrate for 24 h followed by exogenous 2,4-D application at variable concentrations as indicated. Quantitative one-step RT-PCR was used to analyze total RNA extracted from shoots (**Figure 28A**) and roots (**Figure 28B**) (see legend to Figure 27 Expression of *BnSCL1* in response to 2,4-D was also analyzed using quantitative RT-PCR of total RNA isolated from shoots and roots of 10 dpg seedlings in the presence of 50 µM NPA, an auxin transport inhibitor, for 24 h before the exogenous application of 2,4-D (**Figure 28C**).

FIGURE 29 shows in a diagrammatic form several constructs that may be used to regulate gene expression as described in Example 6.

DESCRIPTION OF PREFERRED EMBODIMENT

The present invention relates to the regulation of gene expression. More particularly, the present invention relates to the control of gene expression of one or more nucleotide sequences of interest in transgenic plants using chromatin remodelling factors.

The following description is of a preferred embodiment by way of example only and without limitation to the combination of features necessary for carrying the invention into effect.

Gene regulation can be used in applications such as metabolic engineering to produce plants that accumulate large amounts of certain intermediate compounds. Regulation of gene expression can also be used for control of transgenes across generations, or production of F1 hybrid plants with seed characteristics that would be undesirable in the parental line, for example but not limited to, hyper-high oil, reduced fiber content, low glucosinolate levels, reduced levels of phytotoxins, and the like. In the latter examples, low glucosinolate levels, or other phytotoxins, may be desired in seeds while higher concentrations of these compounds may be required elsewhere, for example in the case of glucosinolates, within cotyledons, due to their role in plant defence. Another non-limiting example for the controlled regulation of a gene of interest during plant development is seed specific down regulation of sinapine biosynthesis, as for example in seeds of *Brassica napus*. In many instances, transgene expression needs to be regulated only in certain plant organs/tissues or at certain stages of development. The methods as described herein may also be used to control the expression of a gene of interest that encodes a protein used to for plant selection purposes. For example, which is to be considered non-limiting, a gene of interest may encode a protein that is capable of metabolizing a compound from a non-toxic form to a toxic form thereby selectively removing plants that express the gene of interest.

The present invention provides a method to regulate the expression of a gene of interest by transforming a plant with one or more constructs comprising:

- 1) a first nucleotide sequence comprising,

a) a nucleic acid sequence of interest operatively linked to a regulatory region,

b) an operator sequence capable of binding a fusion protein, and;

2) a second nucleotide sequence comprising a regulatory region in operative association with a nucleotide sequence encoding a fusion protein, the fusion protein comprising,

a) a DNA binding protein, or a portion of a DNA binding protein capable of binding the operator sequence, and;

b) a recruitment factor protein, or a portion of a recruitment factor protein capable of binding a chromatin remodelling protein,

wherein binding of the fusion protein to the operator sequence of the first nucleotide sequence regulates expression of the nucleic acid sequence of interest from the first nucleotide sequence. The operator sequence of the first nucleotide sequence may be positioned upstream of the ORF of the nucleic acid sequence of interest.

These first and second nucleotide sequences may be placed within the same or within different vectors, genetic constructs, or nucleic acid molecules. Preferably, the first nucleotide sequence and the second nucleotide sequence are chromosomally integrated into a plant or plant cell. The two nucleotide sequences may be integrated into two different genetic loci of a plant or plant cell, or the two nucleotide sequences may be integrated into a singular genetic locus of a plant or plant cell. However, the second nucleotide sequence may be integrated into the DNA of the plant or it may be present as an extra-chromosomal element, for example, but not wishing to be limiting a plasmid.

By "operatively linked" it is meant that the particular sequences interact either directly or indirectly to carry out their intended function, such as mediation or modulation of gene expression. The interaction of operatively linked sequences may, for example, be mediated by proteins that in turn interact with the sequences. A transcriptional regulatory region and a sequence of interest are "operably linked" when the sequences are functionally connected so as to permit transcription of the sequence of interest to be mediated or modulated by the transcriptional regulatory region.

By the term "regulate the expression" it is meant reducing or increasing the level of mRNA, protein, or both mRNA and protein, encoded by a gene or nucleotide sequence of interest in the presence of the fusion protein encoded by the second nucleotide sequence, relative to the level of mRNA, protein or both mRNA and protein encoded by the nucleic acid sequence of interest in the absence of the fusion protein encoded by the second nucleotide sequence.

By the term "fusion protein" it is meant a protein comprising two or more amino acid portions which are not normally found together within the same protein in nature and that are encoded by a single gene. Fusion proteins may be prepared by standard techniques in molecular biology known to those skilled in the art (see for example Figure 17). In the context of the present invention, at least one of the amino acid portions is capable of binding an operator sequence as defined herein.

By the term "binding" it is meant reversible or non-reversible association of two components, for example the operator sequence and the DNA binding domain of a protein, including a fusion protein, or the recruitment factor protein and chromatin remodelling protein as described herein. Preferably, the two components have a tendency to remain associated, but are capable of dissociation under appropriate conditions. Conditions may include, but are not limited to the addition of a third component, chemical, etc which enhances dissociation of the bound components.

By the term "recruitment factor" it is meant a protein or peptide sequence capable of interacting with, or binding a chromatin remodelling protein. Preferably, the recruitment factor and the chromatin remodelling protein interact or bind in a manner such that the activity of the chromatin remodelling protein is retained. However, by binding the recruitment factor, the activity of the chromatin remodelling protein may be modified in some manner. Non-limiting examples of recruitment factors include KID, for example bnKCP1, or fragments thereof (Example 4), BnSCL1, or fragments thereof (Example 5), ADA, SAGA, STAGA, PCAF, TFIID, and TFIIC (Lusser, 2001, Table 1, which is incorporated herein by reference). A recruitment factor may be modified to include a DNA binding region, for example as outlined in Figure 17, [or a native recruitment factor may be utilized to target proteins that interact with genes in their native context]. An example, which is not to be

considered limiting in any manner, bnKCP1, or active fragments thereof (see Example 4) can target transcription factors that are known to bind DNA. Examples of such transcription factors include ERF (Hart et al., 1993), SEBF (Boyle and Brisson, 2001), or CBF (Stockinger et al., 1997). In this manner by over expressing *bnKCP1*, regulation of the expression of a gene that is dependant on ERF, CBF or SEBF activity may be regulated. Another non-limiting example of a recruitment factor is BnSCL1, or active fragments thereof (see Example 5). An example, which is not to be considered limiting, of a protein that interacts with bnKCP1 and BnSCL1 is the chromatin remodelling protein HDAC, for example HDA19.

By the term "chromatin remodelling protein" it is meant a protein that is capable of altering the structure of chromatin. Preferably the chromatin remodelling protein is histone acetyl transferase (HAT) or histone deacetylase (referred to either as HD, HDA, or HDAC). Any HAT protein, HDAC protein, or any derivative of any HAT protein or HDAC protein may be used in the method of the present invention provided that the HAT protein, HDAC protein or derivative thereof exhibits the respective histone acetylase, or histone deacetylase activity in plants.

By the term "HD binding domain" or "histone deacetylase binding domain", it is meant a sequence of amino acid residues which interacts with a histone deacetylase enzyme through protein-protein interactions. Such protein-protein interactions can be monitored in several ways, for example, which is not to be considered limiting, by yeast two-hybrid experiments. Non-limiting examples of proteins comprising a HD binding domain include bnKCP1 and BnSCL1.

By the term "DNA binding protein or portion of a DNA binding protein" it is meant a protein or amino acid sequence capable of binding to a specific operator sequence. By "operator sequence" it is meant a sequence of DNA that is capable of binding to the DNA binding protein or portion of the DNA binding protein. Examples of a DNA binding proteins capable of binding specific operator sequences include, but are not limited to, the ROS repressor, TET repressor, Sin3, VP16, GAL4, Lex A, UMe6, ERF, SEBF and CBF. Any DNA binding protein or portion of any DNA binding protein may be employed in the method of the present invention provided that the protein or portion thereof is capable of binding to an operator sequence. As an

example, but not to be considered limiting in any manner, the ROS repressor may be employed in the method of the present invention. By ROS repressor it is meant any ROS repressor, analog or derivative thereof as known within the art which is capable of binding to an operator sequence. These include ROS repressors as described herein, as well as other microbial ROS repressors, for example but not limited to ROSAR (*Agrobacterium radiobacter*; Brightwell et al., 1995) (SEQ ID NO:64), MucR (*Rhizobium meliloti*; Keller M et al., 1995) (SEQ ID NO:65), and ROSR (*Rhizobium elti*; Bittinger et al., 1997; also see Cooley et al., 1991; Chou et al., 1998; Archdeacon J et al., 2000; D'Souza-Ault M. R., 1993; all of which are incorporated herein by reference) (SEQ ID NO:63). The DNA sequence of ROS, or any other DNA binding protein, may be modified to optimize expression within a plant. Examples of ROS repressors that may be used as described herein are provided in Figures 1(A) to (C) and (SEQ ID NOs: 1-4).

The DNA binding protein, or portion thereof that exhibits DNA binding activity may be fused to a recruitment factor or chromatin remodelling protein as described herein. Examples of such fusion proteins can be prepared, using methods known in the art, for example but not limited to the method outlined in Figure 17. Figure 17 discloses a strategy for creating fusion between the zinc finger domain of the ROS repressor and the KID domain of bnKCP1. This involves amplification of regions encoding the zinc finger domain of the ROS repressor and the KID domain using the following primers:

zinc finger: The forward primer (zf-F) contains a restriction enzyme site at the 5' end and the reverse primer (zf-R) contains 15 nucleotides from the 5' end of the

KID region.;

KID domain: The forward primer (KID-F) contains 15 nucleotides from the 3' region of the zinc finger domain, and the reverse primer (KID-R) contains a restriction enzyme site at the 3' end.

The amplified zinc finger and KID fragments are combined and used as a template for a new round of PCR amplification where only the forward primer (zf-F) of the zinc finger and the reverse primer (KID-R) of the KID domain are used. The two separate templates are amplified to create one single in frame fusion fragment encoding the zinc finger and KID domains, and containing restriction sites at each end. This product is then cloned into a plant expression vector.

However, it is to be understood that fusion of a recruitment factor with a DNA binding protein may not be required in order to regulate expression of a nucleic acid sequence of interest. Recruitment factors are known to bind chromatin remodelling proteins and factors that directly or indirectly bind DNA. For example, bnKCP1 (Example 4) exhibits the property of binding ERF.

Depending upon the chromatin remodelling protein selected, gene expression may be up-regulated or down-regulated. For example, which is not to be considered limiting in any manner, the binding of a fusion protein containing a recruitment factor capable of recruiting HAT to a gene, may result in up-regulation of expression of a nucleic acid sequence of interest, while a fusion protein that recruits HDAC will result in the down-regulation of the expression of a nucleic acid sequence of interest. However, it is within the scope of the present invention that modification to the rate of up-regulation and down-regulation of gene expression may occur depending upon the location of the operator sequence that binds the fusion protein.

The operator sequence is preferably located in proximity to the nucleic acid sequence of interest, either upstream of or downstream of the nucleic acid sequence of interest (see for example Figure 5A-D). Alternatively, the operator sequence may be within the non-coding region of the nucleic acid sequence of interest, for example, but not wishing to be limiting, within an intron of the gene. If it is desired to have the expression of a nucleic acid sequence of interest reduced or repressed, the operator sequence may be located within a nucleotide region that interferes with binding of transcription factors required for transcription of the nucleic acid sequence of interest, for example, interfering with the binding of the RNA polymerase to the nucleic acid sequence of interest, or reducing the rate of migration of the polymerase along a nucleotide sequence, or both.

An operator sequence may consist of a minimal sequence required for binding of a DNA binding protein or fragment thereof, or it may comprise an inverted repeat or palindromic sequences of a specified length. For example, but not wishing to be limiting, the ROS operator sequence may comprise 9 or more nucleotide base pairs (see Figures 1 (D) and (E)) that exhibits the property of binding a DNA binding

domain of a ROS repressor. A consensus sequence of a 10 amino acid region including the 9 amino acid DNA binding site sequence is WATDHWKMAR (SEQ ID NO: 5; Figure 1 (E)). The last amino acid, "R", of the consensus sequence is not required for ROS binding (data not presented). Examples of operator sequences, which are not to be considered limiting in any manner, also include, as is the case with the ROS operator sequence from the *virC* or *virD* gene promoters, a ROS operator made up of two 11bp inverted repeats separated by TTTA:

TATATTTCAATTTTATTGTAATATA (SEQ ID NO: 7); or

the operator sequence of the *IPT* gene:

TATAATTAAAATATTAAGTCTGCATT (SEQ ID NO: 8).

However, it is to be understood that analogs or variants of SEQ ID NO's: 7, 8 and 5 may also be used providing they exhibit the property of binding a DNA binding domain, preferably a DNA binding domain of the ROS repressor. For example, but not to be considered limiting in any manner, in the promoter of the divergent *virC/virD* genes of *Agrobacterium tumefaciens*, ROS binds to a 9 bp inverted repeat sequence in an orientation-independent manner (Chou et al., 1998). The ROS operator sequence in the *ipt* promoter also consists of a similar sequence to that in the *virC/virD* except that it does not form an inverted repeat (Chou et al., 1998). Only the first 9 bp are homologous to ROS box in *virC/virD* indicating that the second 9 bp sequence may not be a requisite for ROS binding. Accordingly, the use of ROS operator sequences or variants thereof that retain the ability to interact with ROS, as operator sequences to selectively control the expression of genes or nucleotide sequences of interest, is within the scope of the present invention.

Other operator sequences include sequences known to bind transcription factors, for example but not limited to:

TAAGAGCCGCC (SEQ ID NO:9), which is known to bind ERF (in ethylene responsive genes; Hart et al., 1993);

GACTGTAC (SEQ ID NO:10), which is known to bind to SEBF (in pathogenesis responsive genes; Boyle and Brisson, 2001);

TACCGACAT (SEQ ID NO:11) and TGGCCGAC (SEQ ID NO:12), which are known to bind CBF (in low temperature responsive genes; Stockinger et al., 1997).

5 The transcription factors ERF, SEBF and CBF are example of factors that can be targeted by the recruitment factor bnKCP1.

By "regulatory region" or "regulatory element" it is meant a portion of nucleic acid typically, but not always, upstream of the protein coding region of a gene, which may be comprised of either DNA or RNA, or both DNA and RNA. When a
10 regulatory region is active and in operative association with a nucleic acid sequence of interest, this may result in expression of the nucleic acid sequence of interest. A regulatory element may be capable of mediating organ specificity, or controlling developmental or temporal gene activation. A "regulatory region" includes promoter elements, core promoter elements exhibiting a basal promoter activity, elements that
15 are inducible in response to an external stimulus, elements that mediate promoter activity such as negative regulatory elements or transcriptional enhancers. "Regulatory region", as used herein, also includes elements that are active following transcription, for example, regulatory elements that modulate gene expression such as translational and transcriptional enhancers, translational and transcriptional
20 repressors, upstream activating sequences, and mRNA instability determinants. Several of these latter elements may be located proximal to the coding region.

In the context of this disclosure, the term "regulatory element" or "regulatory region" typically refers to a sequence of DNA, usually, but not always, upstream (5')
25 to the coding sequence of a structural gene, which controls the expression of the coding region by providing the recognition for RNA polymerase and/or other factors required for transcription to start at a particular site. However, it is to be understood that other nucleotide sequences, located within introns, or 3' of the sequence may also contribute to the regulation of expression of a coding region of interest. An example
30 of a regulatory element that provides for the recognition for RNA polymerase or other transcriptional factors to ensure initiation at a particular site is a promoter element. Most, but not all, eukaryotic promoter elements contain a TATA box, a conserved nucleic acid sequence comprised of adenosine and thymidine nucleotide base pairs usually situated approximately 25 base pairs upstream of a transcriptional start site. A

promoter element comprises a basal promoter element, responsible for the initiation of transcription, as well as other regulatory elements (as listed above) that modify gene expression.

5 There are several types of regulatory regions, including those that are developmentally regulated, inducible or constitutive. A regulatory region that is developmentally regulated, or controls the differential expression of a gene under its control, is activated within certain organs or tissues of an organ at specific times during the development of that organ or tissue. However, some regulatory regions
10 that are developmentally regulated may preferentially be active within certain organs or tissues at specific developmental stages, they may also be active in a developmentally regulated manner, or at a basal level in other organs or tissues within the plant as well.

15 An inducible regulatory region is one that is capable of directly or indirectly activating transcription of one or more DNA sequences or genes in response to an inducer. In the absence of an inducer the DNA sequences or genes will not be transcribed. Typically the protein factor, which binds specifically to an inducible regulatory region to activate transcription, may be present in an inactive form which is
20 then directly or indirectly converted to the active form by the inducer. However, the protein factor may also be absent. The inducer can be a chemical agent such as a protein, metabolite, growth regulator, herbicide or phenolic compound or a physiological stress imposed directly by heat, cold, salt, or toxic elements or indirectly through the action of a pathogen or disease agent such as a virus. A plant
25 cell containing an inducible regulatory region may be exposed to an inducer by externally applying the inducer to the cell or plant such as by spraying, watering, heating or similar methods. Inducible regulatory elements may be derived from either plant or non-plant genes (e.g. Gatz, C. and Lenk, I.R.P.,1998; which is incorporated by reference). Examples, of potential inducible promoters include, but not limited to,
30 teracycline-inducible promoter (Gatz, C.,1997; which is incorporated by reference), steroid inducible promoter (Aoyama, T. and Chua, N.H.,1997; which is incorporated by reference) and ethanol-inducible promoter (Salter, M.G., et al, 1998; Caddick, M.X. et al,1998; which are incorporated by reference) cytokinin inducible IB6 and CKI1 genes (Brandstatter, I. and Kieber, J.J.,1998; Kakimoto, T., 1996; which are

incorporated by reference) and the auxin inducible element, DR5 (Ulmasov, T., et al., 1997; which is incorporated by reference).

5 A constitutive regulatory region directs the expression of a gene throughout the various parts of a plant and continuously throughout plant development. Examples of known constitutive regulatory elements include promoters associated with the CaMV 35S transcript. (Odell et al., 1985), the rice actin 1 (Zhang et al, 1991), actin 2 (An *et al.*, 1996), or tms 2 (U.S. 5,428,147, which is incorporated herein by reference), and triosephosphate isomerase 1 (Xu et. al., 1994) genes, the 10 maize ubiquitin 1 gene (Cornejo et al, 1993), the *Arabidopsis* ubiquitin 1 and 6 genes (Holtorf et al, 1995), and the tobacco translational initiation factor 4A gene (Mandel et al, 1995). The term "constitutive" as used herein does not necessarily indicate that a gene under control of the constitutive regulatory region is expressed at the same level in all cell types, but that the gene is expressed in a wide range of cell types even 15 though variation in abundance is often observed.

The regulatory regions of the first and second nucleotide sequences denoted above, may be the same or different. For example, which is not to be considered limiting in any manner, the regulatory elements of the first and second genetic 20 constructs may both be constitutive. In an aspect of an embodiment, the first and second nucleotide sequences may be maintained in the same plant. In an alternate embodiment the first and second nucleotide sequences are maintained in separate plants, a first and a second plant, respectively. The first nucleotide sequence encoding a nucleic acid sequence of interest is expressed within the first plant. In the second 25 embodiment, the second plant expresses the second nucleic acid sequence encoding the fusion protein capable of regulating the expression of the nucleic acid sequence of interest within the first plant. Crossing of the first and second plants produces a progeny that expresses the fusion protein which regulates the expression of the nucleic acid sequence of interest. In this manner the expression of nucleic acid 30 sequence of interest that is required to maintain parent stocks may be retained within a parent plant but not expressed in a progeny plant. Such a cross may produce sterile offspring.

Alternatively, which is not to be considered limiting in any manner, the second regulatory element may be active before, during, or after the first regulatory element is active. Similarly, the first regulatory element may be active before, during, or after the second regulatory element is active. Other examples, which are not to be considered limiting, include the second regulatory element being an inducible regulatory element that is activated by an external stimulus so that regulation of gene expression may be controlled through the addition of an inducer. The second regulatory element may also be active during a specific developmental stage preceding, during, or following that of the activity of the first regulatory element. In this way the expression of the nucleic acid sequence of interest may be repressed or activated as desired within a plant.

By "nucleic acid sequence of interest", "nucleotide sequence of interest" or "coding region of interest" it is meant any gene or nucleotide sequence that is to be expressed within a host organism. Such a nucleotide sequence of interest may include, but is not limited to, a gene whose product has an effect on plant growth or yield, for example a plant growth regulator such as an auxin or cytokinin and their analogues, or a nucleotide sequence of interest may comprise a herbicide or a pesticide resistance gene, which are well known within the art. A nucleic acid sequence of interest or a coding region of interest, may encode an enzyme involved in the synthesis of, or in the regulation of the synthesis of, a product of interest, for example, but not limited to a protein, or an oil product. A nucleotide sequence of interest or a coding region of interest, may encode an industrial enzyme, protein supplement, nutraceutical, or a value-added product for feed, food, or both feed and food use. Examples of such proteins include, but are not limited to proteases, oxidases, phytases, chitinases, invertases, lipases, cellulases, xylanases; enzymes involved in oil biosynthesis, etc.

A nucleotide sequence of interest or a coding region of interest, may also encode a pharmaceutically active protein, for example growth factors, growth regulators, antibodies, antigens, their derivatives useful for immunization or vaccination and the like. Such proteins include, but are not limited to, interleukins, insulin, G-CSF, GM-CSF, hPG-CSF, M-CSF or combinations thereof, interferons, for example, interferon- α , interferon- β , interferon- γ , blood clotting factors, for example, Factor VIII, Factor IX, or tPA or combinations thereof. If the nucleic acid sequence

of interest or a coding region of interest, encodes a product that is directly or indirectly toxic to the plant, then by using the method of the present invention, such toxicity may be reduced throughout the plant by selectively expressing the nucleic acid sequence of interest within a desired tissue or at a desired stage of plant development.

A nucleotide sequence of interest or a coding region of interest, may also include a gene that encodes a protein involved in regulation of transcription, for example DNA-binding proteins that act as enhancers or basal transcription factors. Moreover, a nucleotide sequence of interest may be comprised of a partial sequence or a chimeric sequence of any of the above genes, in a sense or antisense orientation.

It is also contemplated that a nucleic acid sequence of interest or a coding region of interest, may be involved in the expression of a gene expression cascade, for example but not limited to a developmental cascade. In this embodiment, the nucleic acid sequence of interest is preferably associated with a gene that is involved at an early stage within the gene cascade, for example homeotic genes. Expression of a nucleic acid sequence of interest, for example a repressor of homeotic gene expression, represses the expression of a homeotic gene. Expression of the fusion protein that represses gene expression within the same plant, either via crossing, induction, temporal or developmental expression of the regulatory region, as described herein, de-represses the expression of the homeotic gene thereby initiating a gene cascade. Conversely, using the methods described herein, expression of an introduced (i.e. transgenic) homeotic gene may be activated in a selective manner, so that it is expressed outside of its normal developmental or temporal expression pattern, thereby initiating a cascade of developmental events. This may be achieved by targeting a chromatin remodelling protein to a desired homeotic gene as described herein.

Homeotic genes are well known to one of skill in the art, and include but are not limited to, transcription factor proteins and associated regulatory regions, for example controlling sequences that bind AP2 domain containing transcription factors, for example but not limited to, APETALA2 (a regulator of meristem identity, floral organ specification, seedcoat development and floral homeotic gene expression;

Jofuku *et al.*, 1994), CCAAT box-binding transcription factors (e.g. *LEC1*; WO 98/37184; Lotan, T. et al., 1998), or the controlling factor associated with *PICKLE*, a gene that produces a thickened, primary root meristem (Ogas, J. et al., 1997).

5 A nucleic acid sequence of interest or a coding region of interest, may also be involved in the control of transgenes across generations, or production of F1 hybrid plants with seed characteristics that would be undesirable in the parental line or progeny, for example but not limited to, oil seeds characterized as having reduced levels of sinapine biosynthesis within the oil-free meal. In this case, a nucleic acid
10 sequence of interest may be any enzyme involved in the synthesis of one or more intermediates in sinipine biosynthesis. An example, which is to be considered non-limiting, is caffeic o-methyltransferase (Acc# AAG51676), which is involved in ferulic acid biosynthesis. Other examples of genes of interest include genes that encode proteins involved in fiber, or glucosinolate, biosynthesis, or a protein involved
15 in the biosynthesis of a phytotoxin. Phytotoxins may also be used for plant selection purposes. In this non-limiting example, a nucleic acid sequence of interest may encode a protein that is capable of metabolizing a compound from a non-toxic form to a toxic form thereby selectively removing plants that express the nucleic acid sequence of interest. The phytotoxic compound may be synthesized from endogenous
20 precursors that are metabolized by the nucleic acid sequence of interest into a toxic form, for example plant growth regulators, or the phytotoxic compound may be synthesized from an exogenously applied compound that is only metabolized into a toxic compound in the presence of the nucleic acid sequence of interest. For example, which is not to be considered limiting, the nucleic acid sequence of interest may
25 comprise indole acetamide hydrolase (IAH), that converts exogenously applied indole acetamide (IAM) or naphthaline acetemide (NAM), to indole acetic acid (IAA), or naphthaline acetic acid (NAA), respectively. Over-synthesis of IAA or NAA is toxic to a plant, however, in the absence of IAH, the applied IAM or NAM is non-toxic. Similarly, the nucleic acid sequence of interest may encode a protein involved in
30 herbicide resistance, for example, but not limited to, phosphinothricin acetyl transferase, wherein, in the absence of the gene encoding the transferase, application of phosphinothricin, the toxic compound (herbicide) results in plant death. Other nucleic acid sequence of interest that encode lethal or conditionally lethal products may be found in WO 00/37660 (which is incorporated herein by reference).

The nucleic acid sequence of interest, the nucleotide sequence of interest or a coding region of interest, may be expressed in suitable eukaryotic hosts which are transformed by the nucleotide sequences, or nucleic acid molecules, or genetic constructs, or vectors of the present invention. Examples of suitable hosts include, but are not limited to, insect hosts, mammalian hosts, yeasts and plants. Suitable plant hosts include, but are not limited to agricultural crops including canola, *Brassica* spp., maize, tobacco, alfalfa, rice, soybean, wheat, barley, sunflower, and cotton.

The one or more chimeric genetic constructs of the present invention can further comprise a 3' untranslated region. A 3' untranslated region refers to that portion of a gene comprising a DNA segment that contains a polyadenylation signal and any other regulatory signals capable of effecting mRNA processing or gene expression. The polyadenylation signal is usually characterized by effecting the addition of polyadenylic acid tracks to the 3' end of the mRNA precursor. Polyadenylation signals are commonly recognized by the presence of homology to the canonical form 5'-AATAAA-3' although variations are not uncommon. One or more of the chimeric genetic constructs of the present invention can also include further enhancers, either translation or transcription enhancers, as may be required. These enhancer regions are well known to persons skilled in the art, and can include the ATG initiation codon and adjacent sequences. The initiation codon must be in phase with the reading frame of the coding sequence to ensure translation of the entire sequence.

Examples of suitable 3' regions are the 3' transcribed non-translated regions containing a polyadenylation signal of *Agrobacterium* tumor inducing (Ti) plasmid genes, such as the nopaline synthase (Nos gene) and plant genes such as the soybean storage protein genes and the small subunit of the ribulose-1, 5-bisphosphate carboxylase (ssRUBISCO) gene.

To aid in identification of transformed plant cells, the constructs of this invention may be further manipulated to include selectable markers. Useful selectable markers in plants include enzymes which provide for resistance to chemicals such as an antibiotic for example, gentamycin, hygromycin, kanamycin, or herbicides such as

phosphinothrycin, glyphosate, chlorosulfuron, and the like. Similarly, enzymes providing for production of a compound identifiable by colour change such as GUS (β -glucuronidase), or luminescence, such as luciferase or GFP, are useful.

5 Also considered part of this invention are transgenic eukaryotes, for example but not limited to plants containing the chimeric gene construct of the present invention. However, it is to be understood that the chimeric gene constructs of the present invention may also be combined with nucleic acid sequence of interest for expression within a range of eukaryotic hosts.

10

In instances where the eukaryotic host is a plant, methods of regenerating whole plants from plant cells are also known in the art. In general, transformed plant cells are cultured in an appropriate medium, which may contain selective agents such as antibiotics, where selectable markers are used to facilitate identification of transformed plant cells. Once callus forms, shoot formation can be encouraged by employing the appropriate plant hormones in accordance with known methods and the shoots transferred to rooting medium for regeneration of plants. The plants may then be used to establish repetitive generations, either from seeds or using vegetative propagation techniques. Transgenic plants can also be generated without using tissue cultures (for example, Clough and Bent, 1998).

20

The constructs of the present invention can be introduced into plant cells using Ti plasmids, Ri plasmids, plant virus vectors, direct DNA transformation, micro-injection, electroporation, etc. For reviews of such techniques see for example Weissbach and Weissbach, 1988; Geierman and Corey, 1988; and Miki and Iyer, 1997; Clough and Bent, 1998). The present invention further includes a suitable vector comprising the chimeric gene construct.

25

The DNA binding protein which is employed in the method of the present invention may be naturally produced in an organism other than a plant. For example, but not wishing to be considered limiting, a ROS repressor is encoded by a nucleotide sequence of bacterial origin and, as such the nucleotide sequence may be optimised, for example, by changing its codons to favour plant codon usage, by attaching a nucleotide sequence encoding a nuclear localisation signal (NLS), for example but not

30

limited to SV40 localization signal (see Robbins *et al.*, 1991; Rizzo, P., et al., 1991; which are incorporated herein by reference) in order to improve the efficiency of ROS transport to the plant nucleus to facilitate the interaction with its respective operator, or both optimizing plant codon usage. Addition of an NLS to a fusion protein comprising a binding domain, for example the ROS repressor binding domain, and a recruitment factor, may also ensure targeting of the fusion product to the nuclear compartment. Similar optimization may be performed for other DNA binding proteins of non-plant source, however, such optimization may not always be required. Other possible nuclear localization signals that may be fused to a DNA binding protein include but are not limited to those listed in Table1:

Table 1: nuclear localization signals

	Nuclear Protein	Organism	NLS	Ref
15	AGAMOUS	A	RienttnrqvtfcKRR (SEQ ID NO:13)	1
	TGA-1A	T	RRlaqnreaaRKsRIRKK (SEQ ID NO:14)	2
	TGA-1B	T	KKRaRlvnresaqIsRqRKK (SEQ ID NO:15)	2
	O2 NLS B	M	RKRKkesnresaRRsRyRK (SEQ ID NO:16)	3
	NIa	V	KKnqkhklkm-32aa-KRK (SEQ ID NO:17)	4
20	Nucleoplasmin	X	KRpaaatkagqaKKKKI (SEQ ID NO:18)	5
	NO38	X	KRIapdsaskvpRKKtR (SEQ ID NO:19)	5
	N1/N2	X	KRKteesplKdKdaKK (SEQ ID NO:20)	5
	Glucocorticoid			
	receptor	M,R	RkclqagmnleaRKtKK (SEQ ID NO:21)	5
25	a receptor	H	RKclqagmnleaRKtKK (SEQ ID NO:22)	5
	β receptor	H	RKclqagmnleaRKtKK (SEQ ID NO:23)	5
	Progesterone receptor	C,H,Ra	RKccqagmvlggRKfKK (SEQ ID NO:24)	5
	Androgen receptor	H	RKcyeagmtlgaRKIKK (SEQ ID NO:25)	5
	p53	C	RRcfevrvcacpgRdRK (SEQ ID NO:26)	5

⁺A, *Arabidopsis*; X, *Xenopus*; M, mouse; R, rat; Ra, rabbit; H, human; C, chicken; T, tobacco; M, maize; V, potyvirus.

References:

1. Yanovsky *et al.*, 1990

2. van der Krol and Chua, 1991
3. Varagona *et al.*, 1992
4. Carrington *et al.*, 1991
5. Robbins *et al.*, 1991

5

Incorporation of a nuclear localization signal into the fusion protein of the present invention may facilitate migration of the fusion protein, into the nucleus. Without wishing to be bound by theory, reduced levels of fusion proteins elsewhere within the cell may be important when the DNA binding portion of the fusion protein may bind analogue operator sequences within other organelles, for example within the mitochondrion or chloroplast. Furthermore, the use of a nuclear localization signal may permit the use of a less active promoter or regulatory region to drive the expression of the fusion protein while ensuring that the concentration of the expressed protein remains at a desired level within the nucleus, and that the concentration of the protein is reduced elsewhere in the cell.

Referring now to Figures 2A-C, there is shown aspects of an embodiment of the method of the present invention. Shown in Figure 2A are two constructs which have been introduced within a plant cell. The constructs comprise:

- 1) a first nucleotide sequence (10) comprising,
 - a) a nucleic acid sequence of interest (20) operatively linked to a first regulatory region (30);
 - b) an operator sequence (40) capable of binding a fusion protein (85, Figure 2B), and;
- 2) a second nucleotide sequence (60) comprising a second regulatory region (70) in operative association with a nucleotide sequence (80) encoding a fusion protein (85).

The fusion protein (Figure 2B; 85) encoded by nucleotide sequence (80) comprises

- a) a DNA binding protein (100), or a portion of a DNA binding protein capable of binding the operator sequence (40, Figure 2A), and;
- b) a recruitment factor protein (110), or a portion of a recruitment factor protein capable of binding a chromatin remodelling protein (120), for example but not limited to histone deacetylase, HDAC.

In the example shown in Figure 2 A-C, the operator sequence (40) is shown as being upstream from the regulatory region (30), however, the operator sequence may also be positioned downstream from the regulatory region (40), for example between the regulatory region (40) and the nucleic acid sequence of interest (20; see for example the constructs in Figure 5A-D), within the coding region of the nucleic acid sequence of interest (20), or downstream of the nucleic acid sequence of interest (20).

Referring now to Figure 2C, but without wishing to be bound by theory, transcription and translation of nucleotide sequence (60; Figure 2A) produces fusion protein (80; Figure 2B) which is capable of binding operator sequence (40; Figure 2A) and for example, histone deacetylase (120). Dual binding of histone deacetylase (120) to fusion protein (85) and fusion protein (85) to operator sequence (40) facilitates enzymatic deacetylation of histones (via bound histone deacetylase) in proximity of the nucleic acid sequence of interest (20) thereby causing repression of the nucleic acid sequence of interest (20).

The first (10) and second (60) nucleotide sequences may be placed within the same or within different vectors, genetic constructs, or nucleic acid molecules. Preferably, the first nucleotide sequence and the second nucleotide sequence are chromosomally integrated into a plant or plant cell. The two nucleotide sequences may be integrated into two different genetic loci of a plant or plant cell, or the two nucleotide sequences may be integrated into a singular genetic locus of a plant or plant cell. However, the second nucleotide sequence may be integrated into the DNA of the plant or it may be present as an extra-chromosomal element, for example, but not wishing to be limiting a plasmid. Furthermore, the first and second regulatory regions may be the same or different, and maybe active in a constitutive, temporal, developmental or inducible manner.

Referring now to Figures 3A-C, there is shown aspects of an alternate embodiment of the method of the present invention. Shown in Figure 3A are two constructs which have been introduced into a plant cell. The constructs comprise:

- 1) a first nucleotide sequence (10) comprising,
 - a) a nucleic acid sequence of interest (20) operatively linked to a regulatory region (30),

b) an operator sequence (40) capable of binding a fusion protein (85, Figure 3B), and;

2) a second nucleotide sequence (60) comprising a regulatory region (70) in operative association with a nucleotide sequence (80) encoding a fusion protein (85).

The fusion protein (85) encoded by nucleotide sequence (80) comprises,

a) a DNA binding protein (100), or a portion of a DNA binding protein capable of binding the operator sequence (40), and;

b) a recruitment factor protein (110), or a portion of a recruitment factor protein capable of binding a chromatin remodelling protein, for example but not limited, to free histone acetyltransferase (HAT) (120).

In the example shown in Figure 3 A-C, the operator sequence (40) is shown as being upstream from the regulatory region (30), however, the operator sequence may also be positioned downstream from the regulatory region (40), for example between the regulatory region (40) and the nucleic acid sequence of interest (20; see for example the constructs in Figure 5A-D), within the coding region of the nucleic acid sequence of interest (20), or downstream of the nucleic acid sequence of interest (20).

Referring now to Figure 3C, but without wishing to be bound by theory, transcription and translation of nucleotide sequence (80; Figure 3A) produces fusion protein (85; Figure 3B) which is capable of binding operator sequence (40; Figure 3A) and free histone acetyltransferase (120). Dual binding of histone acetyltransferase (120) to fusion protein (85) and fusion protein (85) to operator sequence (40) facilitates enzymatic acetylation of histones (via bound histone acetyltransferase) in proximity of the nucleic acid sequence of interest (20) thereby causing an increase in the transcription of the nucleic acid sequence of interest (20).

The present invention also relates to a method of enhancing the expression of a nucleic acid sequence of interest or enhancing the transcription of one or more selected nucleotide sequences by transforming a plant with one or more constructs comprising:

1) a first nucleotide sequence comprising,

a) a nucleic acid sequence of interest operatively linked to a regulatory region, and;

b) an operator sequence that interacts with a fusion protein;

2) a second nucleotide sequence comprising a regulatory region in operative association with a nucleotide sequence encoding a fusion protein comprising,

a) a DNA binding protein, or a portion of a DNA binding protein capable of binding the operator sequence, and;

b) a histone acetyltransferase (HAT) protein, or portion of a histone acetyltransferase protein which is capable of increasing histone acetylation;

and wherein binding of the fusion protein to the operator sequence increases histone acetylation in the proximity of the nucleic acid sequence of interest within the first nucleotide sequence thereby increasing the transcription of the nucleic acid sequence of interest.

These first and second nucleotide sequences may be placed within the same or within different vectors, genetic constructs, or nucleic acid molecules. Preferably, the first nucleotide sequence and the second nucleotide sequence are chromosomally integrated into a plant or plant cell. The two nucleotide sequences may be integrated into two different genetic loci of a plant or plant cell, or the two nucleotide sequences may be integrated into a singular genetic locus of a plant or plant cell. However, the second nucleotide sequence may be integrated into the DNA of the plant or it may be present as an extra-chromosomal element, for example, but not wishing to be limiting a plasmid, or transiently expressed, for example when using viral vectors, biolistics for transformation.

Preferably, the operator sequence is located in a nucleotide region that does not sterically hinder binding of transcription factors to the regulatory region, binding of the RNA polymerase to the nucleic acid sequence of interest, or migration of the polymerase along the DNA of the first nucleotide sequence, nucleic acid sequence of interest or both.

Referring now to Figures 4A-C, there is shown aspects of an embodiment of the method of the present invention. Shown in Figure 4A are two constructs which have been introduced within a plant cell. The constructs comprise:

1) a first nucleotide sequence (10) comprising,

a) a nucleic acid sequence of interest (20) operatively linked to a regulatory region (30),

b) an operator sequence (40) capable of binding a fusion protein (85),
and;

5 2) a second nucleotide sequence (60) comprising a regulatory region (70) in operative association with a nucleotide sequence (80) encoding a fusion protein (85).

The fusion protein (85) encoded by nucleotide sequence (80) comprises

10 a) a DNA binding protein (100), or a portion of a DNA binding protein capable of binding the operator sequence (40), and;

b) a histone acetyltransferase protein (130), or a portion of a histone acetyltransferase protein.

15 Referring now to Figure 4C, but without wishing to be bound by theory, transcription and translation of nucleotide sequence (80; Figure 4A) produces fusion protein (85; Figure 4B) which comprises an active HAT protein (130), or portion thereof. Binding of the fusion protein (85) to the operator sequence facilitates enzymatic acetylation of histones in proximity to the nucleic acid sequence of interest
20 (20) thereby enhancing the expression of a nucleic acid sequence of interest.

In the example shown in Figure 4 A-C, the operator sequence (40) is shown as being upstream from the regulatory region (30), however, the operator sequence may also be positioned downstream from the regulatory region (40), for example between
25 the regulatory region (40) and the nucleic acid sequence of interest (20; see for example the constructs in Figure 5A-D), within the coding region of the nucleic acid sequence of interest (20), or downstream of the nucleic acid sequence of interest (20).

Also contemplated by the present invention is the control of gene expression
30 accomplished through combinations of activator, effector and gene of interest constructs as outlined in Figures 29 A and B (see Example 6). With reference to Figure 29A, the expression of a gene of interest (reporter) is regulated using three constructs:

a reporter construct (or gene of interest construct),

an activator construct and
an effector construct.

The gene of interest construct includes a gene of interest, for example but not limited to a reporter gene (e.g. the *lacZ* gene), in operative association with a regulatory
5 element and an operator sequence.

The activator construct comprises a nucleic acid sequence encoding a recruitment factor protein, or a portion thereof, capable of binding a chromatin remodelling protein, fused with a nucleotide sequence encoding a DNA binding
10 protein, or a fragment thereof. The recruitment factor protein may be, for example but not limited to BnSCL1, bnKCP1 or an active fragment thereof; the DNA binding protein could be, for example but not limited to VP16 or GAL4 DNA Binding domain. In this case the activator construct produces a VP16-bNSCL1 fusion protein.

15 The effector plasmid includes a nucleic acid sequence encoding a chromatin remodelling factor, for example but not limited to HDA19, operatively associated with a regulatory element and a nucleic acid sequence encoding a nuclear localisation signal. The constructs are expressed in eukaryotes, for example plant, animal or yeast.

20 When the activator construct is co-expressed with the gene of interest (reporter) construct, the DNA binding sequence binds the operator sequence of the gene of interest construct. This results in modification in the expression of the gene of interest due to interaction of the activator protein within the transcriptional
25 machinery. In this example, the activator protein is fused to a recruitment factor protein, and the VP16-BnSCL1 fusion protein binds the Tet operator sequence of the gene activator construct resulting in increased expression of the gene of interest.

30 Co-expression of the effector construct, inconjunction with the gene of interest and activator constructs, results in synthesis of a chromatin remodelling factor, in this case HAD19, which associates with the recruitment factor protein, BnSCL1. Association of HDAC with the construct expressing the gene of interest, reduces expression of the gene of interest.

In a second aspect, the expression of a gene of interest is regulated using two constructs: a gene of interest (reporter)+activator and an effector construct as shown in Figure 29B. Expression of the reporter+activator construct results in an increased expression of the gene of interest due to binding of the activator portion of the construct to the operator sequence of the gene of interest construct. This association may be inhibited in the presence of tetracycline. As in the case outlined with reference to Figure 29A, above, co-expression of the effector construct results in reduced expression of the gene of interest due to association of HDAC to the activator-recruitment factor fusion protein (VP16-BnSCL1 fusion)

10

The present invention also provides for a method to regulate expression of a nucleic acid sequence of interest, wherein the nucleic acid sequence of interest comprises an endogenous sequence. In this embodiment, a nucleotide sequence comprising a regulatory region in operative association with a nucleotide sequence encoding a recruitment factor, or a portion thereof, that is known to interact with a factor that binds the nucleic acid sequence of interest, is expressed in the host. The recruitment factor protein, or a portion thereof is capable of binding a chromatin remodelling protein, for example but not limited, HDAC or HAT, and the recruitment factors also interacts with endogenous factors that bind the nucleotide sequence of interest (e.g. transcription factors). In this manner, expression of the recruitment factor in a temporal, tissue specific, or induced manner will result in the expression of the recruitment factor that binds the chromatin remodelling factor and transcription factor resulting in modulation of expression of the nucleic acid sequence of interest. A non-limiting example of this embodiment includes the expression of bnKCP1 and its interaction with HDAC and transcription factors ERF, SEBF or CBF.

25

Therefore, the present invention provides a method to regulate expression of an endogenous nucleic acid sequence of interest in a plant comprising:

- i) introducing into the plant a nucleotide sequence comprising, a regulatory region, operatively linked with a nucleotide sequence encoding a recruitment factor protein, the recruitment factor protein capable of binding an endogenous DNA binding protein, the endogenous DNA binding protein characterized in binding a segment of a DNA sequence of the endogenous nucleotide sequence of interest, and;

30

ii) growing the plant, wherein expression of the nucleotide sequence produces the recruitment factor thereby regulating expression of the endogenous nucleic acid sequence of interest.

5 An alternate embodiment of the present invention includes a method to regulate expression of an endogenous nucleic acid sequence of interest. In this example, a DNA binding protein, or a portion thereof, known to interact with the DNA of an endogenous nucleic acid sequence of interest is fused to a chromatin remodelling factor. Expression of the fusion protein permits the recruitment factor
10 portion of the fusion protein to interact or bind with a chromatin remodelling, for example but not limited to HDAC or HAT, and the DNA binding portion of the fusion protein binds the nucleotide sequence of interest. In this manner, expression of the fusion protein in a temporal, tissue specific, or induced manner will result in the expression of a recruitment factor that binds a chromatin remodelling factor and the
15 DNA of a nucleic acid sequence of interest, resulting in modulation of expression of the endogenous nucleic acid sequence of interest. Examples of DNA binding proteins, or portions thereof, that bind endogenous nucleic acid sequences of interest, which are not to be considered limiting, include ERF, SEBF or CBF. A non-limiting example of a recruitment factor is bnKCP1 or BnSCL1.

20

Therefore, the present invention also provides a method to regulate expression of an endogenous nucleic acid sequence of interest in a plant comprising:

i) introducing into the plant a nucleotide sequence comprising, a regulatory region, operatively linked with a nucleotide sequence encoding a fusion protein, the fusion
25 protein comprising,

- a) a DNA binding protein, or a portion thereof, capable of binding a segment of a DNA sequence of the endogenous nucleotide sequence of interest, and;
- b) a recruitment factor protein, or a portion thereof, capable of binding a chromatin remodelling protein; and

30 ii) growing the plant, wherein expression of the nucleotide sequence produces the fusion protein that regulates expression of the endogenous nucleic acid sequence of interest.

Also contemplated by the present invention is a method of increasing cold tolerance in a plant. The method comprises providing a plant having a nucleotide sequence of interest operatively linked to a first regulatory region; the nucleotide sequence of interest encodes bnKCP1, or a fragment thereof. The plant is maintained under conditions where bnKCP1 is expressed. In this manner, the plant expressing bnKCP1 is preconditioned for cold adaptation and exhibits increased cold tolerance.

By the term cold in the context of cold tolerance, it is meant a temperature in the range of about -10°C to about 10°C . An example of cold temperature, without wishing to be limiting, is a temperature in the range of about -8°C to about 8°C ; a further example is a temperature of about -10 to about -1°C .

Sequences of the present invention are listed in Table 2.

Table 2

SEQ ID NO:1	aa seq of wild-type ROS (<i>A. tumefaciens</i>)	Fig 1A (WT-ROS)
SEQ ID NO:2	Nucl seq synthetic ROS optimized for plant, with NLS	Fig 1B
SEQ ID NO:3	Consensus nucl seq of composite ROS	Fig 1C
SEQ ID NO:4	aa seq of synthetic ROS	Fig 1A, 1C
SEQ ID NO:5	ROS binding sequence	Fig 1E
SEQ ID NO:6	aa seq of NLS (PKKKRKV)	
SEQ ID NO:7	ROS operator sequence	
SEQ ID NO:8	IPT gene operator sequence	
SEQ ID NO:9	Operator sequence binding to ERF	
SEQ ID NO:10	Operator sequence binding to SEBF	
SEQ ID NO:11	Operator sequence binding to CBF	
SEQ ID NO:12	Operator sequence binding to CBF	
SEQ ID NO:13	NLS of AGAMOUS protein	Table 1, page 30
SEQ ID NO:14	NLS of TGA-1A protein	Table 1, page 30
SEQ ID NO:15	NLS of TGA-1B protein	Table 1, page 30
SEQ ID NO:16	NLS of O2 NLS B protein	Table 1, page 30
SEQ ID NO:17	NLS of N1a protein	Table 1, page 30
SEQ ID NO:18	NLS of nucleoplasmin protein	Table 1, page 30
SEQ ID NO:19	NLS of NO38 protein	Table 1, page 30
SEQ ID NO:20	NLS of N1/N2 protein	Table 1, page 30
SEQ ID NO:21	NLS of Glucocorticoid receptor	Table 1, page 30
SEQ ID NO:22	NLS of Glucocorticoid a receptor	Table 1, page 30
SEQ ID NO:23	NLS of Glucocorticoid b receptor	Table 1, page 30
SEQ ID NO:24	NLS of Progesterone receptor	Table 1, page 30
SEQ ID NO:25	NLS of Androgen receptor	Table 1, page 30

SEQ ID NO:26	NLS of p53 protein	Table 1, page 30
SEQ ID NO:27	VirC/VirD operator seq	Fig 1D
SEQ ID NO:28	ROS-OPDS, p74-315	
SEQ ID NO:29	ROS-OPDA, p74-315	
SEQ ID NO:30	ROS-OPUS, p74-316	
SEQ ID NO:31	ROS-OPUA, p74-316	
SEQ ID NO:32	ROS-OPPS, p74-309	
SEQ ID NO:33	ROS-OPPA, p74-309	
SEQ ID NO:34	ROS-OP1, p74-508	
SEQ ID NO:35	ROS-OP2, p74-508	
SEQ ID NO:36	tms2 promoter sense primer, p74-508	
SEQ ID NO:37	tms2 promoter anti-sense primer, p74-508	
SEQ ID NO:38	Actin2 promoter sense primer, p74-501	
SEQ ID NO:39	Actin2 promoter anti-sense primer, p74-501	
SEQ ID NO:40	p74-315 seq from EcoRV to ATG of GUS	
SEQ ID NO:41	p74-316 seq from EcoRV to ATG of GUS	
SEQ ID NO:42	p74-309 seq from EcoRV to ATG of GUS	
SEQ ID NO:43	p74-118 seq from EcoRV to ATG of GUS	
SEQ ID NO:44	Forward primer for HDA19 <i>A. thaliana</i> , pDBLeu-HDA19	
SEQ ID NO:45	Reverse primer for HDA19 <i>A. thaliana</i> , pDBLeu-HDA19	
SEQ ID NO:46	Forward primer for Gcn5 <i>Arabidopsis</i> , GST-Gcn5	
SEQ ID NO:47	Reverse primer for Gcn5 <i>Arabidopsis</i> , GST-Gcn5	
SEQ ID NO:48	Reverse primer for HDA19, GST-HDA19	
SEQ ID NO:49	Forward primer for bnKCP1, 1-80, 1-160 (generation of mutants)	
SEQ ID NO:50	Reverse primer for bnKCP1 1-160 (generation of mutants)	
SEQ ID NO:51	Reverse primer for bnKCP1 1-80 (generation of mutants)	
SEQ ID NO:52	Reverse primer for bnKCP1 (generation of mutants)	
SEQ ID NO:53	Forward primer for bnKCP1, 1-80 and 1-160 (in vivo assay and transactivation assay)	
SEQ ID NO:54	Reverse primer for bnKCP1 (in vivo assay and transactivation assay) and 81-215 (transactivation assay)	
SEQ ID NO:55	Reverse primer for bnKCP1 1-160 (in vivo assay and transactivation assay)	
SEQ ID NO:56	Reverse primer for bnKCP1 1-80 (in vivo assay and transactivation assay)	
SEQ ID NO:57	Forward primer for bnKCP1G188	
SEQ ID NO:58	Reverse primer for bnKCP1G188	
SEQ ID NO:59	Forward primer for bnKCP1 81-215 (transactivation assay)	
SEQ ID NO:60	Forward primer for entire coding region of bnKCP1	
SEQ ID NO:61	Reverse primer for entire coding region of bnKCP1	
SEQ ID NO:62	pat7 NLS (PLNKKRR)	
SEQ ID NO:63	aa seq of ROSR (ROS repressor)	Fig 1A
SEQ ID NO:64	aa seq of ROSAR (ROS repressor)	Fig 1A
SEQ ID NO:65	aa seq of MucR (ROS repressor)	Fig 1A
SEQ ID NO:66	VirC/VirD DNA binding site seq (1)	Fig 1D
SEQ ID NO:67	VirC/VirD DNA binding site seq (2)	Fig 1D
SEQ ID NO:68	ipt DNA binding site seq (1)	Fig 1D

SEQ ID NO:69	ipt DNA binding site seq (2)	Fig 1D
SEQ ID NO:70	Consensus DNA binding site seq	Fig 1D
SEQ ID NO:71	bnKCP aa seq	Fig 10A
SEQ ID NO:72	atKCP aa seq	Fig 10A
SEQ ID NO:73	atKCL1 aa seq	Fig 10A
SEQ ID NO:74	atKCL2 aa seq	Fig 10A
SEQ ID NO:75	bnKCP aa seq	Fig 10B
SEQ ID NO:76	ATF-1 aa seq	Fig 10B
SEQ ID NO:77	hyCREB aa seq	Fig 10B
SEQ ID NO:78	CREB aa seq	Fig 10B
SEQ ID NO:79	CREM aa seq	Fig 10B
SEQ ID NO:80	cCREM aa seq	Fig 10B
SEQ ID NO:81	aa seq of BnSCL1	Fig 20
SEQ ID NO:82	aa seq of atSCL15	Fig 20
SEQ ID NO:83	aa seq of lsSCR	Fig 20
SEQ ID NO:84	BnSCL1 sense primer	
SEQ ID NO:85	BnSCL1 anti-sense primer	
SEQ ID NO:86	BnIAA1 sense primer	
SEQ ID NO:87	BnIAA1 anti-sense primer	
SEQ ID NO:88	BnIAA12 sense primer	
SEQ ID NO:89	BnIAA12 anti-sense primer	
SEQ ID NO:90	Forward primer for <i>BnSCL1</i> , <i>BnSCL1</i> ¹⁻³⁵⁸ , <i>BnSCL1</i> ¹⁻²⁶¹ , <i>BnSCL1</i> ¹⁻²¹⁷ and <i>BnSCL1</i> ¹⁻¹⁴⁵ for pET-28b vector	
SEQ ID NO:91	Reverse primer for <i>BnSCL1</i> for pET-28b vector	
SEQ ID NO:92	Reverse primer for <i>BnSCL1</i> ¹⁻³⁵⁸ for pET-28b vector	
SEQ ID NO:93	Reverse primer for <i>BnSCL1</i> ¹⁻²⁶¹ for pET-28b vector	
SEQ ID NO:94	Reverse primer for <i>BnSCL1</i> ¹⁻²¹⁷ for pET-28b vector	
SEQ ID NO:95	Reverse primer for <i>BnSCL1</i> ¹⁻¹⁴⁵ for pET-28b vector	
SEQ ID NO:96	Forward primer for <i>BnSCL1</i> , <i>BnSCL1</i> ¹⁻³⁵⁸ , <i>BnSCL1</i> ¹⁻²⁶¹ , <i>BnSCL1</i> ¹⁻²¹⁷ and <i>BnSCL1</i> ¹⁻¹⁴⁵ for pPC86 vector	
SEQ ID NO:97	Forward primer for <i>BnSCL1</i> ¹⁴⁶⁻³⁵⁸ for PC86 vector	
SEQ ID NO:98	Forward primer for <i>BnSCL1</i> ²¹⁸⁻⁴³⁴ for PC86 vector	
SEQ ID NO:99	Reverse primer for <i>BnSCL1</i> and <i>BnSCL1</i> ²¹⁸⁻⁴³⁴ for PC86 vector	
SEQ ID NO:100	Reverse primer for <i>BnSCL1</i> ¹⁻³⁵⁸ for PC86 vector	
SEQ ID NO:101	Reverse primer for <i>BnSCL1</i> ¹⁻²⁶¹ for PC86 vector	
SEQ ID NO:102	Reverse primer for <i>BnSCL1</i> ¹⁻²¹⁷ for PC86 vector	
SEQ ID NO:103	Reverse primer for <i>BnSCL1</i> ¹⁻¹⁴⁵ for PC86 vector	
SEQ ID NO:104	aa seq of LXXLL motif (¹⁴⁸ LGSLL ¹⁵²)	

The above description is not intended to limit the claimed invention in any manner, furthermore, the discussed combination of features might not be absolutely necessary for the inventive solution.

The present invention will be further illustrated in the following examples. However it is to be understood that these examples are for illustrative purposes only, and should not be used to limit the scope of the present invention in any manner.

5 Examples

Materials and Methods

Plant Material

10

Wild type *Arabidopsis thaliana*, ecotype Columbia; seeds were germinated on RediEarth (W.R. Grace & Co.) soil in pots covered with window screens under green house conditions (~25°C, 16 hr light). Emerging bolts were cut back to encourage further bolting. Plants were used for transformation once multiple secondary bolts had
15 been generated.

Plant Transformation

Plant transformation was carried out according to the floral dip procedure
20 described in Clough and Bent (1998). Essentially, *Agrobacterium tumefaciens* transformed with the construct of interest (using standard methods as known in the art) was grown overnight in a 100ml Luria-Bertani Broth (10 g/L NaCl, 10 g/L tryptone, 5 g/L yeast extract) containing 50 µg/ml kanamycin. The cell suspension culture was centrifuged at 3000 X g for 15 min. The pellet was resuspended in 1L of
25 the transformation buffer (sucrose (5%), Silwet L77 (0.05%)(Loveland Industries). The above-ground parts of the *Arabidopsis* plants were dipped into the *Agrobacterium* suspension for ~1 min and the plants were then transferred to the greenhouse. The entire transformation process was repeated twice more at two day intervals. Plants were grown to maturity and seeds collected. To select for transformants, seeds were
30 surface sterilized by washing in 0.05% Tween 20 for 5 minutes, with 95% ethanol for 5 min, and then with a solution containing sodium hypochlorite (1.575%) and Tween 20 (0.05%) for 10 min followed by 5 washings in sterile water. Sterile seeds were plated onto either Pete Lite medium (20-20-20 Peter's Professional Pete Lite fertilizer (Scott) (0.762 g/l), agar (0.7%), kanamycin (50 µg/ml), pH 5.5) or MS medium (MS

salts (0.5X)(Sigma), B5 vitamins (1X), agar (0.7%), kanamycin (50 μ g/ml) pH 5.7). Plates were incubated at 20°C, 16hr light/ 8 hr dark in a growth room. After approximately two weeks, seedlings possessing green primary leaves were transferred to soil for further screening and analysis.

5

Example 1: Optimization of ROS protein coding region.

The *ros* nucleotide sequence is derived from *Agrobacterium tumefaciens* (SEQ ID NO:1; Figure 1A). Analysis of the protein coding region of the *ros* nucleotide
10 sequence indicates that the codon usage may be altered to better conform to plant translational machinery. The protein coding region of the *ros* nucleotide sequence was therefore modified to optimize expression in plants (SEQ ID NO:2; Figure 1B). The nucleic acid sequence of the ROS repressor was examined and the coding region modified to optimize for expression of the gene in plants, using a procedure similar to
15 that outlined by Sardana et al. (1996). A table of codon usage from highly expressed genes of dicotyledonous plants was compiled using the data of Murray et al. (1989). The *ros* nucleotide sequence was also modified (SEQ ID NO:2; Figure 1B) to ensure localization of the ROS repressor to the nucleus of plant cells, by adding a SV40 nuclear localization signal (Rizzo, P. et al., 1999; The nuclear localization signal
20 resides at amino acid positions 126-132; accession number AAF28270).

The *ros* gene is cloned from *Agrobacterium tumefaciens* by PCR. The nucleotide sequence encoding the ROS protein is expressed in, and purified from, *E. coli*, and the ROS protein used to generate an anti-ROS antiserum in rabbits using
25 standard methods (Sambrook et al.).

**Example 2: Constructs placing a nucleic acid sequence of interest under transcriptional control of regulatory regions that have been modified to contain
30 ROS operator sites, and preparation of reporter lines.**

p74-315: Construct for The Expression of GUS Gene Driven by a CaMV 35S Promoter Containing a ROS Operator Downstream of TATA Box (Figure 5(A)).

The *Bam*HI-*Eco*RV fragment of CaMV 35S promoter in pBI121 is cut out and replaced with a similar synthesized DNA fragment in which the 25 bp immediately downstream of the TATA box were replaced with the ROS operator sequence:

5

TATATTTCAATTTTATTGTAATATA (SEQ ID NO: 7).

Two complementary oligos, ROS-OPDS (SEQ ID NO:28) and ROS-OPDA (SEQ ID NO:29), with built-in *Bam*HI-*Eco*RV ends, and spanning the *Bam*HI-*Eco*RV region of CaMV35S, in which the 25 bp immediately downstream of the TATA box are replaced with the ROS operator sequence (SEQ ID NO: 7), are annealed together and then ligated into the *Bam*HI-*Eco*RV sites of CaMV35S.

10

15

ROS-OPDS: 5'-ATC TCC ACT GAC GTA AGG GAT GAC GCA CAA TCC CAC
TAT CCT TCG CAA GAC CCT TCC TCT ATA TAA TAT ATT
TCA ATT TTA TTG TAA TAT AAC ACG GGG GAC TCT AGA G-
3' (SEQ ID NO:28)

20

ROS-OPDA: 5'- G ATC CTC TAG AGT CCC CCG TGT TAT ATT ACA ATA
AAA TTG AAA TAT ATT ATA TAG AGG AAG GGT CTT GCG
AAG GAT AGT GGG ATT GTG CGT CAT CCC TTA CGT CAG
TGG AGA T-3' (SEQ ID NO:29)

25

The p74-315 sequence from the *Eco*RV site (GAT ATC) to the first codon (ATG) of GUS is shown below (TATA box - lower case in bold; the synthetic ROS sequence - bold caps; a transcription start site - ACA, bold italics; *Bam*HI site - GGA TCC; and the first of GUS, ATG, in italics; are also indicated):

30

5'-GAT ATC TCC ACT GAC GTA AGG GAT GAC GCA CAA TCC CAC TAT
CCT TCG CAA GAC CCT TCC TCT **ata taA** TAT ATT TCA ATT TTA TTG
TAA TAT AAc ACG GGG GAC TCT AGA GGA TCC CCG GGT GGT CAG TCC
CTT *ATG*-3'
(SEQ ID NO:40)

p74-316: Construct for The Expression of GUS Driven by a CaMV 35S Promoter Containing a ROS Operator Upstream of TATA Box (Figure 5(B)).

The *Bam*HI-*Eco*RV fragment of CaMV 35S promoter in pBI121 is cut out
 5 and replaced with a similar synthesized DNA fragment in which the 25 bp immediately upstream of the TATA box are replaced with the ROS operator sequence (SEQ ID NO: 7). Two complementary oligos, ROS-OPUS (SEQ ID NO:30) and ROS-OPUA (SEQ ID NO:31), with built-in *Bam*HI-*Eco*RV ends, and spanning the *Bam*HI-*Eco*RV region of CaMV35S, in which the 25 bp immediately upstream of the
 10 TATA box were replaced with a ROS operator sequence (SEQ ID NO: 7), are annealed together and then ligated into the *Bam*HI-*Eco*RV sites of CaMV35S.

ROS-OPUS: 5'-ATC TCC ACT GAC GTA AGG GAT GAC GCA CAA TCT ATA
 TTT CAA TTT TAT TGT AAT ATA CTA TAT AAG GAA GTT
 15 CAT TTC ATT TGG AGA GAA CAC GGG GGA CTC TAG AG -3'
 (SEQ ID NO:30)

ROS-OPUA: 5'- G ATC CTC TAG AGT CCC CCG TGT TCT CTC CAA ATG
 AAA TGA ACT TCC TTA TAT AGT ATA TTA CAA TAA AAT
 20 TGA AAT ATA GAT TGT GCG TCA TCC CTT ACG TCA GTG
 GAG AT-3' (SEQ ID NO:31)

The **p74-316** sequence from the *Eco*RV site (GAT ATC) to the first codon (ATG) of GUS is shown below (TATA box - lower case in bold; the synthetic ROS sequence -
 25 bold caps; a transcription start site - ACA, bold italics; *Bam*HI site - GGA TCC; the first codon of GUS, ATG -italics, are also indicated):

5'-GAT ATC TCC ACT GAC GTA AGG GAT GAC GCA CAA TCT ATA TTT
 CAA TTT TAT TGT AAT ATA **Cta tat a**AG GAA GTT CAT TTC ATT TGG
 30 AGA GAA **CAC** GGG GGA CTC TAG **AGG ATC** **CCC** GGG TGG TCA GTC CCT
 TAT G-3' (SEQ ID NO:41)

p74-309: Construct for The Expression of GUS Driven by a CaMV 35S Promoter Containing ROS Operators Upstream and Downstream of TATA Box (Figure 5(C)).

5 The *Bam*HI-*Eco*RV fragment of CaMV 35S promoter in pBI121 is cut out and replaced with a similar synthesized DNA fragment in which the 25 bp immediately upstream and downstream of the TATA box were replaced with two ROS operator sequences (SEQ ID NO: 7). Two complementary oligos, ROS-OPPS (SEQ ID NO:32) and ROS-OPPA (SEQ ID NO:33), with built-in *Bam*HI-*Eco*RV
10 ends, and spanning the *Bam*HI-*Eco*RV region of CaMV35S, in which the 25 bp immediately upstream and downstream of the TATA box are replaced with two ROS operator sequences, each comprising the sequence of SEQ ID NO: 7 (in italics, below), are annealed together and ligated into the *Bam*HI-*Eco*RV sites of CaMV35S.

15 ROS-OPPS: 5'-ATC TCC ACT GAC GTA AGG GAT GAC GCA CAA TCT *ATA TTT CAA TTT TAT TGT AAT ATA CTA TAT AAT ATA TTT CAA TTT TAT TGT AAT ATA ACA CGG GGG ACT CTA GAG*-3' (SEQ ID NO:32)

ROS-OPPA: 5'-G ATC CTC TAG AGT CCC CCG TGT TAT ATT ACA ATA AAA
20 TTG AAA TAT ATT ATA TAG *TAT ATT ACA ATA AAA TTG AAA TAT AGA TTG TGC GTC ATC CCT TAC GTC AGT GGA GAT*-3' (SEQ ID NO:33)

The **p74-309** sequence from the *Eco*RV site (GAT ATC) to the first codon (ATG) of
25 GUS is shown below (TATA box - lower case in bold; two synthetic ROS sequence - bold caps; a transcription start site - ACA, bold italics; *Bam*HI site - GGA TCC; the first codon of GUS, ATG -italics, are also indicated):

30 5'-GAT ATC TCC ACT GAC GTA AGG GAT GAC GCA CAA TCT ATA TTT CAA TTT TAT TGT AAT ATA Cta tat aAT ATA TTT CAA TTT TAT TGT AAT ATA *ACA* CGG GGG ACT CTA GAG GAT CCC CGG GTG GTC AGT CCC TTA TG-3' (SEQ ID NO:42)

p74-118 Construct for The Expression of GUS Driven by a CaMV 35S Promoter Containing three ROS Operators Downstream of TATA Box (Figure 5(D)).

5 The *Bam*HI-*Eco*RV fragment of CaMV 35S promoter in pBI121 is cut out and replaced with a similar synthesized DNA fragment in which a region downstream of the TATA box was replaced with three ROS operator sequences (SEQ ID NO:43). The first of the three synthetic ROS operator sequences is positioned immediately of the TAT box, the other two ROS operator sequence are located downstream of the
10 transcriptional start site (ACA). Two complementary oligos with built-in *Bam*HI-*Eco*RV ends were prepared as describe above for the other constructs were annealed together and ligated into the *Bam*HI-*Eco*RV sites of CaMV35S.

The **p74-118** sequence from the *Eco*RV site (GAT ATC) to the first codon
15 (ATG) of GUS is shown below (TATA box - lower case in bold; three synthetic ROS sequence - bold caps; a transcription start site - ACA, bold italics; *Bam*HI site - GGA TCC; the first codon of GUS, ATG -italics, are also indicated):

5'-GAT ATC TCC ACT GAC GTA AGG GAT GAC GCA CAA TCC CAC TAT
20 CCT TCG CAA GAC CCT TCC TCT **ata taA** TAT ATT TCA ATT TTA TTG
TAA TAT **AAC ACG** GGG GAC TCT AGA GGA TCC TAT ATT TCA ATT TTA
TTG TAA TAT AGC TAT ATT TCA ATT TTA TTG TAA TAT AAT CGA TTT
CGA ACC CGG GGT ACC GAA TTC CTC GAG TCT AGA GGA TCC CCG GGT
GGT CAG TCC CTT *ATG*-3' (SEQ ID NO:43)

25 **p76-508**: Construct for The Expression of The GUS Gene Driven by the tms2 Promoter Containing a ROS Operator (Figure 6(B)).

The tms2 promoter is PCR amplified from genomic DNA of *Agrobacterium*
30 *tumefaciens* 33970 using the following primers:

sense primer: 5'-TGC GGA TGC ATA AGC TTG CTG ACA TTG CTA GAA
AAG- 3' (SEQ ID NO:36)

anti-sense primer: 5'-CGG GGA TCC TTT CAG GGC CAT TTC AG- 3'(SEQ ID NO:37)

The 352 bp PCR fragment is cloned into the *EcoRV* site of pBluescript, and sub-cloned into pGEM-7Zf(+). Two complementary oligos, ROS-OP1 (SEQ ID NO:34) and ROS-OP2 (SEQ ID NO:35), containing two ROS operators (in italics, below), are annealed together and cloned into pGEM-7Zf(+) as a *Bam*HI/*Cla*I fragment at the 3' end of the *tms2* promoter. This promoter/operator fragment is then sub-cloned into pBI121 as a *Hind*III/*Xba*I fragment, replacing the CaMV 35S promoter fragment.

ROS-OP1: 5'-GAT CCT ATA TTT CAA TTT TAT TGT AAT ATA GCT *ATA TTT CAA TTT TAT TGT AAT ATA* AT-3' (SEQ ID NO:34)

ROS-P2: 5'-CGA TTA TAT TAC AAT AAA ATT GAA ATA TAG *CTA TAT TAC AAT AAA ATT GAA ATA* TAG-3'(SEQ ID NO:35).

As a control, p76-507 comprising a *tms2* promoter (without any operator sequence) fused to GUS (Figure 4(A)), is also prepared.

p74-501: Construct for The Expression of The GUS Gene Driven by The Actin2 Promoter Containing a ROS operator (Figure 7B)).

The Actin2 promoter is PCR amplified from genomic DNA of *Arabidopsis thaliana* ecotype Columbia using the following primers:

Sense primer: 5'- AAG CTT ATG TAT GCA AGA GTC AGC-3'(SEQ ID NO:38)

SpeI

Anti-sense primer: 5'- TTG ACT AGT ATC AGC CTC AGC CAT-3'(SEQ ID NO:39)

The PCR fragment is cloned into pGEM-T-Easy. Two complementary oligos, ROS-OP1 (SEQ ID NO:34) and ROS-OP2 (SEQ ID NO:35), with built-in *Bam*HI and *Cla*I sites, and containing two ROS operators, are annealed together and inserted into the

Actin2 promoter at the *Bgl*II/*Cla*I sites replacing the *Bgl*II/*Cla*I fragment. This modified promoter is inserted into pBI121 vector as a *Hind*III/*Bam*HI fragment.

As a control, p75-101, comprising an actin2 promoter (without any operator sequence) fused to GUS (Figure 7(A)), is also prepared.

The various constructs are introduced into *Arabidopsis*, as described above, and transgenic plants are generated. Transformed plants are verified using PCR or Southern analysis. Figure 8(A) show Southern analysis of transgenic plants comprising a first genetic construct, for example, p74-309 (35S-ROS operator sequence-GUS, Figure 5(C))

Example 3: Crossing of transgenic lines containing fusion constructs with transgenic lines containing GUS reporter constructs.

Transgenic *Arabidopsis* lines containing fusion constructs (second genetic constructs) are crossed with lines containing appropriate reporter (GUS) constructs (first genetic constructs). To perform the crossing, open flowers are removed from plants of the reporter lines. Fully formed buds of plants of the repressor lines are gently opened and emasculated by removing all stamens. The stigmas are then pollinated with pollen from plants of the repressor lines and pollinated buds are tagged and bagged. Once siliques formed, the bags are removed, and mature seeds are collected. Plants generated from these seeds are then used to determine the level of reporter gene (GUS) repression by GUS staining. Levels of GUS expression in the hybrid lines are compared to those of the original reporter lines. Plants showing a modified GUS expression levels are further characterized using PCR, Southern and Northern analysis.

Example 4: Preparation of a Chromatin Remodelling Factor

HDAC was used as an example of a chromatin remodelling factor that may be isolated from an organism. Transcription factors that recruit histone deacetylase (HDAC) to target promoters in *Brassica napus* were identified *in vivo* by screening a yeast two-hybrid library using the *Arabidopsis thaliana* HDA19 as bait. A cDNA

clone that encodes a novel protein, bnKCP1, containing a kinase-inducible domain (KID) was identified. Southern blot analysis indicated that the *bnKCP1* gene belongs to a small gene family of at least three members, and northern blot analysis showed that it was strongly expressed in stems, flowers, roots and immature siliques seeds, but not in leaf blades. *In vitro* protein binding assays showed that the protein is able to interact with both HDA19 and histone acetyltransferase (HAT) and that the KID domain is required for this interaction with HDA19 and HAT *in vitro*. When assayed *in vivo*, bnKCP1 exerted modest activation of transcription of a reporter gene in yeast.

The cAMP-responsive element (CRE) binding protein (CREB) binds to the CREB-binding protein (CBP) in response to extracellular stimuli that induce intracellular accumulation of secondary messengers Ca^{2+} and cAMP. The KID domain is highly conserved in the CREB family proteins, CREB, CREM and ATF-1 (Montminy, 1997). Each protein in this family has a serine phosphorylation site (RRPS¹³³) within the KID domain, which is recognised by protein kinase A (PK-A) that phosphorylates S¹³³. PK-A in turn is induced by outside stimuli that induce intracellular accumulation of Ca^{2+} and cAMP. CREB binding activity is regulated through S¹³³ phosphorylation, which leads to interaction of CREB with CBP. The KIX domain of CBP is required for interaction with the KID domain of CREB having a phosphorylated S¹³³ (see review Montminy, 1997). Interestingly, CBP possesses intrinsic HAT activity (Bannister and Kouzarides, 1996; Ogryzko et al., 1996) suggesting that recruitment of CBP to target promoters by the transcription activator CREB may contribute to the transcriptional activation of CRE-dependent genes by the involvement of histone acetylation at the genetic loci of target genes.

In *Arabidopsis*, a HAT gene encoding an ortholog of the yeast GCN5 was found to bind *in vitro* to two proteins similar to the yeast HAT-adaptor proteins ADA2, ADA2a and ADA2b (Stockinger et al., 2001). Moreover, the transcription activator CBF1 was found to bind to both HAT and ADA2, indicating that these proteins might be recruited to target cold-inducible genes by binding to CBF1 (Stockinger et al., 2001). The finding that the *Arabidopsis* ADA2 and GCN5 genes share similarity with their counterparts in yeast and humans suggests that chromatin remodelling complexes are conserved even among evolutionary distant organisms.

Experimental Procedures

Brassica napus L. cv Cascade (winter type), Westar (spring type) and DES010 (spring type) were used for the isolation of genomic DNA and total RNA. Leaves, flowers, stems, siliques and immature seeds were harvested from plants cultured in a controlled-environment greenhouse programmed for a photoperiod of 16h day and 8h night. Roots were obtained by culturing sterilized seeds in 0.8% agar plates containing ½ MS medium and 1% sucrose. For cold acclimation (4°C), abscisic acid (250 µM), drought and high salt (850 mM NaCl) treatments, four-leaf stage seedlings were treated and fourth fully expanded leaf blades were harvested as described by Gao et al. (2002). LaCl₃ and inomycin treatments were carried out by watering four-leaf stage plants with 20 mM LaCl₃ and 10 µM inomycin, respectively. Plants were covered with Saran Wrap to slow evaporation.

15 Yeast two-hybrid screening and cloning

A yeast two-hybrid cDNA library (Dr. Isobel Parkin, Agriculture and Agri-Food Canada Research Centre, Saskatoon) was constructed from poly(A) mRNA isolated from the above-ground parts of the four-leaf stage seedlings of *B. napus* L. cv. DH12075 and cloned into a GAL4 AD (activation domain) vector pPC86 using the SuperScript Plasmid System for cDNA Synthesis and Plasmid Cloning (GibcoL BRL).

To generate the pDBLeu-HDA19 construct, the entire coding region of *Arabidopsis thaliana* RPD3-type HDA19 cDNA (Accession # AF195547) was PCR amplified using PWO DNA polymerase (Roche) with a forward primer:

5'-GCGTCGACGATGGATACTGGCGGCAATTCGC-3' (SEQ ID NO: 44)

30 and a reverse primer:

5'-AGGCGGCCGCTTATGTTTTAGGAGGAAACGCC-3'. (SEQ ID NO: 45)

The identity of the PCR product was confirmed by DNA sequence analysis and inserted into the *SaII* and *NotI* sites of the Gal4 DB (DNA binding domain) vector pDBLeu in-frame with the GAL4 sequence and used as a bait to screen the *B. napus* cDNA library using PROQUEST Two-Hybrid System (GibcoL BRL).

5

Approximately 1×10^6 transformants were subjected to the two-hybrid selection on synthetic complete (SC) medium lacking leucine, tryptophan and histidine but containing 15 mM 3-amino-1,2,4-triazole (3AT®). The expression of the *HIS3* reporter gene allowed colonies to grow on the selective medium and the putative His⁺ (3AT®) positive transformants were tested for the induction of the two other reporter genes, *URA3* and *lacZ*. The positive colonies were reassessed by retransformation assays and the cloned cDNAs were identified by PCR and DNA sequence analysis.

10

15 Southern blot analysis

Total genomic DNA was isolated from the leaves of *B. napus* L. cv Westar using a modified CTAB (cetyltriethylammonium bromide) extraction method (Gao et al., 2002). Briefly, 10 µg of total genomic DNA was digested with *EcoRI*, *XbaI*, *HindIII*, *PstI*, *EcoRV* and *KpnI* restriction endonucleases, separated on a 0.8% agarose gel, transferred to Hybond-XL membranes (Amersham Pharmacia) and hybridized with the *bnKCP1* open reading frame (ORF) labeled with [α -³²P]dCTP using random primer labeling procedure. The DNA fragment to be used as a probe was isolated from a 0.8% agarose gel and purified with a QIAquick Gel Extraction Kit (Qiagen), and the probe was purified with a ProbeQuant G-50 Micro Column (Amersham Pharmacia). Hybridization was performed under high stringency conditions (Gao, M.-J. et al., 2002).

20

25

Northern blot analysis

30

Total RNA was isolated from the tissues of *B. napus* L. cv DES010. These included leaves and stems of four-leaf stage seedlings, flowers, immature siliques of adult plants, and roots of cultured seedlings as described by Gao et al. (2001). Probe

labelling, hybridization, washing and membrane stripping were performed as described above in the Southern blot analysis Section.

Expression and purification of recombinant Gcn5 and HDA19

5

The full coding regions of the *Arabidopsis* HAT, Gcn5 (Dr. M. Thomashow, Michigan State University, MI), and HDA19 (Accession # AF195547) were PCR amplified, sequence analyzed and inserted in-frame with the GST (glutathione s-transferase) into the *SalI* and *NotI* sites of vector pGEX-6P-2 (Amersham Pharmacia). The forward used for the amplification of Gcn5 was:

10

5'- GCGTCGACGATGGACTCTCACTCTTCCCACC-3' (SEQ IDNO: 46)

and the reverse primer for Gcn5 was:

15

5'-GCGCGGCCCGCCTATTGAGATTTAGCACCAGA-3' (SEQ IDNO: 47)

20

The forward primer for HDA19 was SEQ ID NO: 44, as listed above, and the reverse primer was:

5'-GCGCGGCCCGCTTATGTTTTAGGAGGAAACGC-3' (SEQ ID NO:48).

25

Recombinant pGEX-6P-2 plasmids were used to transform *E. coli* BL21-CodonPlus (DE3)-RP competent cells (Stratagene). Expression and purification under non-denaturing conditions were carried out as described by Gao et al. (Gao, M.-J. et al., 2002). The GST-Gcn5 and GST-HDA19 fusion proteins were analyzed by 7.5% SDS-PAGE (SDS-polyacrylamide gel electrophoresis) and western blotting with rabbit anti-GST-Pi polyclonal antibody (Chemicon) using ECL Western blotting analysis system (Amersham Pharmacia).

30

Generation of deletion mutants of bnKCP1

The two fragments, *bnKCP1*¹⁻¹⁶⁰ and *bnKCP1*¹⁻⁸⁰, and the entire coding region of *bnKCP1* DNA encoding amino acids 1-80, 1-160 and 1-215, respectively, were amplified by PCR and cloned into the *Hind*III and *Xho*I sites of pET-28-b vector (Novagen, Madison, WI). The primers used for the amplification were as follows:

5 *bnKCP1*¹⁻¹⁶⁰ (240bp): forward primer:

5'-GCAAGCTTATGGCAGGAGGAGGACCAACT-3' (SEQ ID NO:49),

reverse primer:

10

5'-CGCTCGAGCTCCTCCTCATCATTGTCTTC-3' (SEQ ID NO:50);

*bnKCP1*¹⁻⁸⁰ (480bp): forward primer:

15 5'-GCAAGCTTATGGCAGGAGGAGGACCAACT-3' (SEQ ID NO:49),

reverse primer

5'- CGCTCGAGATGAACAGGCAAAAGAGGCAT-3' (SEQ ID NO:51);

20

bnKCP1 (645bp): forward primer:

5'-GCAAGCTTATGGCAGGAGGAGGACCAACT-3'(SEQ ID NO:49),

25 reverse primer

5'- CGCTCGAGCTCaTCTTCTTCTTCTTCTTC-3' (SEQ ID NO:52).

In vitro protein interaction assays

30 Full-length *bnKCP1* and truncated mutant *bnKCP1*¹⁻¹⁶⁰ and *bnKCP1*¹⁻⁸⁰ proteins labeled with [³⁵S]methionine were produced using TNT-Quick Coupled Transcription/Translation System (Promega) according to the manufacture's instructions, with some modifications. A total of 1 µl of RNase inhibitor (GibcoL BRL) and 1 µl of protease inhibitors set (Roche) were added to the lysate reaction.

After incubation for 30 min at 30°C, RNase A was added to the reaction to a final concentration of 0.2 mg/ml and incubated for 5 min at the same temperature.

In vitro protein interaction was detected with GST pulldown affinity assays as described by Ahmad et al. (1999) with some modifications. Briefly, 6 µg of GST or 4 µg of GST-fusion protein was incubated with 5 µl of [³⁵S]Met-labeled translation mixture in 200 µl of bead-binding buffer (50 mM K-phosphate, pH 7.6, 450 mM KCl, 10 mM MgCl₂, 10% glycerol, 1% Triton X-100, 1% BSA and 1 µl of diluted 1:12 protease inhibitors set) for 1h at room temperature. After incubation, 20 µl of 50% slurry of glutathione-Sepharose beads containing 10 mg/ml of BSA and 4 µg of EtBr was mixed with the reaction mixture followed by gentle rotation for 1h at 4°C. After washing six times with 1.2 ml of bead-binding buffer without BSA and EtBr but containing 12 µl of protease inhibitors set (Roche), the bound proteins were eluted with 30 µl of 2 X SDS loading buffer, boiled for 2 min and analyzed by 12% SDS-PAGE. After electrophoresis, the gels were dried, treated with Amplify (Amersham Pharmacia) and subjected to fluorography.

In vivo protein assays

The entire region of *bnKCP1* and the two fragments, *bnKCP1*¹⁻¹⁶⁰ and *bnKCP1*¹⁻⁸⁰, were PCR amplified and cloned into the *SalI* and *NotI* sites of pPC86 vector (GibcoL BRL) in-frame with the GAL4 AD sequences to generate constructs pPC86-*bnKCP1*, pPC86-*bnKCP1*¹⁻¹⁶⁰ and pPC86-*bnKCP1*¹⁻⁸⁰. The oligonucleotide primers used in PCR amplification were as follows:

25

bnKCP1, *bnKCP1*¹⁻¹⁶⁰ and *bnKCP1*¹⁻⁸⁰ forward primer

5'- GCGTCGACGATGGCAGGAGGAGGACCAACT-3' (SEQ ID NO:53)

bnKCP1 reverse primer

30

5'- GCGCGGCCGCTCATCTTCTTCTTCTTCCTC -3' (SEQ ID NO:54)

*bnKCP1*¹⁻¹⁶⁰ reverse primer

5'- GCGCGGCCGCTGAACAGGCAAAAGAGGCAT -3' (SEQ ID NO:55)

*bnKCP1*¹⁻⁸⁰ reverse primer

5'- GCGCGGCCGCCTCCTCCTCATCATTGTCTTC-3' (SEQ ID NO:56)

For in vivo protein interaction assays, the MaV203 yeast cells carrying the reporter gene *lacZ* and the construct pDBLeu-HDA19, in which the HDA19 was fused in-frame with GAL4DB, were transfected with either of the plasmids pPC86-*bnKCP1*, pPC86-*bnKCP1*¹⁻¹⁶⁰ and pPC86-*bnKCP1*¹⁻⁸⁰ or the vector alone. The expression of *lacZ* reporter gene was quantified by measuring the β -galactosidase activity using chlorophenol red- β -D-galactopyranoside (CPRG) according to the manufacturer's instructions (GibcoL BRL). Two yeast control strains A and B (GibcoL BRL) were used as negative and positive controls, respectively.

Site-directed mutagenesis (SDM)

The QuickChange site-directed mutagenesis kit (Stratagene) was used to replace the serine residue in the PK-A phosphorylation site (RRPS¹⁸⁸) within the KID domain with a glycine residue to generate *bnKCP1G*¹⁸⁸ according to the manufacturer's instructions. The two oligonucleotide primers used in SDM were as follows:

20

forward primer:

5'- GATGTTCTTGCGAGGAGACCAGGATTCAAGAACAGAGCATTGAAG-3'
(SEQ ID NO:57)

25

reverse primer:

5'- CTTCAATGCTCTGTTCTTGAATCCTGGTCTCCTCGCAAGAACATC-3'
(SEQ ID NO:58)

30

The introduced mutation was confirmed by DNA sequencing, and the mutated *bnKCP1G*¹⁸⁸ was cloned into the *HindIII* and *XhoI* sites of pET-28b vector to generate pET-*bnKCP1G*¹⁸⁸, which was then used for in vitro protein interaction assays as described above.

Transactivation assay using yeast one-hybrid system

Effector plasmids pDBLeu-bnKCP1¹⁻¹⁶⁰, pDBLeu-bnKCP1¹⁻⁸⁰, pDBLeu-bnKCP1⁸¹⁻²¹⁵ and pDBLeu-bnKCP1 were constructed by ligating the PCR-amplified fragments Δ bnKCP1¹⁻¹⁶⁰, Δ bnKCP1¹⁻⁸⁰, Δ bnKCP1⁸¹⁻²¹⁵ and the coding region of bnKCP1 into the *Sall/NotI* sites of pDBLeu vector (GibcoL BRL) in-frame with the GAL4 DB sequence. The oligonucleotide primers for PCR amplification were as follows:

10 *bnKCP1* forward primer

5'-GCGTCGACGATGGCAGGAGGAGGACCAACT-3' (SEQ ID NO: 53),

bnKCP1 reverse primer

5'-GCGCGGCCGCCTCATCTTCTTCTTCTCCTC-3' (SEQ ID NO:54)

15

*bnKCP1*¹⁻¹⁶⁰ forward primer

5'-GCGTCGACGATGGCAGGAGGAGGACCAACT-3' (SEQ ID NO: 53),

*bnKCP1*¹⁻¹⁶⁰ reverse primer

20 5'- GCGCGGCCGCATGAACAGGCAAAGAGGCAT -3' (SEQ ID NO:55)

*bnKCP1*¹⁻⁸⁰ forward primer

5'-GCGTCGACGATGGCAGGAGGAGGACCAACT-3' (SEQ ID NO: 53),

25 *bnKCP1*¹⁻⁸⁰ reverse primer

5'- GCGCGGCCGCCTCCTCCTCATCATTGTCTTC -3' (SEQ ID NO:56)

*bnKCP1*⁸¹⁻²¹⁵ forward primer

5'-GCGTCGACGCTAGGGTTGGCTTCATTGAGA-3' (SEQ ID NO:59)

30

*bnKCP1*⁸¹⁻²¹⁵ reverse primer

5'-GCGCGGCCGCCTCATCTTCTTCTTCTCCTC-3' (SEQ ID NO:54)

The three reporter genes, *lacZ*, *HIS3* and *URA3*, which were chromosomally integrated in the genome of MaV203 yeast cells were driven by unrelated promoters containing GAL4 DNA binding sites (GibcoL BRL). For transient assays, the effector constructs or the negative control vector pDBLeu were transferred to the MaV203 yeast cells. The β -galactosidase activity was measured using CPRG (chlorophenol red- β -D-galactopyranoside) according to the manufacturer's instructions (GibcoL BRL). The MaV203 cells containing plasmids pDBLeu-HDA19 and pPC86-bnKCP1 were used as the positive control. In addition, we used three yeast control strains A, B, and C (GibcoL BRL), which were developed to contain plasmid pairs expressing fusion proteins with none, weak and moderately strong protein-protein interaction strength, respectively.

Transient expression of the GUS-bnCKP1 fusion protein

The oligonucleotide primers for PCR amplification of the entire coding region of *bnKCP1* were as follows:

forward primer

5'-GCGAATTCATGGCAGGAGGAGGACCAACT-3' (SEQ ID NO:60),

reverse primer

5'-CGGAGCTCCTCaTCTTCTTCTTCTTCTTC-3' (SEQ ID NO:61).

The amplified sequence was cloned into the *EcoRI* and *ScaI* sites of the binary vector p79-637, a derivative of the vector CB301, to generate construct p77-132, which contains GUS-bnKCP1 fusion under control of the CaMV35S promoter. The onion epidermal layers were transformed with *Agrobacterium* culture prepared as described by Kapila et al (1997) with a few modifications. Briefly, the onion inner epidermal layers were peeled, placed into a culture of *Agrobacterium tumefaciens* strain GV3101 pMP90 containing either p79-637, for GUS expression only, or p77-132 and subjected to continuous vacuum of -85 kPa for 20 min. After incubation at 22°C under 16h light condition for 7 days the tissues were placed into GUS staining solution [100 mM potassium phosphate buffer (pH 7.4), 1 mM EDTA, 0.5 mM $K_3Fe(CN)_6$, 0.5 mM $K_4Fe(CN)_6$, 0.1% Triton X-100, 1 mM 5-bromo-4-chloro-3-

indolyl- β -D-glucuronide (X-gluc)], vacuum infiltrated for 20 min at -85 kPa and incubated overnight at 37°C. To determine the intercellular location of nuclei, tissues were stained with the nucleus-specific 4',6-diamidino-2-phenylindole (DAPI) solution (14 μ g/ml DAPI, 0.1 x PBS, 90% glycerol) (Varagona et al, 1991) and viewed under a
5 Zeiss microscope using both fluorescence and bright-field optics.

Cloning of the *B. napus* KCP protein

To identify proteins that interact with HDA19 in *B. napus*, the ORF of
10 *Arabidopsis* HDA19 fused to the yeast Gal4 DNA binding domain was used as bait in a yeast two-hybrid screening of a *B. napus* cDNA library linked to the yeast Gal4 activation domain. Several positive clones were obtained on the basis of the induction of three yeast reporter genes, *HIS3*, *URA3* and *lacZ* and DNA sequence analysis. One of these clones (963 bp), pPC86-bnKCP1, encodes a 23.5 kDa protein that contains a
15 putative kinase-inducible domain (KID)-like motif, and hence was designated *bnKCP1* (*B. napus* KID-containing protein 1).

Alignment of deduced amino acid sequences indicated that bnKCP1 shares an 82% amino acid identity with atKCP, an *Arabidopsis* unknown 26.6 kDa protein
20 (AY088175, At5g24890). It also shares high similarity in the conserved region of approximately 55 amino acids (GKSKS domain) with other two other atKCP-like *Arabidopsis* unknown proteins, atKCL1 (CAB45910, At4g31510) and atKCL2 (AAD23890, At2g24550) (Figure10A).

25 To estimate the *bnKCP1* gene copy number in *Brassica napus* we carried out Southern blot analysis on of total genomic DNA digested with restriction endonucleases using the entire open reading frame of *bnKCP1* for probing under high stringency conditions (Figure. 12). Digestion with *EcoRI* (EI), *HindIII* (H), *PstI* (P), *EcoRV* (EV) and *KpnI*, none of which has a cutting site within *bnKCP1*, resulted in
30 the detection of three bands, whereas digestion with *XbaI* generated six bands, because of the existence of an internal cutting site for *XbaI* in the *bnKCP1* gene. This result indicates that *bnKCP1* belongs to a small gene family of three members in the *Brassica. napus* genomes.

Structural features of the bnKCP1 protein

The ORF of *bnKCP1* gene codes for a 215 amino acid polypeptide product of polypeptide with several functional motifs (Figure 11). Based on a search of protein localization sites using PSORT program (<http://psort.nibb.ac.jp>; Nakai and Kanehisa, 1992), bnKCP1 appears to be is a nuclear protein containing a pat7 nuclear localization signal (NLS) PLNKKRR (SEQ ID NO: 62; Figure 10A, residues 127-133). Three acidic motifs (I, II and III) and a serine-rich (S-rich) region (residues 34-58) may function in transcription activation by bnKCP1 (Johnson et al., 1993). The charged motif GKSKS (residues 88-143), which is conserved in all four protein orthologs (Fig. 10A), is rich in basic residues and encompasses the NLS. This suggests that this domain serve the may function of a DNA-binding motif (Figure 11). In addition, bnKCP1 is extremely hydrophilic (Figure 11) suggesting bnKCP1 is an active element in the nuclear matrix.

15

Amino acid sequence analysis also revealed that bnKCP1 has a KID-like motif (residues 161-215, Figure 10A) with alpha structure at its C-terminal region (Figure 11). The KID is highly conserved in mammalian CREB protein family and functions in transactivation and protein binding (Montminy et al., 1997). The KID in bnKCP1 has a high similarity to the CREB family member ATF-1 (Figure 10B, C) and contains a protein kinase A (PK-A) phosphorylation site (RRPS) that is conserved in the CREB family of proteins (Figure 10B).

20

Interaction of bnKCP1 with HDA19 and Gcn5

25

To confirm the interaction detected in the yeast two-hybrid system between the bnKCP1 protein and HDA19, GST pulldown assays were performed using *in vitro* translated bnKCP1 labeled with [³⁵S]Methionine. The bnKCP1 protein was tested for its ability to interact with recombinant GST-HDA19 or GST-Gcn5 fusions expressed in *E. coli*.

30

As shown in Figure 13B, bnKCP1 bound to both GST-HDA19 and GST-Gcn5 fusion proteins, but not to GST alone. To reassess the interaction of bnKCP1 with Gcn5 *in vivo*, the ORF of the *Arabidopsis* Gcn5 was fused to the yeast Gal4 DNA

binding domain in pDBLeu vector and then used to transform yeast MaV203 cells expressing *bnKCP1* fused to the yeast Gal4 activation domain in pPC86 vector. The transformants showed induction of the three reporter genes, *HIS3*, *URA3* and *lacZ* at a relatively lower level when compared with the induction levels in transformants with *bnKCP1* and HDA19 (data not shown). This result suggests that *bnKCP1* has a preference for binding to HDA19 *in vivo*.

To map the protein binding domain of the *bnKCP1* protein, two C-terminal truncated mutants of *bnKCP1* lacking the KID domain were constructed. These are $\Delta\text{bnKCP1}^{1-160}$ (residues 1-160) and $\Delta\text{bnKCP1}^{1-80}$ (residues 1-80) as shown in Figure 13A. These truncated mutants were assayed for *in vitro* interaction with the recombinant GST-HDA19 or GST-Gcn5 fusion proteins. The two mutant proteins, $\Delta\text{bnKCP1}^{1-160}$ and $\Delta\text{bnKCP1}^{1-80}$, exhibited no interaction with either GST-HDA19 or GST-Gcn5 indicating that the KID domain of *bnKCP1* protein is essential for binding to HDA19 and Gcn5.

The importance of the KID domain for protein binding was also determined *in vivo* using the yeast two-hybrid system. MaV203 yeast cells were co-transformed with pDBLeu-HDA19, and either pPC86-*bnKCP1*, pPC86- bnKCP1^{1-160} , pPC86- bnKCP1^{1-80} or pPC86 alone (Figure 13C). β -galactosidase activity was reduced by at least 50% when pDBLeu-expressing cells were transformed with plasmids expressing either $\Delta\text{bnKCP1}^{1-160}$ or $\Delta\text{bnKCP1}^{1-80}$, both of which lacked KID, as compared to the full-length *bnKCP1*. This finding demonstrates that KID is critical for *bnKCP1* interaction with HDA19 *in vivo*.

To investigate the importance of S¹⁸⁸ for *bnKCP1* interaction with HDA19, the S¹⁸⁸ residue in *bnKCP1* was mutated to G¹⁸⁸ using site-directed mutagenesis to obtain *bnKCPG*¹⁸⁸ protein (Fig 14). This mutated protein was then tested for binding to HDA19 *in vitro*. When compared to *bnKCP1*, the mutated protein, *bnKCPG*¹⁸⁸, has significantly reduced binding to HDA19 (Fig 14). This confirms that S¹⁸⁸ is essential for optimal interaction between *bnKCP1* and HDA19.

Expression pattern of the *bnKCP1* gene

The expression pattern of the *bnKCP1* gene was analyzed by Northern blot analysis of total RNA extracted from various organs of *B. napus*. As shown in Figure 15, two transcripts of similar sizes appear to hybridize to *bnKCP1*, indicating the existence of two homologs of *bnKCP1* mRNAs in *B. napus*. These transcripts accumulated at high levels in flowers, roots, stems and immature siliques, and at low levels in leaves with petioles, but were undetectable in leaf blades (Figures 15, 16).

To investigate the pattern of *bnKCP1* expression in response to environmental stress conditions, total RNA was isolated from leaf blades of four-leaf stage *B. napus* seedlings that were exposed to low temperature (4°C), drought, high salt (NaCl), and ABA treatment, and used for northern blot analysis using a *bnKCP1* probe. Transcripts of both *bnKCP1* homologs accumulated in leaves in response to cold treatment. The lower size (~0.9 kb) transcript appears to be induced within 4h of cold treatment and about 4h earlier than the higher molecular weight (1.1kb) one (Figure 16A). The *bnKCP1* transcript appears to accumulate in response to low temperature (4°C), but expression was not detected in leaf blades of plants grown under drought condition for up to 4 days, high salt stress for up to 11 days, or upon exogenous application of ABA for up to 8 hours (data not shown). Expression of *bnKCP1* in the stems, was repressed upon cold treatment (Figure 16A), suggesting the response of *bnKCP1* transcript to low temperature or the recruitment of HDA19 and HAT to the promoters of cold responsive genes is organ specific.

Since cold acclimation is known to be associated with elevated levels of intracellular concentrations of Ca^{2+} , tests to determine whether Ca^{+2} has any effect on *bnKCP1* expression were performed. Northern blot analysis was performed using total RNA isolated from leaves of seedlings treated with Ca^{2+} channel blocker LaCl_3 and the Ca^{2+} ionophore inomycin at room temperature. Induction of *bnKCP1* expression upon treatment with inomycin was rapid (2 hrs) but short-lived. The *bnKCP1* transcript was undetectable in leaves of seedlings treated with the LaCl_3 (Figure 16B).

Transcription activation by *bnKCP1*

To determine whether bnKCP1 functions as a transcription activator, transactivation experiments were carried out in yeast. A yeast strain carrying three reporter genes, *lacZ*, *HIS3* and *URA3*, driven by promoters fused to GAL4 DNA binding sites and independently integrated into the yeast genome were transfected with the effector plasmid pDBLeu-bnKCP1 comprising *bnKCP1* fused to the GAL4 DB under the control of ADH promoter. The effector stimulated β -galactosidase activity about 8-fold relative to either GAL4 DB alone or yeast control strain A that contains plasmid pairs expressing fusion proteins without protein-protein interaction. A similar result was obtained when the yeast cells were co-transformed with the positive control plasmids pDBLeu-HDA19 and pPC86-bnKCP1 identified by the two-hybrid selection (Figure 17A). Reporter genes *HIS3* and *URA3* were also modestly activated by bnKCP1 (data not shown). Based on these findings, it can be concluded that bnKCP1 exerts transactivation of target genes in *Brassica napus*.

These data demonstrate the isolation of a plant protein that contains a putative KID domain, which interacts with both GCN5 (HAT) and HDA19. *bnKCP1* was highly expressed in all organs tested, except leaf blades, where it was induced in response to cold acclimation, which also resulted in repressing its expression in stems. Furthermore, bnKCP1 exerts transcription activation of a reporter gene when tested in yeast, indicating the function of bnKCP1 as a transcription factor.

To map the transactivation domain of the bnKCP1 protein, one N-terminal truncated mutant of bnKCP1, Δ bnKCP1⁸¹⁻²¹⁵, and two C-terminal truncated mutants, Δ bnKCP1¹⁻¹⁶⁰ and Δ bnKCP1¹⁻⁸⁰ (Fig 17B) were generated and used in *in vivo* transactivation assays in yeast. As shown in Fig 17C, deletion of the KID or GKSKS domains had no significant influence on β -galactosidase activity, whereas deletion of the N-terminus resulted in approximately 65% reduction in β -galactosidase activity.

Nuclear localization of the bnKCP1 protein

Structural and functional analyses showed bnKCP1 to have features typical of transcription factors. To confirm that bnKCP1 is a nuclear proteins, onion epidermal cell layers were transformed with constructs for the expression of either a GUS-bnKCP1 fusion or GUS alone (Fig 18). Using an Agrobacterium-mediated

transformation method (Kapila et al, 1997). As shown in Figure 18, GUS activity was visualized exclusively in the cytoplasm of control onion cell layers. In contrast, a blue precipitate was localized in the nuclei of cell layers transformed with GUS-bnKCP1 fusion construct, although there was still a certain amount of cytoplasm staining, indicating that at least some targeting to the nucleus occurs with the fusion protein.

Expression of *bnKCP1* is organ-specific

The *bnKCP1* gene appears to be part of a multigene family of three members based on Southern blot hybridization. Northern blot analyses showed that two members of this gene family are of similar transcript sizes and expression patterns. This is consistent with information about bnKCP1 orthologs in *Arabidopsis*, where there are one *atKCP* (At5g24890) and two *atKCP-like* members (At4g31510 and At2g24550) of similar sizes ranging from 1kb to 1.2kb. Northern blot analysis revealed that *bnKCP1* mRNA was expressed in flowers, roots, stems and immature siliques (Figure 14). The transcript accumulation, however, was undetectable in leaf blades of *B. napus* seedlings, suggesting tissue/organ-specific expression of the *bnKCP1* gene. However, cold treatment induced bnKCP1 expression in leaves, but repressed it in stems.

The KID domain is conserved in *bnKCP1*

Structural analysis of the bnKCP1 protein revealed that it was a strongly hydrophilic protein (23.5 kDa, pI 4.2) and had characteristic features of a transcription factor, including a putative nuclear localization signal (NLS), a putative basic DNA binding domain, putative acidic activation domains and a protein-protein interaction domain.

An important structural feature of bnKCP1 is the presence of a putative kinase-inducible domain (KID) with alpha secondary structure at the C-terminal region. The KID domain was first identified in mammalian CREB family members CREB, CREM and ATF-1. The KID domain in mammalian CREB is involved in at least two functions, interaction with CBP/p300 and the site for protein kinase A (PK-A) phosphorylation of S¹³³ (Montminy et al., 1997; Gonzalez et al., 1991; Quinn,

1993; Chrivia *et al.*, 1993; Shaywitz *et al.*, 2000). Similar to its counterpart in CREB, which is involved in protein binding, the KID domain of bnKCP1 is required for binding to both HDA19 and GCN5 *in vitro* and *in vivo*. The ability of bnKCP1 to interact with HDA19 indicates that bnKCP1-mediated transcription control requires direct or indirect recruitment of these transcription regulators to promoter regions of target genes regulated by bnKCP1.

Phosphorylation of CREB at Ser¹³³ is required for the interaction of CREB via its KID with CBP and for CREB to activate transcription in response to some extracellular stimuli (Gonzalez *et al.*, 1989; Chrivia *et al.*, 1993). The KID domain in bnKCP1 also contains a putative PK-A phosphorylation site (RRPS¹⁸⁸), which corresponds to the RRPS¹³³ in mammalian CREB.

Intracellular level of Ca⁺² affect *bnKCP1* expression

In mammalian cells, outside stimuli that increase intracellular concentrations of Ca²⁺ or cAMP induce the expression of not only PK-A, but also the *CREB* gene (Meyer *et al.*, 1993). Therefore, tests to determine whether conditions that increase intracellular concentrations of Ca²⁺ would induce *bnKCP1* expression were done. *B. napus* seedlings were subjected to one of two treatments, cold or ionomycin. Cold acclimation is known to increase intracellular Ca²⁺ concentrations (Monroy and Dhindsa, 1995; Knight *et al.*, 1996), and ionomycin is a known calcium ionophore that increases Ca²⁺ influx (Hurley *et al.*, 1996). These treatments resulted in the induction of *bnKCP1* expression to varying degrees (Figure 16), which indicated that *bnKCP1* is induced by high intracellular Ca⁺² concentrations.

These results suggest a molecular mechanism by which *bnKCP1* functions as a transcription factor to regulate gene expression by recruiting HDAC to the promoter regions of target genes.

Example 5: Characterization of the recruitment factor SCL1 and its interaction with the chromatin remodelling factor HDA19

To search for transcription factors additional that recruit histone deacetylase (HDAC) to target promoters in *Brassica napus*, a yeast two-hybrid library was screened using the *Arabidopsis thaliana* HDA19 as bait. This screening resulted in the isolation of a cDNA clone that encodes a SCARECROW-like protein, BnSCL1, which contains a number of putative functional motifs typical of the GRAS family of transcription factors. Southern blot analysis indicated that the *BnSCL1* gene belongs to a small gene family of about three members. *In vitro* and *in vivo* protein interaction assays revealed that BnSCL1 interacts physically with HDA19 through the VHIID domain. BnSCL1 also exerted strong transactivation of the *lacZ* reporter gene in yeast, and both N- and C-terminal regions are critical for the transient expression. Quantitative RT-PCR and RNA gel blot analysis showed that *BnSCL1* was expressed at relatively high level in roots, moderate level in flowers, weak in mature leaves and stems, and barely detectable in immature siliques. The accumulation of *BnSCL1* transcript was regulated by 2,4-D in shoots, roots and matured leaves. Furthermore, the response of *BnSCL1* to 2,4-D was modulated by histone deacetylase HDA19. These results strongly suggest a molecular mechanism by which BnSCL1 functions as a transcription factor to regulate gene expression by recruiting HDAC to the promoter regions of auxin-responsive genes.

Plant materials

Brassica napus L. cv. DH12075 was used for DNA and total RNA isolation. Leaves, flowers, stems, siliques and immature seeds were harvested from plants cultured in a controlled-environment greenhouse programmed for a photoperiod of 16h day and 8h night. Roots were obtained by culturing sterilized seeds in 0.8% agar plates containing ½ MS medium (Murashige and Skoog, 1962) and 1% sucrose.

Tissue treatment

In exogenous applied auxin treatments, four-leaf stage seedlings grown at 20°C were treated with a foliar spray containing 1mM 2,4-D and 50 mM sodium phosphate, pH 7.5. The four leaves were collected at 30 min, 60 min and 180 min after the first foliar application of 2,4-D. For the measurement of response of shoots and roots to auxin, sterilized seeds were germinated on plates in a growth chamber

with continuous light at 20°C, and 10 dpg seedlings were supplied with varied concentration of 2,4-D. In the auxin transport inhibition experiments, 9 dpg seedlings were incubated in the medium supplemented with 50 µM NPA dissolved in 0.1% DMSO for 24 h before the 2,4-D treatment. For the HDAC inhibitor treatments, 10 mM sodium butyrate was added onto the growth medium and incubated for 24 h followed by exogenous 2,4-D application at varied concentrations.

Yeast two-hybrid screening and cloning

A yeast two-hybrid cDNA library was constructed from seedlings of *B. napus* L. cv. DH12075 and screened using a *Arabidopsis thaliana* RPD3-type HDAC (*HDA19*) as bait, with the methods of PROQUEST Two-Hybrid System (GibcoL-BRL) as previously described by Gao *et al.* (2003). The positive colonies were reassessed with retransformation experiments and confirmed with *in vitro* protein interaction assays, and the cloned cDNAs were identified by PCR and DNA sequence analysis.

Gel Blot Analysis

Total genomic DNA was extracted from the leaves of four-leaf stage *B. napus* using a modified CTAB (cetyltriethylammonium bromide) extraction method, and DNA gel blots were prepared and hybridized with the *BnSCL1* open reading frame labeled with [α -³²P]dCTP using random primer labeling procedure as described by Gao *et al.* (2003). Total RNA was isolated using hot phenol method with the first extraction for 30 sec at 80°C as previously described (Gao *et al.* 2002). RNA was isolated from various tissues, including leaves and stems of four-leaf stage seedlings, flowers, immature seeds and siliques of adult plants, and roots of cultured seedlings.

Quantitative RT-PCR

Total RNA extracted as described above was treated with Amplification Grade Deoxyribonuclease I (GibcoL BRL) following the manufacture's instructions. The RNA samples were then directly used for reverse transcription prior to amplification without purification. The RT-PCR was quantitatively performed and completed in a

one-step reaction using Superscript One-Step RT-PCR System (GibcoL BRL) as described by Gao *et al.* (2002). Gene-specific sense and anti-sense primers used to generate a 960 bp fragment of *Brassica napus Actin*, as an internal standard, were as described in Gao *et al.*, (2002). Gene-specific primers for the generation of *BnSCL1*,
5 *BnIAA1* and *BnIAA12* fragments were as follows:

BnSCL1 (435 bp)

sense: 5'-GATGGACGAACATGCCATGCGTTCCA-3' (SEQ ID NO:84)

anti-sense: 5'-CGCTCGGATCTTCTGAACAAT-3' (SEQ ID NO:85)

10

BnIAA1 (537bp)

sense: 5'- CCACGCGTCCGGTACGATGAT-3' (SEQ ID NO:86)

anti-sense: 5'- GAAGTTGAGAAATGGTTTATGA-3' (SEQ ID NO:87)

15 *BnIAA12* (659bp)

sense: 5'- ACGCTGGTGCTTCTCCTCCTC-3' (SEQ ID NO:88)

anti-sense: 5'- AAAACCCATTAGAAGAACCAAGAA-3' (SEQ ID NO:89)

20 *BnIAA1* and *BnIAA12* are clones ML2798 and ML4744, which are homologs of *Arabidopsis IAA1* and *IAA12*, respectively, and were identified in a database of *Brassica napus* ESTs that were generated at the Saskatoon Research Centre of Agriculture and Agri-Food Canada (www.brassica.ca).

Expression and purification of recombinant HDA19

25 The open reading frame (ORF) of the *HDA19* was PCR amplified, sequence analyzed, inserted in-frame with the GST (glutathione s-transferase) into the vector pGEX-6P-2 (Amersham Pharmacia), and transformed into *E. coli* BL21-CodonPlus (DE3)-RP competent cells (Stratagene) as previously described (Gao *et al.*, 2003). The recombinant HDA19 protein was expressed and purified under non-denaturing
30 conditions as described by Gao *et al.*, 2002). The GST-HDA19 fusion protein was analyzed by western blotting with rabbit anti-GST-Pi polyclonal antibody (Chemicon) using ECL Western blotting analysis system (Amersham Pharmacia).

In vitro protein interaction assays

The entire coding region of *BnSCL1* and four fragments, *BnSCL1*¹⁻³⁵⁸, *BnSCL1*¹⁻²⁶¹, *BnSCL1*¹⁻²¹⁷, and *BnSCL1*¹⁻¹⁴⁵ encoding amino acids 1-434, 1-358, 1-261 and 1-217, respectively, were amplified by PCR and cloned into the *HindIII* and *XhoI* sites of the expression vector pET-28b (Novagen) in-frame with the His-Tag sequence. The primers used for amplification were as follows:

Forward primer for *BnSCL1*, *BnSCL1*¹⁻³⁵⁸, *BnSCL1*¹⁻²⁶¹, *BnSCL1*¹⁻²¹⁷ and *BnSCL1*¹⁻¹⁴⁵:

5'- GCAAGCTTATGGACGAACATGCCATGCGTTCCA-3' (SEQ ID NO:90)

10

Reverse primer for *BnSCL1*:

5'- CGCTCGAGAAAGCGCCACGCTGACGTGGC-3' (SEQ ID NO:91)

Reverse primer for *BnSCL1*¹⁻³⁵⁸:

15 5'- CGCTCGAGCGCGGAGATCTTCGGACGTAA-3' (SEQ ID NO:92)

Reverse primer for *BnSCL1*¹⁻²⁶¹:

5'- CGCTCGAGCCTAATCGCCTTGAAAGATAA-3' (SEQ ID NO:93)

20 Reverse primer for *BnSCL1*¹⁻²¹⁷:

5'- CGCTCGAGCGCCACAACCGCCGTGACTCT-3' (SEQ ID NO:94)

Reverse primer for *BnSCL1*¹⁻¹⁴⁵:

5'- CGCTCGAGCGCTCGGATCTTCTGAACAAT-3' (SEQ ID NO:95).

25

The TNT-Quick Coupled Transcription/Translation System (Promega) was used to produce the full-length BnSCL1 protein and the truncated mutants Δ BnSCL1¹⁻³⁵⁸, Δ BnSCL1¹⁻²⁶¹, Δ BnSCL1¹⁻²¹⁷ and Δ BnSCL1¹⁻¹⁴⁵ labeled with [³⁵S]methionine as previously described (Gao *et al.*, 2003). *In vitro* protein interaction was detected with GST pulldown affinity assays as described by Ahmad *et al.* (1999) and Gao *et al.*, (2003).

30

In vivo protein interaction assays

The six DNA fragments, *BnSCL1*¹⁻³⁵⁸, *BnSCL1*¹⁻²⁶¹, *BnSCL1*¹⁻²¹⁷, *BnSCL1*¹⁻¹⁴⁵, *BnSCL1*¹⁴⁶⁻³⁵⁸ and *BnSCL1*²¹⁸⁻⁴³⁸ and the ORF of *BnSCL1* encoding amino acids 1-358, 1-261, 1-217, 1-145, 146-358, 218-438 and 1-434, respectively, were PCR amplified and cloned into the *SaII* and *NotI* sites of pPC86 vector (GibcoL BRL) in-frame with the *GAL4* AD sequences to generate constructs pPC86-*BnSCL1*¹⁻³⁵⁸, pPC86-*BnSCL1*¹⁻²⁶¹, pPC86-*BnSCL1*¹⁻²¹⁷, pPC86-*BnSCL1*¹⁻¹⁴⁵, pPC86-*BnSCL1*¹⁴⁶⁻³⁵⁸, pPC86-*BnSCL1*²¹⁸⁻⁴³⁸ and pPC86-*BnSCL1*. PCR amplification was carried out using the following primers:

10

Forward primer for *BnSCL1*, *BnSCL1*¹⁻³⁵⁸, *BnSCL1*¹⁻²⁶¹, *BnSCL1*¹⁻²¹⁷ and *BnSCL1*¹⁻¹⁴⁵:
5'-GCGTCGACGATGGACGAACATGCCATGCGTTCCA-3' (SEQ ID NO:96)

Forward primer for *BnSCL1*¹⁴⁶⁻³⁵⁸:

15 5'- GCGTCGACGATTAAGGAGTTTTCCGGTATA-3' (SEQ ID NO:97)

Forward primer for *BnSCL1*²¹⁸⁻⁴³⁴:

5'-GCGTCGACGGAGGATTGCGCCGTCGAGACG-3' (SEQ ID NO:98)

20 Reverse primer for *BnSCL1* and *BnSCL1*²¹⁸⁻⁴³⁴:

5'-GCGCGGCCGCAAAGCGCCACGCTGACGTGGC-3' (SEQ ID NO:99)

Reverse primer for *BnSCL1*¹⁻³⁵⁸:

5'- GCGCGGCCGCGCGGAGATCTTCGGAC GTAA-3' (SEQ ID NO:100)

25 Reverse primer for *BnSCL1*¹⁻²⁶¹:

5'-GCGCGGCCGCCCCTAATCGCCTTGAAAGATAA-3' (SEQ ID NO:101)

Reverse primer for *BnSCL1*¹⁻²¹⁷:

5'-GCGCGGCCGCGCCACAACCGCCGTGACTCT-3' (SEQ ID NO:102)

30

Reverse primer for *BnSCL1*¹⁻¹⁴⁵:

5'-GCGCGGCCGCGCTCGGATCTTCTGAACAAT-3' (SEQ ID NO:103)

Reverse primer for *BnSCL1*¹⁴⁶⁻³⁵⁸:

5'-GCGCGGCCCGGCGGAGATCTTCGGACGTAA-3' (SEQ ID NO:100).

For *in vivo* protein interaction assays, the MaV203 yeast competent cells carrying the *lacZ* reporter gene were co-transfected with the construct pDBLeu-HDA19, in which the HDA19 was fused in-frame with GAL4 DB and either of the plasmids pPC86-BnSCL1, pPC86-BnSCL1¹⁻³⁵⁸, pPC86-BnSCL1¹⁻²⁶¹, pPC86-BnSCL1¹⁻²¹⁷, pPC86-BnSCL1¹⁻¹⁴⁵, pPC86-BnSCL1¹⁴⁶⁻³⁵⁸, pPC86-BnSCL1²¹⁸⁻⁴³⁸ and or the vector pPC86 alone. The expression of *lacZ* reporter gene was quantified by measuring the β -galactosidase activity using CPRG (chlorophenol red- β -D-galactopyranoside) according to the manufacturer's instructions (GibcoL BRL). Three yeast control strains A, B, and C (GibcoL BRL) that contain plasmid pairs expressing fusion proteins with none, weak and moderately strong interaction strengths, respectively, were used as controls.

15 Transactivation assay

MaV203 yeast cells expressing the *lacZ* reporter gene driven by a promoter containing GAL4 DNA binding sites (GibcoL BRL) were transformed with the pDBLeu-bnKCP1¹⁻¹⁶⁰, pDBLeu-bnKCP1¹⁻⁸⁰, pDBLeu-bnKCP1⁸¹⁻²¹⁵ and pDBLeu-bnKCP1. These vectors were constructed by ligating the PCR-amplified fragments, Δ BnSCL1¹⁻³⁵⁸, Δ BnSCL1¹⁻²⁶¹, Δ BnSCL1¹⁻²¹⁷, Δ BnSCL1¹⁻¹⁴⁵, Δ BnSCL1¹⁴⁶⁻³⁵⁸ and Δ BnSCL1²¹⁸⁻⁴³⁴ and the entire coding region of *BnSCL1*, respectively, into the *SalI* and *NotI* sites of the vector pDBLeu (GibcoL BRL) in-frame with the GAL4 DB sequence. The oligonucleotide primers for the amplification were the same as those used for the *in vivo* protein interaction assays. The β -galactosidase activity was measured using CPRG according to the manufacturer's instructions (GibcoL BRL). In addition to the yeast strains A, B and C, the yeast strains D (GibcoL BRL) that contain plasmid pairs expressing fusion protein with strong interaction strength was used as controls.

30

Cloning and Sequence Analysis of the *BnSCL1* Gene

HDAC or HAT is recruited to specific loci by large protein complexes made up of transcription activators/co-activators and repressors/co-repressors, respectively (See reviews Kuo and Allis, 1998; Meyer, 2001). Identification of these transcription regulatory proteins that interact with HDAC or HAT is a direct approach to defining nuclear factors that recruit these chromatin remodelling regulators to their target promoters and hence affect the expression of the target genes. To isolate proteins that bind to HDAC in *B. napus*, the ORF of *Arabidopsis thaliana* HDA19 fused to the yeast Gal4 DNA binding domain was used as bait in a yeast two-hybrid screening of a *B. napus* cDNA library linked to the yeast Gal4 activation domain. A number of positive clones were obtained on the basis of the induction of three yeast reporter genes *HIS3*, *URA3* and *lacZ* followed by retransformation and sequencing analysis. One of these clones encodes a 51.2 kDa protein with pI 5.1, designated BnSCL1 (*Brassica napus* SCARECROW-like protein 1; SEQ ID NO:81). As shown in figure 20, BnSCL1 contains several domains of the SCARECROW (SCR) family of transcription factors (Laurenzio et al., 1996).

Sequence analysis revealed that BnSCL1 cDNA (2781 bp) contains two open reading frames (ORFs). The first ORF (ORF1) encodes BnSCL1, a polypeptide of 461 amino acid residues starting at 82 bp from the 5' end, and ORF2 codes for a polypeptide of 281 amino acids starting at 1687 bp from the 5' end. The linking region of the two ORFs is a short sequence of 200 bp. Database search using NCBI blast program (Altschul et al., 1997) indicated that the deduced amino acid sequence encoded by ORF2 was similar to the human polyposis coli region hypothetical protein DP1 (accession number A39658), which contains a TB2_DP1_HVA22 domain. However, the GENESCAN program (Burge and Karlin, 1997) predicts that the 2781 bps of BnSCL1 cDNA encodes one polypeptide only, i.e. the deduced amino acid sequence of ORF1.

Comparison of the deduced BnSCL1 amino acid sequence to the NCBI (<http://www.ncbi.nlm.nih.gov>) and TAIR (arabidopsis.org) databases results in a list of proteins with considerable similarity (Fig. 21). According to the NTI computer program (InforMax, Inc.), BnSCL1 shares an 89% amino acid identity with AtSCL15 (Pysh et al., 1999) or VHS5 (Silverstone et al., 1998), an *Arabidopsis* SCARECROW-like protein (accession number Z99708, At4g36710), while it is 37% identical to

AtSCR (accession number U62797). Interestingly, it also shares high similarity (66% sequence identity) with a tomato (*Lycopersicon esculentum*) protein (accession number AF273333), a member of the GRAS/VHID protein family, encoded by the Lateral suppressor gene (Ls) (Schumacher et al., 1999) (Fig. 20). Consistent with these data, phylogenetic analysis using either NTI Vector or DNA Star program classified BnSCL1, AtSCL15 and LsSCL (Ls) in the same subgroup (Fig. 21).

The *BnSCL1* copy number in *B. napus* was estimated using DNA gel blot analysis on total genomic DNA digested with restriction endonucleases and hybridized with the ORF of *BnSCL1* under high stringency conditions (Fig. 22). Digestion with *EcoRI*, *XbaI*, *HindIII*, *PstI* and *KpnI* resulted in the detection of about three bands, whereas digestion with *EcoRV* generated approximately six bands due to the existence of an internal cutting site for *EcoRV* within the *BnSCL1* gene. This result indicates that *BnSCL1* belongs to a small gene family of approximately three members in the *B. napus* genomes.

BnSCL1 is a Member of GRAS/VHID Family

The BnSCL1 gene encodes a polypeptide of 461 amino acids with several suggestive functional domains or motifs (Fig. 20). It has two MAT $\alpha 2$ -like nuclear localization signals (NLSs) (residues 169-173 and 436-440) (Raikhel, 1992). It also has a LXXLL motif (¹⁴⁸LGSLL¹⁵² (SEQ ID NO:104)) that was shown to mediate interaction of transcription coactivators with nuclear receptors (Heery et al., 1997). Amino acid sequence analysis also revealed that BnSCL1 has the characteristic structure for GRAS/VHID regulatory proteins (Pysh et al., 1999), including a VHID motif that encompasses a putative NLS, two leucine heptad repeats (LHRs) that surround the conserved VHID motif, a PFYRE motif and a C-terminal SAW motif that encompasses a putative NLS (Fig. 20). The LHRI-VHID-LHRII region has been thought to function in protein-protein and DNA-protein interactions (Pysh et al., 1999).

BnSCL1 Interacts Physically with HDA19 *in vitro* and *in vivo*

To confirm the interaction of BnSCL1 protein with HDA19 that was detected in the yeast two-hybrid system, GST pulldown affinity assays were carried out using *in vitro*-translated BnSCL1 labeled with [³⁵S]Methionine. The BnSCL1 protein was tested for its binding ability to GST-HDA19 fusion protein that was expressed in *Escherichia coli* and purified under non-denaturing conditions. As shown in figure 23, BnSCL1 bound to recombinant HDA19 protein, while it did not bind to GST alone (data not shown).

To map the protein binding domain of the BnSCL1 protein, four C-terminal truncated mutants of BnSCL1 lacking either of the SWA, PFYRE, LHRII or VHID motif (Fig. 23a) were constructed. These truncated mutants were assayed for *in vitro* interaction with the recombinant HDA19 protein. As shown in Figure 23b, the mutant proteins exhibited interaction with GST-HDA19 fusion protein with the truncation from C-terminal end until the VHID region was deleted, indicating that the VHID domain is essential for BnSCL1 protein binding to HDA19.

The requirement of the VHID domain for protein-protein interaction was also demonstrated *in vivo* using the yeast two-hybrid system (Fig. 24). MaV203 yeast cells were co-transformed with plasmid pDBLeu-HDA19 and either pPC86-BnSCL1, pPC86-BnSCL1¹⁻³⁵⁸, pPC86-BnSCL1¹⁻²⁶¹, pPC86-BnSCL1¹⁻²¹⁷, pPC86-BnSCL1¹⁻¹⁴⁵, pPC86-BnSCL1¹⁴⁶⁻³⁵⁸, pPC86-BnSCL1²¹⁸⁻⁴³⁸ and or the vector pPC86 alone. Although β -galactosidase activity was reduced by at least 50% when pDBLeu-expressing cells were transformed with plasmids expressing either of the six mutants of BnSCL1 protein, as compared to the wild type BnSCL1, the transformants with plasmids expressing either pPC86-BnSCL1¹⁻¹⁴⁵ or pPC86-BnSCL1²¹⁸⁻⁴³⁸, both of which lacked VHID motif, showed a further at least 50% reduction in β -galactosidase activity as compared to the other mutants. This finding indicates that VHID domain is critical for BnSCL1 interaction with HDA19 *in vivo*.

BnSCL1 Activates Transcription of a Reporter Gene in Yeast

To further characterize the biological function of BnSCL1, its functions as a transcription activator was investigated. Transactivation experiments were performed

in yeast (Fig. 25), whereby a yeast strain carrying three reporter genes, *lacZ*, *HIS3* and *URA3*, driven by promoters fused to GAL4 DNA binding sites and independently integrated into the yeast genome were transfected with the effector plasmid pDBLeu-BnSCL1 comprising *BnSCL1* fused to the GAL4 DB under the control of the ADH promoter. Transformation with the effector plasmid resulted in increasing β -galactosidase activity similar with yeast strain D that contains plasmid pairs expressing fusion proteins with strong protein-protein interaction and approximately 20-fold relative to either vector pDBLeu alone or yeast control strain A, which contains plasmid pairs expressing fusion proteins without protein-protein interaction (Fig. 25). Reporter genes *HIS3* and *URA3* were also strongly transactivated by BnSCL1 protein (data not shown). These results indicate that BnSCL1 significantly exhibits transcription activator activity in yeast.

To map the transactivation domain of the BnSCL1 activator, a series of deletion mutants of BnSCL1 protein were generated (Fig. 25a) and used in *in vivo* transactivation assays in yeast. As shown in figure 6b, either of the deletions from C-terminal of BnSCL1 or any truncation from the N-terminal resulted in a decrease of at least 85% in β -galactosidase activity relative to the wild type BnSCL1 protein. This demonstrates that the transactivation domain of bnKCP1 may reside in both the N- and C-terminal regions.

BnSCL1 Gene is Expressed Mainly in Roots

The expression pattern of the *BnSCL1* gene was analyzed by RNA gel blot analysis and quantitative RT-PCR using total RNA extracted from various organs of *B. napus* (Fig. 26). As shown in figure 26a, there were two *bnSCL1* transcripts of 1.6 kb and 2.8 kb in the RNA blot probed with the ORF of *BnSCL1*, suggesting the existence of either two species of *BnSCL1* cDNA produced by alternative splicing in *B. napus* genome or a *BnSCL1* homologue cross-hybridizing to the probe. Both of them accumulated at highest levels in roots, whereas its expression was weak in flowers and stems, and undetectable in leaves and siliques. Results obtained using quantitative RT-PCR analysis (Fig. 26b) were consistent with those obtained with northern blotting. In addition, RT-PCR analysis revealed strong expression in seedling

shoots (Fig. 26b). This expression pattern is similar to that of *Arabidopsis* SCR gene (Laurenzio et al., 1996) and to those of most SCLs (Pysh et al., 1999). This suggests that BnSCL1 and SCR may share similar functions in the regulation of root development.

5

BnSCL1 Responds to Auxin Treatment

The plant hormone auxin plays an important role in cell division, cell elongation, cell differentiation, lateral root initiation and gravitropism (Davies, 1995; Berleth and Sachs, 2001; Liscum and Stowe-Evans, 2000). Recent studies have demonstrated that auxin distribution organizes the pattern and polarity in the root meristem (Sabatini et al., 1999). To determine whether the dominant role of SCARECROW-like proteins (SCLs) in root biology is associated with auxin, quantitative RT-PCR was used to examine the expression of BnSCL1 gene in four-leaf stage- and 10 dpg-seedlings treated with the synthetic auxin 2,4-D. As shown in Figure 27, *BnSCL1* mRNA accumulation increased by approximately 50% within 30 min of application of 1 mM 2,4-D, and then decreased rapidly to a lower level, when compared to untreated plants (Fig. 27).

Auxin levels are known to modulate the degradation rate of Aux/IAA (auxin/indole-3-acetic acid protein) family members through a proteolytic regulation mechanism (Zenser et al., 2001). To examine whether auxin levels also influences the expression pattern of *BnSCL1* gene, quantitative RT-PCR was used to analyse total RNA isolated from shoots and roots of 10 dpg seedlings treated with variable concentrations of 2,4-D ranging from 1 pM to 1 mM (Fig. 28). Expression of *BnSCL1* in shoots was rapidly downregulated by auxin even at the lowest level (1 pM) of 2,4-D, indicating that *BnSCL1* response to auxin is very sensitive (Fig. 28a). *BnSCL1* expression in roots, however, was upregulated by auxin although application of a higher concentration (100 μ M) of auxin was required to produce an effect (Fig. 28b). To determine whether response of *BnSCL1* gene to auxin was due to the exogenous application rather than the intercellular auxin synthesis, seedlings were treated for 24 h with 50 μ M of naphthylphthalamic acid (NPA), a polar auxin transport inhibitor, and the expression of *BnSCL1* in response to auxin was analysed using quantitative One-Step RT-PCR. As can be seen in Figure 28c, the *BnSCL1* mRNA accumulation

profiles were not changed both in shoots and in roots after NPA treatment followed by the application of auxin at different concentrations. These results suggest that the response of *BnSCL1* to the application of exogenous auxin was tissue-specific, or the expression of *BnSCL1* may be regulated by auxin distribution in plants.

5

Expression of SCR in apical meristems was found to be controlled by chromatin assembly factor-1 (CAF-1) (Kaya et al., 2001), and auxin gene expression mutations to be located within an *Arabidopsis* RPD3-like histone deacetylase gene, HDA6, using map-based cloning approach (Murfett et al., 2001). However, no alterations in gene expression of endogenous auxin response genes were detected in the mutants and no effect of auxin-inducible GUS expression was found after seedlings were treated with HDAC inhibitor sodium butyrate at concentration up to 1 mM for 24 h (Murfett et al., 2001). To determine whether *BnSCL1* response to auxin is modulated by HDA19, 9 dpg seedlings were treated with 2,4-D at concentrations ranging from 10^{-6} to 10^3 μ M or treated with 50 mM of sodium phosphate buffer as control after sodium butyrate treatment for 24 h at a concentration of 10 mM. Relative expression was investigated using quantitative One-Step RT-PCR to analyze RNA extracted from shoots and roots of seedlings. As shown in Figure 28, although the expression pattern of *BnSCL1* in response to auxin in shoots was different from that in roots, the inhibition of histone deacetylase led to the expression profiles of *BnSCL1* in shoots were similar to those in roots, i.e. the expression was upregulated by auxin at concentration of 1 pM and downregulated by auxin at higher concentrations. The fact that HDAC inhibition led to the alteration of *BnSCL1* expression in response to auxin suggests that the response of *BnSCL1* to auxin is modulated by histone deacetylase.

25

These results suggest a molecular mechanism by which *BnSCL1* functions as a transcription factor to regulate gene expression by recruiting HDAC to the promoter regions of target genes.

30

Example 6: Modulation of activity of a gene of interest using a recruitment factor

Two constructs are prepared: 1) an activator+reporter construct (Fig. 29B) carrying the *lacZ* reporter gene downstream from a Tet operator sequence (Tet-7X), and the *BnSCL1* and *VP16* genes encoding a VP16-SCL fusion protein that is able to bind the Tet operator sequence; and 2) an effector construct carrying the *HDA19* gene (Fig. 29B).

The activator+report construct is introduced and expressed in yeast cells, for example MaV203 cells as described in Example 4, to produce a reporter yeast. Activity of *lacZ* product is quantified by measuring the β -galactosidase activity using chlorophenol red- β -D-galactopyranoside (CPRG) (GibcoL BRL). In the reporter yeast, expression of the activator+reporter construct results in the expression of the VP16-SCL fusion protein that binds to the Tet operator sequence, thereby activating expression of the *LacZ* reporter gene due to VP16.

The reporter yeast expressing the activator+reporter construct is treated with tetracycline. Expression of *lacZ* reporter gene is quantified by measuring the β -galactosidase activity using chlorophenol red- β -D-galactopyranoside (CPRG). The expression of the activator+reporter construct in the presence of tetracycline in yeast cells produces a baseline level of LacZ activity.

The effector construct is then introduced into the reporter yeast so that the activator+reporter and the effector constructs are both expressed, and the activity of the *LacZ* product determined as indicated above. Results demonstrate that LacZ activity is reduced in the yeast expressing both the activator+reporter and the effector constructs, when compared to LacZ activity determined in the reporter yeast expressing only the activator+reporter construct, and approximates the level of activity of LacZ activity produced by the reporter yeast when treated with tetracycline.

This result indicate that the expression of a gene of interest (in this case *LacZ*) may be reduced by targeting a recruitment factor, for example SCL1, to the nucleotide sequence encoding the gene of interest, and permitting the recruitment factor to bind an HDAC.

A similar set of assays is carried out comprising three constructs: 1) a reporter construct carrying the *lacZ* reporter gene, 2) an activator construct carrying the *BnSCL1* and *VP16* genes, and 3) an effector construct carrying the *HDA19* gene (see Fig. 29A). The constructs are expressed in yeast cells, for example MaV203 cells as described above in Example 4, in the following combinations:

- reporter construct alone,
- reporter and activator constructs,
- reporter, activator and effector constructs.

The expression of *lacZ* reporter gene is quantified by measuring the β -galactosidase activity using chlorophenol red- β -D-galactopyranoside (CPRG) (GibcoL BRL).

The expression of the reporter construct alone in yeast cells produces a baseline level of β -galactosidase activity. Expression of both the reporter and activator constructs yields an elevated level of β -galactosidase activity, when compared with the activity observed in the presence of the reporter construct alone, while the reporter, activator and effector constructs together results in approximately background levels of β -galactosidase activity.

All citations are herein incorporated by reference.

The present invention has been described with regard to preferred embodiments. However, it will be obvious to persons skilled in the art that a number of variations and modifications can be made without departing from the scope of the invention as described herein.

References

Ahmad, A., Takami, Y. and Nakayama, T. (1999) WD repeats of the p48 subunit of chicken chromatin assembly factor-1 required for in vitro interaction with chicken histone deacetylase-2. *J. Biol. Chem.* 274, 16646-16653.

5

An, Y.Q., McDowell, J.M., Huang S., McKinney, E.C., Chambliss S. and Meagher, R.B. (1996) Strong, constitutive expression of the Arabidopsis ACT2/ACT8 actin subclass in vegetative tissues. *Plant J.*, 10: 107-121

10

Aoyama, T. and Chua, N.H., 1997, *Plant J.* 2, 397-404

10

Altschul, S.F., Madden, T.L., Schäffer, A.A., Zhang, J., Zhang, Z., Miller, W. and Lipman, D.J. (1997) Gapped BLAST and PSI-BLAST: a new generation of protein database search programs. *Nucleic Acids Res.* 25, 3389-3402.

15

Archdeacon, J., Bouhouche, N., O'Connell, F., Kado, C.I. (2000) A single amino acid substitution beyond the C2H2-zinc finger in Ros derepresses virulence and T-DNA genes in *Agrobacterium tumefaciens*. *FEMS Microbiol Let.* 187, 175-178

20

Bannister, A.J. and Kouzarides, T. (1996) The CBP co-activator is a histone acetyltransferase. *Nature*, 384, 641-643

25

Beetham, P.R., Kipp, P.B., Sawycky, X.L., Arntzen, C.J., May, G.D. (1999) A tool for functional plant genomics: chimeric RNA/DNA oligonucleotides cause in vivo gene-specific mutations. *Proc. Natl. Acad. Sci. USA*, 96: 8774-8778

Berleth T, Sachs T. (2001) Plant morphogenesis: long-distance coordination and local patterning. *Curr Opin Plant Biol*, 4:57-62.

30

Bittinger, M.A., Milner, J.L., Saville, B.J., Handelsman, J. (1997) *rosR*, a determinant of nodulation competitiveness in *Rhizobium etli*. *Mol. Plant Microbe Interact.* 10: 180-186

- Boyle, B. and Brisson, N. (2001) Repression of the defense gene PR-10a by the single-stranded DNA binding protein SEBF. *Plant Cell* 13, 2525-2537.
- Brandstatter, I. and Kieber, J.J. (1998) Two genes with similarity to bacterial response regulators are rapidly and specifically induced by cytokinin in Arabidopsis. *Plant Cell* 10, 1009-1019
- Brightwell, G., Hussain, H., Tiburtius, A., Yeoman, K.H., Johnston, A.W. (1995) Pleiotropic effects of regulatory *ros* mutants of *Agrobacterium radiobacter* and their interaction with Fe and glucose. *Mol. Plant Microbe Interact.* 8: 747-754
- Burge, C. and Karlin, S. (1997) Prediction of complete gene structures in human genomic DNA. *J. Mol. Biol.* 268, 78-94.
- Caddick, M.X., Greenland, A.J., Jepson, I., Krause, K.P., Qu, N., Riddell, K.V., Salter, M.G., Schuch, W., Sonnewald, U., Tomsett, A.B. (1998) An ethanol inducible gene switch for plants used to manipulate carbon metabolism. *Nature Biotech.* 16, 177-180
- Carrington, J.C., Freed, D.D., Leinicke, A.J. (1991) Bipartite signal sequence mediates nuclear translocation of the plant potyviral NIa protein. *Plant Cell*, 3: 953-962
- Chou, A.Y., Archdeacon, J., Kado, C.I. (1998) *Agrobacterium* transcriptional regulator *Ros* is a prokaryotic zinc finger protein that regulates the plant oncogene *ipt*. *Proc. Natl. Acad. Sci.*, 95: 5293
- Chrivia, J.C., Kwok, R.P., Lamb, N., Hagiwara, M., Montminy, M.R. and Goodman, R.H. (1993) Photophosphorylated CREB binds specifically to the nuclear protein CBP. *Nature* 365, 855-859.
- Clough, S.J. and Bent, A.F. (1998) Floral dip: a simplified method for *Agrobacterium*-mediated transformation of *Arabidopsis thaliana*. *Plant J.* 16, 735-743

- Cooley, M.B., D'Souza, M.R., Kado, C.I. (1991) The *virC* and *virD* operons of the *Agrobacterium* Ti plasmid are regulated by the *ros* chromosomal gene: analysis of the cloned *ros* gene. *J. Bacteriol.* 173: 2608-2616
- 5 Cornejo et al, 1993, *Plant Mol. Biol.* 29: 637-646
- Davies, P.J. (1995) *Plant Hormones* (Dordrecht, The Netherlands: Kluwer Academic Publishers).
- 10 D'Souza-Ault, M. R., Cooley, M.B. and Kado, C.I. (1993) Analysis of the *Ros* repressor of *Agrobacterium virC* and *virD* operons: molecular intercommunication between plasmid and chromosomal genes. *J Bacteriol* 175: 3486-3490
- Eisner et al., 1998, *Ther. Appl. Genet.*, 97: 801
- 15 Emiliani S., Fischle, W., Van Lint, C., Al-Abed, Y., Verdin, E. (1998) Characterization of a human RPD3 ortholog, HDAC3. *Proc Natl Acad Sci U S A.* 95, 2795-800.
- 20 Fischle, W., Emiliani, S., Hendzel, M.J., Nagase, T., Nomura, N., Voelter, W., Verdin, E. (1999) A new family of human histone deacetylases related to *Saccharomyces cerevisiae* HDA1p. *J Biol Chem.* 274, 11713-20.
- Fukaki, H., Wysocka-Diller, J., Kato, T., Fujisawa, H., Benfey, P.N. and Tasaka, M.
- 25 (1998) Genetic evidence that the endodermis is essential for shoot gravitropism in *Arabidopsis thaliana*. *Plant J.*, 14: 425-430.
- Gao, M.-J., Allard, G., Byass, L., Flanagan, A.M. and Singh, J. (2002) Regulation and characterization of four *CBF* transcription factors from *Brassica napus*. *Plant Mol.*
- 30 *Biol.* 49: 459-471.
- Gao, M.-J. Schäfer, U.A., Parkin, I.A.P., Hegedus, D.D., Lydiate, D.J. and Hannoufa, A. (2003) A novel protein from *Brassica napus* has a putative KID-domain and responds to low temperature. *Plant J.* 33: 1073-1086.

- Gao, M.-J., Dvorak, J. and Travis, R.L. (2001) Expression of the extrinsic 23-kDa protein photosystem II in response to salt stress is associated with the K^+/Na^+ discrimination locus *Kna1* in wheat. *Plant Cell Rep.* 20, 774-778.
- 5 Gatz, C., 1997) *Ann. Rev. Plant Physiol. Plant Mol. Biol.* 48, 89-108
Gatz, C. and Lenk, I.R.P., 1998, *Trends Plant Sci.* 3, 352-358
- Geierson and Corey, *Plant Molecular Biology*, 2d Ed. (1988)
- 10 Gelmetti, V., Zhang, J., Fanelli, M., Minucci, S., Pelicci, P.G., Lazar, M.A. (1998) Aberrant recruitment of the nuclear receptor corepressor-histone deacetylase complex by the acute myeloid leukemia fusion partner ETO. *Mol Cell Biol.* 18, 7185-91.
- 15 Gonzalez, G.A., Menzel, P. Leonard, J., Fischer, W.H. and Montminy, M.R. (1991) Characterization of motifs which are critical for activity of the cyclic AMP-responsive transcription factor CREB. *Mol. Cell Biol.* 11, 1306-1312.
- Gonzalez, G.A. and Montminy, M.R. (1989) Cyclic AMP stimulates somatostatin
20 gene transcription by phosphorylation of CREB at serine 133. *Cell* 59, 675-680.
- Grunstein, M. (1997) Histone acetylation in chromatin structure and transcription. *Nature*, 389, 349-352.
- 25 Hart, C.M., Nagy, F., Meins, F. Jr. (1993) A 61 bp enhancer element of the tobacco beta-1,3-glucanase B gene interacts with one or more regulated nuclear proteins. *Plant Molec. Bio* 21:121-131
- Hassig, C.A. and Schreiber, S.L. (1997) Nuclear histone acetylases and deacetylases
30 and transcriptional regulation: HATs off to HDACs. *Curr Opin Chem Biol.* 1, 300-8.
OR
Hassig, C.A., Fleischer, T.C., Billin, A.N., Schreiber, S.L., Ayer, D.E. (1997) Histone deacetylase activity is required for full transcriptional repression by mSin3A. *Cell* 89, 341-7.

- Hassig, C.A., Tong, J.K., Fleischer, T.C., Owa, T., Grable, P.G., Ayer, D.E., Schreiber, S.L. (1998) A role for histone deacetylase activity in HDAC1-mediated transcriptional repression. *Proc Natl Acad Sci U S A.* 95, 3519-24.
- 5 Helariutta, Y., Fukaki, H., Wysocka-Diller, J., Nakajima, K., Jung, J., Sena, G., Hauser, M.-T. and Benfey, P.N. (2000) The *SHORT-ROOT* gene controls radial patterning of the Arabidopsis root through radial signaling. *Cell*, 101: 555-567.
- 10 Holtorf, S., Apel, K. and Bohlmann, H. (1995) Comparison of different constitutive and inducible promoters for the overexpression of transgenes in Arabidopsis thaliana. *Plant Mol. Biol.* 29: 637-646
- Hurley, T.W., Ryan, M.P. and Moore, W.C. (1996) Regulation of changes in cytosolic Ca^{2+} and Na^{+} concentrations in rat submandibular gland acini exposed to carbachol and ATP. *J. Cell Physiol.*, 168: 229-238
- 15 Ca²⁺ and Na⁺ concentrations in rat submandibular gland acini exposed to carbachol and ATP. *J. Cell Physiol.*, 168: 229-238
- Jofuku, K.D., den Boer, B.G., Van Montagu, M., Okamoto, J.K. (1994) Control of Arabidopsis flower and seed development by the homeotic gene APETALA2. *Plant*
- 20 *Cell*. 6, 1211-25.
- Johnson, C. and Turner, B.M. (1998) Histone deacetylases: complex transducers of nuclear signals. *Cell Dev. Biol.* 10, 179-188.
- 25 Johnson, P.F., Stemeck, E. and Williams, S.C. (1993) Activation domains of transcriptional regulatory proteins. *J. Nutr. Biochem.* 4, 386-398.
- Kadosh, D. and Struhl, K. (1997) Repression by Ume6 involves recruitment of a complex containing Sin3 corepressor and Rpd3 histone deacetylase to target
- 30 promoters. *Cell* 89, 365-71.
- Kakimoto, T. (1996) CKI1, a histidine kinase homolog implicated in cytokinin signal transduction. *Science* 274, 982-985

- Kapila, J., Rycke, R.D., Montagu, M.V. and Anjenon, G. (1997) An *Agrobacterium*-mediated transient gene expression system for intact leaves. *Plant. Sci.* 122, 101-108.
- Kaya, H., Shibahara, K., Taoka, K., Iwabuchi, M., Stillman, B. and Araki, T. (2001)
5 FASCIATA genes for chromatin assembly factor-1 in *Arabidopsis* maintain the cellular organization of apical meristem. *Cell*, 104: 131-142.
- Keller, M., Roxlau, A., Weng, W.M., Schmidt, M., Quandt, J., Niehaus, K., Jording, D., Arnold, W., Puhler, A. (1995) Molecular analysis of the *Rhizobium meliloti* mucR
10 gene regulating the biosynthesis of the exopolysaccharides succinoglycan and galactoglucan. *Mol. Plant Microbe Interact.* 8: 267-277
- Khochbin, S. and Wolffe, A.P. (1997) The origin and utility of histone deacetylases. *FEBS Lett.* 419, 157-60.
15
- Knight, H., Trewavas, A.J., Knight, M.R. (1996) Cold calcium signaling in *Arabidopsis* involves two cellular pools and a change in calcium signature after acclimation. *Plant Cell*, 8, 489-503.
- 20 Kohno-Murase, J., Murase, M., Ichikawa, H., Imamura, J. (1994) Effects of an antisense napin gene on seed storage compounds in transgenic *Brassica napus* seeds. *Plant Mol. Biol.*, 26: 1115-24
- Kolle, D., Sarg, B., Lindner, H., Loidl, P. (1998) Substrate and sequential site
25 specificity of cytoplasmic histone acetyltransferases of maize and rat liver. *FEBS Lett.* 421: 109-114
- Kuo, M.H. and Allis, C.D. (1998) Roles of histone acetyltransferases and deacetylases in gene regulation. *Bioessays*, 20, 615-626.
30
- Laurenzio, L.D., Wysocka-Diller, J., Malamy, J.E., Pysh, L., Helariutta, Y., Freshour, G., Hahn, M.G., Feldmann, K.A. and Benfey, P.N. (1996) The *SCARECROW* gene regulates an asymmetric cell division that is essential for generating the radial organization of the *Arabidopsis* root. *Cell*, 86: 423-433.

Liscum E, Stowe-Evans EL. (2000) Phototropism: a "simple" physiological response modulated by multiple interacting photosensory-response pathways. *Photochem Photobiol*, 72:273-282.

5

Lotan, T., Ohto, M., Yee, K.M., West, M.A., Lo, R., Kwong, R.W., Yamagishi, K., Fischer, R.L., Goldberg, R.B., Harada, J.J. (1998) Arabidopsis LEAFY COTYLEDON1 is sufficient to induce embryo development in vegetative cells. *Cell* 93, 1195-1205

10

Lusser, A., Kolle, D., Loidl, P. (2001) Histone acetylation: lessons from the plant kingdom. *Trends in Plant Sci.* 6:59-65

15

Mandel, T., Fleming, A.J., Krahenbuhl, R., Kuhlemeier, C. (1995) Definition of constitutive gene expression in plants: the translation initiation factor 4A gene as a model. *Plant Mol. Biol.* 29: 995-1004

20

Meyer, T.E., Waeber, G., Lin, J., Beckmann, W. and Habener, J.F. (1993) The promoter of the gene encoding-3',5'-cyclic adenosine monophosphate (camp) response element binding protein contains camp response elements: evidence for positive autoregulation of gene transcription. *Endocrinology*, 132, 770-780

25

Miki and Iyer, Fundamentals of Gene Transfer in Plants. In Plant Metabolism, 2d Ed. DT. Dennis, DH Turpin, DD Lefebvre, DB Layzell (eds), Addison Wesley, Langmans Ltd. London, pp. 561-579 (1997)

Monroy and Dhindsa (1995) *Annu. Rev. Biochem.* 66, 807-822

30

Montminy, M.R. (1997) Transcriptional regulation by cyclic AMP. *Annu. Rev. Biochem.* 66, 807-822

Murashige, T. and Skoog, F. (1962) A revised medium for rapid growth and bioassays with tobacco tissue culture. *Physiol. Plant.* 15: 473-495.

Murashige and Skoog, 1962

- 5 Murfett, J., Wang, X.J., Hagen, G. and Guilfoyle, T.J. (2001) Identification of Arabidopsis histone deacetylase HDA6 mutants that affect transgene expression. *Plant Cell*, 13: 1047-1061.

Murray, E.E., Lotzer, J., Eberle, M. (1989) Codon usage in plant genes. *Nuc Acids Res.* 17:477-498.

- 10 Nagy et al., 1997;

Nakai, K. and Kanehisa, M. (1992) A knowledge base for predicting protein localization sites in eukaryotic cells. *Genomics* 14, 897-911.

- 15 Nakajima K, Sena G, Nawy T, Benfey PN. (2001) Intercellular movement of the putative transcription factor SHR in root patterning. *Nature*, 20: 413:307-11.

Odell, J.T., Nagy, F., Chua, N.H. (1985) Identification of DNA sequences required for activity of the cauliflower mosaic virus 35S promoter. *Nature* 313, 810-812

20

Ogas, J., Cheng, J.C., Sung, Z.R., Somerville, C. (1997) Cellular differentiation regulated by gibberellin in the Arabidopsis thaliana pickle mutant. *Science* 277, 91-94

- 25 Ogryzko, V.V., Schiltz, R.L., Russanova, V., Howard, B.H. and Nakatani, Y. (1996) The transcriptional coactivators p300 and CBP are histone acetyltransferases. *Cell*, 87, 953-959

Pazin, M.J. and Kadonaga, J.T. (1997) What's up and down with histone deacetylation and transcription? *Cell* 89, 325-8.

30

Pysh, L.D., Wysocka-Diller, J.W., Camilleri, C., Bouchez, D. and Benfey, P. (1999) The GRAS gene family in Arabidopsis: sequence characterization and basic expression analysis of the *SCARECROW-LIKE* genes. *Plant J.*, 18: 111-119.

Quinn, P.G. (1998) Distinct activation domains within camp response element-binding protein (CREB) mediate basal and camp-stimulated transcription. *J. Biol. Chem.* 268, 16999-117009.

- 5 Ridgeway, P. and Almouzni, G. (2000) CAF-1 and the inheritance of chromatin states: at the crossroads of DNA replication and repair. *J. Cell Sci.*, 113: 2647-2658.

Rizzo, P., Di Resta, I., Powers, A., Ratner, H. and Carbone, M. (1999) Unique strains of SV40 in commercial poliovaccines from 1955 not readily identifiable with current
10 testing for SV40 infection. *Cancer Res.* 59, 6103-6108.

Robbins, J., Dilworth, S.M., Laskey, R.A., Dingwall, C. (1991) Two interdependent basic domains in nucleoplasmin nuclear targeting sequence: identification of a class of bipartite nuclear targeting sequence. *Cell*, 64: 615-623

15

Rundlett, S.E., Carmen, A.A., Kobayashi, R., Bavykin, S., Turner, B.M., Grunstein, M. (1996) HDA1 and RPD3 are members of distinct yeast histone deacetylase complexes that regulate silencing and transcription. *Proc Natl Acad Sci U S A.* 93, 14503-8.

20

Salter, M.G., et al, 1998, *Plant Journal* 16, 127-132

Sambrook, Fritsch, and Maniatis, *Molecular Cloning: A Laboratory Manual* (1989), Cold Spring Harbor

25

Sardana et al. (*Plant Cell Reports* 15:677-681; 1996).

Scheres, B., Di Laurenzio, L., Willemsen, V., Hauser, M.-T., Janmaat, K., Weisbeek, P. and Benfey, P.N. (1995) Mutations affecting the radial organization of the
30 *Arabidopsis* root display specific defects throughout the radial axis. *Development*, 121: 53-62.

Schumacher, K., Schmitt, T., Rossberg, M., Schmitz, G. and Theres, K. (1999) The *lateral suppressor (Ls)* gene of tomato encodes a new member of the VHIID protein family. *Proc. Natl. Acad. Sci. USA*, 96: 290-295.

- 5 Shaywitz, A.J., Dove, S.L., Kornhauser, J.M., Hochschild, A., Greenberg, M.E. (2000) Magnitude of the CREB-dependent transcriptional response is determined by the strength of the interaction between the kinase-inducible domain of CREB and the KIX domain of CREB-binding protein. *Mol. Cell. Biol.* 20, 9409-9422

- 10 Silverstone, A., Ciampaglio, C.N. and Sun T. (1998) The *Arabidopsis RGA* gene encodes a transcriptional regulator repressing the gibberellin signal transduction pathway. *Plant Cell*, 10: 155-169.

- 15 Stockinger, E.J., Gilmour, S.J. and Thomashow, M.F. (1997) *Arabidopsis thaliana* CBF1 encodes an AP2 domain-containing transcriptional activator that binds to the C-repeat/DRE, a *cis*-acting DNA regulatory element that stimulates transcription in response to low temperature and water deficit. *Proc. Natl. Acad. Sci. USA* 94, 1035-1040.

- 20 Stockinger, E.J., Mao, Y., Regier, M.K., Triezenberg, S.J. and Thomashow, M.F. (2001) Transcriptional adaptor and histone acetyltransferase proteins in *Arabidopsis* and their interaction with CBF1, a transcriptional activator involved in cold-regulated gene expression. *Nucleic Acids Res.* 29, 1524-1533.

- 25 Struhl, K. (1998) Histone acetylation and transcriptional regulatory mechanisms. *Genes Dev.* 12, 599-606.

- Tian, L. and Chen, Z.J. (2001) Blocking histone deacetylation in *Arabidopsis* induces pleiotropic effects on plant gene regulation and development. *Proc. Natl. Acad. Sci.*
30 *USA*, 98: 200-205.

Tian, Q., Uhler, N.J. and Reed, J.W. (2002) *Arabidopsis* SHY2/IAA3 inhibits auxin-regulated gene expression. *Plant Cell*, 14: 301-319.

Ulmasov, T., Murfett, J., Hagen, G., Guilfoyle, T.J. (1997) Aux/IAA proteins repress expression of reporter genes containing natural and highly active synthetic auxin response elements. *Plant Cell* 9, 1963-1971

- 5 van der Krol, A.R. and Chua, N.H. (1991) The basic domain of plant B-ZIP proteins facilitates import of a reporter protein into plant nuclei. *Plant Cell*, 3: 667-675

- Varagona, M.J., Schmidt, R.J., Raikhel, N.V. (1992) Nuclear localization signal(s) required for nuclear targeting of the maize regulatory protein Opaque-2. *Plant Cell*, 4:
10 1213-1227.

Varagona, M.J., Schmidt, R.J. and Raikhel, N.V. (1991) Monocot regulatory protein Opaque-2 is localized in the nucleus of maize endosperm and transformed tobacco plants. *Plant Cell* 3, 105-113.

- 15 Verbsky, M. and Richards, E.J. (2001) Chromatin remodeling in plants. *Curr. Opin. Plant Biol.* 4, 494-500.

- Verdel, A. and Khochbin, S. (1999) Identification of a new family of higher
20 eukaryotic histone deacetylases. Coordinate expression of differentiation-dependent chromatin modifiers. *J Biol Chem.* 274, 2440-5. .

- Vidal, M. and Gaber, R.F. (1991) RPD3 encodes a second factor required to achieve maximum positive and negative transcriptional states in *Saccharomyces cerevisiae*.
25 *Mol Cell Biol.* 11, 6317-27.

Weissbach and Weissbach, *Methods for Plant Molecular Biology*, Academy Press, New York VIII, pp. 421-463 (1988)

- 30 Wu, K., Malik, K., Tian, L., Brown, D. and Miki, B. (2000a) Functional analysis of a RPD3 histone deacetylase homologue in *Arabidopsis thaliana*. *Plant Mol Biol.* 44:167-176.

Wu, K., Tian L., Malik K., Brown D. and Miki B. (2000b) Functional analysis of HD2 histone deacetylase homologues in *Arabidopsis thaliana*. *Plant J.* 22: 19-27.

(is this the correct full citation for Wu et al. 2000, *Plant J.* 22:1-9??)

- 5 Xu, Y., Yu, H., Hall, T.C. (1994) Rice Triosephosphate Isomerase Gene 5[prime] Sequence Directs [beta]-Glucuronidase Activity in Transgenic Tobacco but Requires an Intron for Expression in Rice. *Plant Physiol.* 106: 459-467.

Yanovsky *et al.*, 1990, *Nature*, 346: 35-39

10

Zenser, N., Ellsmore, A., Leasure, C. and Callis, J. (2001) Auxin modulates the degradation rate of Aux/IAA proteins. *Proc. Natl. Acad. Sci. USA*, 98: 11795-11800.

- Zhang, W., McElroy, D., Wu, R. (1991) Analysis of rice Act1 5' region activity in
15 transgenic rice plants. *Plant Cell*, 3: 1155-1165

Zhu, T., Peterson, D.J., Tagliani, L., St Clair, G., Baszczynski, C.L., Bowen, B. (1999) Targeted manipulation of maize genes in vivo using chimeric RNA/DNA oligonucleotides. *Proc. Natl. Acad. Sci. USA*, 96: 8768-73.

20

**THE EMBODIMENTS OF THE INVENTION IN WHICH AN EXCLUSIVE
PROPERTY OF PRIVILEGE IS CLAIMED ARE DEFINED AS FOLLOWS:**

1. A method to regulate expression of a nucleic acid sequence of interest
5 comprising:
 - i) providing a eukaryote having:
 - 1) a first nucleotide sequence comprising,
 - a) said nucleic acid sequence of interest operatively linked to a first
10 regulatory region,
 - b) an operator sequence capable of binding a fusion protein, and;
 - 2) a second nucleotide sequence comprising a second regulatory region in
operative association with a nucleotide sequence encoding said fusion protein,
said fusion protein comprising,
 - a) a DNA binding protein, or a portion thereof, capable of binding said
15 operator sequence, and;
 - b) a recruitment factor protein, or a portion thereof, capable of binding
a chromatin remodelling protein; and
 - ii) growing said eukaryote, wherein expression of said second nucleotide sequence
produces said fusion protein that regulates expression of said nucleic acid sequence of
20 interest.
2. The method of claim 1, wherein the eukaryote is a plant.
3. The method of claim 1, wherein in said step of introducing (step i)), said
25 operator sequence is selected from the group consisting of a ROS operator, a Tet
operator, Sin3, VP16, GAL4, Lex A, UMe6, ERF, SEBF, CBF and a DNA binding
domain of a transcription factor.
- The method of claim 1, wherein the recruitment factor is characterized as
30 having a histone deacetylase binding domain or a histone acetylase binding domain.
4. The method of claim 1, wherein in said step of introducing (step ii)), said
recruitment factor protein is selected from the group consisting of histone acetylase

recruitment factor, histone deacetylase recruitment factor, KID, ADA, SAGA, STAGA, PCAF, TFIID, TFIIC, bnKCP1 and BnSCL1.

5. A method of enhancing expression of a nucleic acid sequence of interest
5 comprising:
- i) providing a plant with one or more constructs comprising:
 - 1) a first nucleotide sequence comprising,
 - a) said nucleic acid sequence of interest operatively linked to a first
regulatory region, and;
 - 10 b) an operator sequence capable of binding a fusion protein;
 - 2) a second nucleotide sequence comprising a second regulatory region in
operative association with a nucleotide sequence encoding said fusion protein
comprising,
 - a) a DNA binding protein, or a portion thereof capable of binding said
15 operator sequence, and;
 - b) a recruitment factor, or portion thereof, that binds a histone
acetyltransferase (HAT) protein;
 - ii) growing said plant, and
 - iii) expressing said second nucleotide sequence such that said fusion protein is
20 produced and expression of said nucleic acid sequence of interest is increased.
6. The method of claim 5, wherein the second regulatory region comprises an
inducible promoter.
- 25 7. The method of claim 5, wherein the HAT is Gcn5.
8. The method of claim 5, wherein in said step of introducing (step i)), said
operator sequence is selected from the group consisting of a ROS operator, a Tet
operator, Sin3, VP16, GAL4, Lex A, UMe6, ERF, SEBF, CBF and a DNA binding
30 domain of a transcription factor.
9. A method for selectively controlling the transcription of a nucleic acid
sequence of interest, comprising:

- i) providing a first plant comprising a first genetic construct, said first genetic construct comprising a first regulatory region operatively linked to a nucleic acid sequence of interest and at least one ROS operator sequence capable of controlling the activity of said first regulatory region;
 - 5 ii) providing a second plant comprising a second genetic construct, said second genetic construct comprising a second regulatory region in operative association with a nucleic acid molecule encoding a fusion protein comprising a ROS repressor, or a fragment thereof, and a recruitment factor characterized as having a histone deacetylase binding domain, or a fragment thereof;
 - 10 iii) crossing said first plant and said second plant to obtain progeny, said progeny comprising both said first genetic construct and said second genetic construct, and characterized in that the expression of said second genetic construct represses expression of said first genetic construct.
- 15 10. The method of claim 6, wherein said first and second regulatory regions are either the same or different and are selected from the group consisting of a constitutive promoter, an inducible promoter, a tissue specific promoter, and a developmental promoter.
- 20 11. The method of claim 1, wherein, in said step of introducing (step i)), said first, second, or both said first and second nucleotide sequences are incorporated into said plant by crossing.
- 25 12. The method of claim 8, wherein said crossing comprises crossing a first plant comprising said first nucleotide sequence with a second plant comprising said second nucleotide sequence, to obtain progeny.
- 30 13. The method of claim 1, wherein, in said step of introducing (step i)), said first, second, or both said first and second nucleotide sequences are incorporated into said plant by transformation.
14. A method to regulate expression of an endogenous nucleic acid sequence of interest comprising:

i) providing a eukaryote having a nucleotide sequence comprising, a regulatory region, operatively linked with a nucleotide sequence encoding a fusion protein, said fusion protein comprising,

a) a DNA binding protein, or a portion thereof, capable of binding a segment of a DNA sequence of said endogenous nucleotide sequence of interest; and

b) a recruitment factor protein, or a portion thereof; and

ii) growing said eukaryote, wherein expression of said nucleotide sequence produces said fusion protein that regulates expression of said endogenous nucleic acid sequence of interest.

15. The method of claim 11, wherein in said step of introducing (step i)), said recruitment factor protein is selected from the group consisting of histone acetylase recruitment factor, and histone deacetylase recruitment factor.

16. An isolated nucleic acid sequence encoding the sequence of bnKCP1 (SEQ ID NO:71).

17. An isolated nucleic acid sequence encoding amino acids 1 to 80 of SEQ ID NO:71.

18. An isolated nucleic acid sequence encoding amino acids 1 to 160 of SEQ ID NO:71.

19. An isolated nucleic acid sequence encoding amino acids 81 to 215 of SEQ ID NO:71.

20. The method of claim 1, wherein the recruitment factor protein is bnKCP1 (SEQ ID NO:71) or a fragment thereof.

21. The method of claim 11, wherein the recruitment factor protein is bnKCP1 (SEQ ID NO:71) or a fragment thereof.

22. An isolated nucleic acid encoding a bnKCP1 fusion protein, GAL4DB-bnKCP1.

23. An isolated nucleic acid encoding a HDAC fusion protein, GAL4DB-HDAC.
24. An isolated nucleic acid sequence encoding the sequence of BnSCL1 (SEQ ID
5 NO:81).
25. An isolated nucleic acid sequence encoding amino acids 1 to 358 of SEQ ID
NO:81.
- 10 26. An isolated nucleic acid sequence encoding amino acids 1 to 261 of SEQ ID
NO:81.
27. An isolated nucleic acid sequence encoding amino acids 1 to 217 of SEQ ID
NO:81.
- 15 28. An isolated nucleic acid sequence encoding amino acids 146 to 358 of SEQ ID
NO:81.
29. The method of claim 1, wherein the recruitment factor protein is BnSCL1
20 (SEQ ID NO:81) or a fragment thereof.
30. The method of claim 11, wherein the recruitment factor protein is BnSCL1
(SEQ ID NO:81) or a fragment thereof.
- 25 31. A method to regulate expression of a nucleic acid sequence of interest in a
plant comprising:
i) introducing into said plant:
1) a first nucleotide sequence comprising,
a) said nucleic acid sequence of interest operatively linked to a first
30 regulatory region,
b) an operator sequence capable of binding a bnKCP-fusion protein,
and;

2) a second nucleotide sequence comprising a second regulatory region in operative association with a nucleotide sequence encoding said bnKCP-fusion protein, said bnKCP-fusion protein comprising,

a) a DNA binding protein, or a portion thereof, capable of binding said operator sequence, and;

b) a bnKCP1, or a portion thereof; and

ii) growing said plant, wherein expression of said second nucleotide sequence produces said fusion protein that regulates expression of said nucleic acid sequence of interest.

32. A method to regulate expression of a nucleic acid sequence of interest in a plant comprising:

i) introducing into said plant:

1) a first nucleotide sequence comprising,

a) said nucleic acid sequence of interest operatively linked to a first regulatory region,

b) an operator sequence capable of binding a BnSCL-fusion protein, and;

2) a second nucleotide sequence comprising a second regulatory region in operative association with a nucleotide sequence encoding said BnSCL-fusion protein, said BnSCL-fusion protein comprising,

a) a DNA binding protein, or a portion thereof, capable of binding said operator sequence, and;

b) a BnSCL1, or a portion thereof; and

ii) growing said plant, wherein expression of said second nucleotide sequence produces said fusion protein that regulates expression of said nucleic acid sequence of interest.

33. A method of increasing cold tolerance in a plant, comprising:

i) providing a plant having a nucleotide sequence of interest operatively linked to a first regulatory region, the nucleotide sequence of interest encoding bnKCP1, or fragments thereof; and

ii) maintaining the plant under conditions where bnKCP1 is expressed thereby increasing cold tolerance in the plant.

34. A method of controlling expression of a nucleic acid sequence of interest, comprising:

i) providing a eukaryote having:

1) a first nucleotide sequence comprising

a) said nucleic acid sequence of interest operatively linked to a first regulatory region,

b) an operator sequence capable of binding a fusion protein, and

c) a second regulatory region in operative association with a nucleotide sequence encoding said fusion protein, the fusion protein including a DNA binding protein, or a portion thereof, capable of binding said operator sequence and a recruitment factor protein, or a portion thereof, capable of binding a chromatin remodelling protein; and

2) a second nucleotide sequence comprising a third regulatory region in operative association with a nucleotide sequence encoding a chromatin remodelling protein; and

ii) growing said eukaryote, wherein expression of said first nucleotide sequence produces said fusion protein that increases expression of said nucleic acid sequence of interest and wherein expression of said second nucleotide sequence produces said chromatin remodelling protein to repress expression of said nucleic acid sequence of interest.

35. The method of claim 34, wherein the chromatin remodelling protein is HDA19.

36. The method of claim 35, wherein the recruitment factor protein is BnSCL1 or bnKCP1.

37. The method of claim 35, wherein the DNA binding protein is VP16 or GAL4.

38. A method of controlling expression of a nucleic acid sequence of interest, comprising:

i) providing a eukaryote having:

1) a first nucleotide sequence comprising,

a) said nucleic acid sequence of interest operatively linked to a first regulatory region, and

b) an operator sequence capable of binding a fusion protein, and

5 2) a second nucleotide sequence comprising a regulatory region in operative association with a nucleotide sequence encoding said fusion protein, the fusion protein including a DNA binding protein, or a portion thereof, capable of binding said operator sequence and a recruitment factor protein, or a portion thereof, capable of binding a chromatin remodelling protein; and

10 2) a third nucleotide sequence comprising a third regulatory region in operative association with a nucleotide sequence encoding a chromatin remodelling protein; and

 ii) growing said eukaryote, wherein expression of said second nucleotide sequence produces said fusion protein that increases expression of said nucleic acid sequence of
15 interest and wherein expression of said third nucleotide sequence produces said chromatin remodelling protein to repress expression of said nucleic acid sequence of interest.

39. The method of claim 38, wherein the chromatin remodelling protein is
20 HDA19.

40. The method of claim 39, wherein the recruitment factor protein is BnSCL1 or bnKCP1.

25 41. The method of claim 39, wherein the DNA binding protein is VP16 or GAL4.

M	T	E	T	A		G	N	A	Q	D	L	L	V	E	WT-ROS
M	T	E	T	A	Y	G	N	A	Q	D	L	L	V	E	SYNROS
M	T	D	M	A	T	G	N	A	P	E	L	L	V	E	ROS-R
M	T	E	T	A	Y	G	N	A	Q	D	L	L	V	E	ROS-AR
M	T	<u>E</u>	<u>T</u>	<u>S</u>	<u>L</u>	G	<u>T</u>	<u>S</u>	<u>N</u>	<u>E</u>	L	L	V	E	MUC-R
L	T	A	D	I	V	A	A	Y	V	S	N	H	V	V	WT-ROS
L	T	A	D	I	V	A	A	Y	V	S	N	H	V	V	SYNROS
L	T	A	D	I	V	A	A	Y	V	S	N	H	V	V	ROS-R
L	T	A	D	I	V	A	A	Y	V	S	N	H	V	V	ROS-AR
L	T	A	E	I	V	A	A	Y	V	S	N	H	V	V	MUC-R
P	V	T	E	L	P	G	L	I	S	D	V	H	T	A	WT-ROS
P	V	T	E	L	P	G	L	I	S	D	V	H	T	A	SYNROS
P	V	S	D	L	A	N	L	I	S	D	V	H	S	A	ROS-R
P	V	T	E	L	P	G	L	I	S	D	V	H	T	A	ROS-AR
P	V	<u>A</u>	<u>E</u>	<u>L</u>	<u>P</u>	<u>T</u>	<u>L</u>	<u>I</u>	<u>A</u>	<u>D</u>	<u>V</u>	<u>H</u>	<u>S</u>	<u>A</u>	MUC-R
L	S	G	T	S	A	P	A	S	V	A	V	N	V	E	WT-ROS
L	S	G	T	S	A	P	A	S	V	A	V	N	V	E	SYNROS
L	S	N	T	S	V	P	Q	P	A	A	A	V	V	E	ROS-R
L	S	G	T	S	A	P	A	S	V	A	V	N	V	E	ROS-AR
L	N	<u>N</u>	<u>T</u>	<u>T</u>	<u>A</u>	<u>P</u>	<u>A</u>	<u>P</u>	<u>V</u>	<u>V</u>	<u>V</u>	<u>P</u>	<u>V</u>	<u>E</u>	MUC-R
K	Q	K	P	A	V	S	V	R	K	S	V	Q	D	D	WT-ROS
K	Q	K	P	A	V	S	V	R	K	S	V	Q	D	D	SYNROS
K	Q	K	P	A	V	S	V	R	K	S	V	Q	D	E	ROS-R
K	Q	K	P	A	V	S	V	R	K	S	V	Q	D	D	ROS-AR
K	<u>P</u>	K	P	A	V	S	V	R	K	S	V	Q	D	<u>D</u>	MUC-R
H	I	V	C	L	E	C	G	G	S	F	K	S	L	K	WT-ROS
H	I	V	C	L	E	C	G	G	S	F	K	S	L	K	SYNROS
Q	I	T	C	L	E	C	G	G	N	F	K	S	L	K	ROS-R
H	I	V	C	L	E	C	G	G	S	F	K	S	L	K	ROS-AR
Q	I	T	C	L	E	C	G	G	T	F	K	S	L	K	MUC-R
R	H	L	T	T	H	H	S	M	T	P	E	E	Y	R	WT-ROS
R	H	L	T	T	H	H	S	M	T	P	E	E	Y	R	SYNROS
R	H	L	M	T	H	H	S	L	S	P	E	E	Y	R	ROS-R
R	H	L	T	T	H	H	S	M	T	P	E	E	Y	R	ROS-AR
R	H	L	M	T	H	H	<u>N</u>	<u>L</u>	<u>S</u>	<u>P</u>	<u>E</u>	<u>E</u>	<u>Y</u>	<u>R</u>	MUC-R
E	K	W	D	L	P	V	D	Y	P	M	V	A	P	A	WT-ROS
E	K	W	D	L	P	V	D	Y	P	M	V	A	P	A	SYNROS
E	K	W	D	L	P	T	D	Y	P	M	V	A	P	A	ROS-R
E	K	W	D	L	Q	V	D	Y	P	M	V	A	P	A	ROS-AR
D	K	W	D	L	P	A	D	Y	P	M	V	A	P	A	MUC-R
Y	A	E	A	R	S	R	L	A	K	E	M	G	L	G	WT-ROS
Y	A	E	A	R	S	R	L	A	K	E	M	G	L	G	SYNROS
Y	A	E	A	R	S	R	L	A	K	E	M	G	L	G	ROS-R
Y	A	E	A	R	S	R	L	A	K	E	M	G	L	G	ROS-AR
Y	A	E	A	R	S	R	L	A	K	E	M	G	L	G	MUC-AR
Q	R	R	K	A	N	R									WT-ROS
Q	R	R	K	A	N	R	P	K	K	K	R	K	V		SYNROS
Q	R	R	K	R	G	R	G								ROS-R
Q	R	R	K	A	N	R									ROS-AR
Q	R	R	K	R	R	G	K								MUC-AR

FIG. 1A

<u>GCGGATCCCC</u>	<u>GGGTATGACT</u>	GAGACTGCTT	ACGGTAACGC
TCAGGATCTT	CTTGTTGAGC	TTACTGCTGA	TATCGTTGCT
GCTTACGTTT	CTAACCACGT	TGTTCCCTGTT	ACTGAGCTTC
CTGGACTTAT	CTCTGATGTT	CATACTGCAC	TTTCTGGAAC
ATCTGCTCCT	GCTTCTGTTG	CTGTTAACGT	TGAGAAGCAG
AAGCCTGCTG	TTTCTGTTCG	TAAGTCTGTT	CAGGATGATC
ATATCGTTTG	TTTGGAGTGT	GGTGGTTCTT	TCAAGTCTCT
CAAGCGTCAC	CTTACTACTC	ATCACTCTAT	GACTCCAGAG
GAGTATAGAG	AGAAGTGGA	TCTTCCTGTT	GATTACCCTA
TGGTTGCTCC	TGCTTACGCT	GAGGCTCGTT	CTCGTCTCGC
TAAGGAGATG	GGTCTCGGTC	AGCGTCGTAA	GGCTAACCGT
CCAAAAAAGA	AGCGTAAGGT	CTGAGAGCTC	GC

FIG. 1B

M T E T A Y G N A Q D L L V E
 ATG ACN GAR ACN GCN TAY GGN AAY GCN CAR GAY YTN YTN GTN GAR

 L T A D I V A A Y V S N H V V
 YTN ACN GCN GAY ATH GTN GCN GCN TAY GTN WSN AAY CAY GTN GTN

 P V T E L P G L I S D V H T A
 CCN GTN ACN GAR YTN CCN GGN YTN ATH WSN GAY GTN CAY ACN GCN

 L S G T S A P A S V A V N V E
 YTN WSN GGN ACN WSN GCN CCN GCN WSN GTN GCN GTN AAY GTN GAR

 K Q K P A V S V R K S V Q D D
 AAR CAR AAR CCN GCN GTN WSN GTN MGN AAR WSN GTN CAR GAY GAY

 H I V C L E C G G S F K S L K
 CAY ATH GTN TGY YTN GAR TGY GGN GGN WSN TTY AAR WSN YTN AAR

 R H L T T H H S M T P E E Y R
 MGN CAY YTN ACN ACN CAY CAY WSN ATG ACN CCN GAR GAR TAY MGN

 E K W D L P V D Y P M V A P A
 GAR AAR TGG GAY YTN CCN GTN GAY TAY CCN ATG GTN GCN CCN GCN

 Y A E A R S R L A K E M G L G
 TAY GCN GAR GCN MGN WSN MGN YTN GCN AAR GAR ATG GGN YTN GGN

 Q R R K A N R P K K K R K V
 CAR MGN MGN AAR GCN AAY MGN CCN AAR AAR AAR MGN AAR GTN

FIG. 1C

ROS Inverted Repeat
DNA Binding Sites (Operator sequences)

TATATTTCAA-TTTTA-TTGTAATATA	<i>virC/virD</i>
***** ** * ** * ** *	
TATAATTAAAATATTAAGTGCATT	<i>ipt</i>




FIG. 1D

Comparison of ROS DNA Binding Site (Operator) Sequences




<i>VirC/VirD</i>	TATATTTCAA
	TATATTACAA
<i>ipt</i>	TATAATTAAA
	AATGCGACAG
	TATAHTtCAA
	a g gaa g
Consensus	WATDHWKMAR

FIG. 1E




5/36

**FIG. 2A****FIG. 2B****FIG. 2C**


6/36

**FIG. 3A****FIG. 3B****FIG. 3C**


7/36

**FIG. 4A****FIG. 4B****FIG. 4C**


8/36



p74-315

FIG. 5A


p74-316

FIG. 5B

p74-309

FIG. 5C


9/36




p74-118

FIG. 5D

10/36




p76-507

FIG. 6A


p76-508

FIG. 6B

11/36



p75-101

FIG. 7A

p74-501

FIG. 7B




FIG. 8A

P74-101

RS 91

RS 93

RS 121




FIG. 8B

Columbia wt

pB1121



p74-501



buffer

FIG. 9

bnKCP	(1)	M-AGGGPTFSIELSAYG-SDLPTDKASGDIP-----NEEGSGLSRVGSIGIW
atKCP	(1)	MELMAKPTFSIEVSQYGTDLDPATEKASSSSSSFETTNEEG-VEESGLSRIW
atKCL1	(1)	M-----EVLVGSTFRDRSSVTTHDQAVP-----AS-LSSRIGLRRC
atKCL2	(1)	M---VGSSFGIGMAAYVRDHRGVSAQDKAVQTALFLADESGRGGSQIGIGLR

bnKCP	(45)	SG----RTVDYSSSESSSIGTPGDSEEEDEESEEDNDEEEL-----GLASL
atKCP	(52)	SG----QTADYSSDSSS-IGTPGDSEEEDEESEENENDDVSSKELGLRGLASM
atKCL1	(36)	GR-----SPPPESSSSVGETSENEEDEDDAVSSSQGRWLN-----SFS
atKCL2	(50)	MSNNNNKSPPESSDSSSIGESSENEEEEEEDDAVSCQRGTLD-----SFS

bnKCP	(87)	RSLEDSLPSK-GLSSHYKGKSKSFGNLGEIG-SVKEVPKQENPLNKKRRLQI
atKCP	(99)	SSLEDSLPSKRGLSNHYKGKSKSFGNLGEIG-SVKEVAKQENPLNKKRRLQI
atKCL1	(74)	SSLEDSLPIKRGLSNHYIGKSKSFGNLMEAS-NTNDLVKVESPLNKKRRLLI
atKCL2	(96)	SSLEDSLPIKRGLSNHYVGKSKSFGNLMEAASKAKDLEKVENPFNKRRRLVI

bnKCP	(137)	YNKLARKS-----FYSWQNPKSMPLLPVHEDNDDEEGDDG-----
atKCP	(150)	CNKLARKS-----FYSWQNPKSMPLLPVNEDEDDDDDEEDDLKSGFDEN
atKCL1	(125)	ANKLRRRSSLSFSIYTKINPNSMPLLALQESDNEDHKLNDDDDDDDDS---S
atKCL2	(148)	ANKLRRR-----GRSITYEEDHHIHNDYEDDDG-----

◆◆◆◆


bnKCP	(172)	-DLSDEERGVDVLARRPSFKNRALKSMSCFALS DLQEEEE---EEEDE
atKCP	(196)	KSSSDEEGVKVVRKGSFKNRAYKSRSCFALS DLIEED---DDDDQ
atKCL1	(174)	SDETSKLKEKRMKMTNHRDFMVPQTKSCFSLTSFQDDDDR-----
atKCL2	(177)	----DGDDHRKIMMMMKNKELMAQTRSCFCLSSLQEEDDGDDDEDE

FIG. 10A

Fig. 10B

♦♦♦♦

bnKCP	GDDGDLSDDEERGGDVLARRPSFKNRALKSMSCFALSDLQEEE
ATF-1	DSSDSIGSSQQAHGILARRPSYRKILKDLSSDTRGRKGDGE
hyCREB	ESVDSVTDSQKRREILSRRPSYRKILNDLSSDAPGVPRIEEE
CREB	ESVDSVTDSQKRREILSRRPSYRKILNDLSSDAPGVPRIEEE
CREM	SADSEVIDSHKRREILSRRPSYRKILNELSSDVPVGIPKIEEE
cCREM	AESEGVIDSHKRREILSRRPSYRKILNELSSDVPVGVPKIEEE

Fig. 10C**FIG. 10**




FIG. 11

EI X H P EV K




FIG. 12



Fig. 13A**Fig. 13B****FIG. 13**

Fig. 13C-1




Fig. 13C-2




Fig. 13C-3




FIG. 13 cont'd

Fig. 14A

Wild type KID GDDGDLSDEERGGDVLARRPSFKNRALKSMSCFALSDLQEEE
(RRPS¹⁸⁸)

↓

Mutant KID GDDGDLSDEERGGDVLARRPGFKNRALKSMSCFALSDLQEEE
(RRPG¹⁸⁸)

Fig. 14B




FIG. 14





FIG. 15

Fig. 16A

Cold Treatment (h) – Leaf Blade

0 0.5 1 4 8 16



Cold Treatment (h) - Stem

0 1 4 8 16




Fig. 16B

LaCl₃ Treatment (h)

0 1 2 3 4

Inomycin Treatment (h)

0.5 1 2 3 4




FIG. 16

Fig. 17A




Fig. 17B




FIG. 17

Fig. 18A




Fig. 18B




FIG. 18

Strategy for cloning zinc finger domain fusion with KID




FIG. 19

27/36

BnSCL1	(1)	MKIFASSPQDNQ-----PSNT-----
AtSCL15	(1)	MKIFASSPQDTT-----NNNN-----
LeSCL	(1)	MKVFESTNDIVSSKPLVNSNNSFTFPAATNGSNLCYEPKSVLELRSPSP
BnSCL1	(17)	-----TNNSTDSNHLSDDEHAMR-SMDWDSIMKELEVDDDSA
AtSCL15	(17)	-----NTNSTDSNHLSDDEHVMR-SMDWDSIMKELELDDSA
LeSCL	(51)	IVDKQIITTNPDLSALCGGEDPLQLGDHVLSNFEDWDSLMRELGLDDSA
BnSCL1	(53)	EYDQOP---S---S-----FNIPEVFPD-----IDSSDVYPGPN
AtSCL15	(53)	ENSTKTGFITTTTDSITLPIYAVDSNLEGGPDQIQPSDFESSSDVYPGON
LeSCL	(101)	SLSKTNPLTHSESLTQFHNISEFSAESNQFFSPDFSFSDTNEQQQPTVN
BnSCL1	(80)	QITCYGENSLDSVDNG---GFDYLEDLIRWVDCIESDEHLAHVVLSQL
AtSCL15	(103)	QITCYGENSLDSVDNG---GFDYLEDLIRWVDCVESDELOLAGVVLSQL
LeSCL	(151)	QASFINALILEGDIHONWSVGFDYVDELIRFAECHETNAEOLAHVILARL
LHRI		
BnSCL1	(126)	NQRLOTSAGRPLORAAFYFKEALGSLITGTRN--QIFSWSDIVOKIRAM *****
AtSCL15	(149)	NQIRSEAGRPLORAAFYFKEALGSELTGSTRNPIRESSWSEIVORIRAI
LeSCL	(201)	NQRLRSAAGKPLORAAFYFKEALQAQLAGSARQT-RSSSSSDVIOHKSYS
BnSCL1	(174)	KEFSGISPIPLFSEFTANOATLDSLSSOSSSPFVHVVDFFIGFGGOYASL
AtSCL15	(199)	KEYSGISPIPLFSEFTANOATLDSLSSOSSSPFVHVVDFFIGFGGOYASL
LeSCL	(250)	KILSNISPIPMFSSFTANOAVLEAVDG---SMIVHVVIDFDIGLGGHWASE
VHIID		
BnSCL1	(224)	MRELAEKS---ANGGELRVTAVVAEDCAVETRLVKENLTQFAAEKIRF
AtSCL15	(249)	MREITEKS---VSGGELRVTAVVAEECAVETRLVKENLTQFAAEKIRF
LeSCL	(297)	MKELADKAECRKANAPILRTALVPEEYAVESRLIRENLTQFAARELNIGE
LHRII		
BnSCL1	(270)	QIEFVLMKTFEILSFKAIREYDGERTVVLISPAIFRRVIGIAEFVNNLGR
AtSCL15	(295)	QIEFVLMKTFEMLSFKAIREYEGERTVVLISPAIFRRLSCTDFVNNLRR
LeSCL	(347)	EIDFVLIRTFELLSFKAIKFMEGEKTAVLLSPAIFRRVG--SEFVNALRR
BnSCL1	(320)	VSPNVVVFVDSEGCPETAGSGSFRREIVSAIEFYIMVLESIDAAAPFG--
AtSCL15	(345)	VSPKVVVFVDSEGWLEIAGSGSFRREIVSALIEFYIMVLESIDAAAPFG--
LeSCL	(395)	ISENVVVFVDSEGLMGYG-AMSFROTVIDGLEFYSTLLESLEAANIGGGN
PFYRE		
BnSCL1	(368)	-DLYKKTVEETFLRPKISAAVETAAARRSACOMTWREMLCAAGMRPVOLS
AtSCL15	(393)	-DLYKKTVEAFVLRPKISAAVETAADRRHTICEMTWREMLCAAGMRPIQOS
LeSCL	(444)	CDWMRKIENFVLFPKIVDMIGAVG--RRGGGGSWRDAMVDAGERPVGUS
SAW		
BnSCL1	(417)	QFADFOAECLLEKAQVRGFHVAKROGELYLCWHGRALVATSARRE *****
AtSCL15	(442)	QFADFOAECLLEKAQVRGFHVAKROGELYLCWHGRALVATSARRE
LeSCL	(492)	QFADFOADCLLGRVQVRGFHVAKROAEMLLCWHGRALVATSARRE

FIG. 20




FIG. 21



FIG. 22

Fig. 23A




Fig. 23B




FIG. 23

Fig. 24A




Fig. 24B




FIG. 24

Fig. 25A




Fig. 25B




FIG. 25

Fig. 26A




Fig. 26B




FIG. 26




FIG. 27

Fig. 28A





Fig. 28B





Fig. 28C







FIG. 28

Fig. 29A**Fig. 29B****FIG. 29**

SEQUENCE LISTING

<110> Her Majesty the Queen in Right of Canada as Represented by the
Minister of Agriculture and Agri-Food

<120> Regulation Of Gene Expression Using Chromatin Remodelling Factors

<130> 08-890985WO

<150> US 60/387,088

<151> 2002-06-06

<160> 104

<170> PatentIn version 3.0

<210> 1

<211> 142

<212> PRT

<213> WT-ROS

<400> 1

Met	Thr	Glu	Thr	Ala	Tyr	Gly	Asn	Ala	Gln	Asp	Leu	Leu	Val	Glu	Leu	1	5	10	15
Thr	Ala	Asp	Ile	Val	Ala	Ala	Tyr	Val	Ser	Asn	His	Val	Val	Pro	Val	20	25	30	
Thr	Glu	Leu	Pro	Gly	Leu	Ile	Ser	Asp	Val	His	Thr	Ala	Leu	Ser	Gly	35	40	45	
Thr	Ser	Ala	Pro	Ala	Ser	Val	Ala	Val	Asn	Val	Glu	Lys	Gln	Lys	Pro	50	55	60	
Ala	Val	Ser	Val	Arg	Lys	Ser	Val	Gln	Asp	Asp	His	Ile	Val	Cys	Leu	65	70	75	80
Glu	Cys	Gly	Gly	Ser	Phe	Lys	Ser	Leu	Lys	Arg	His	Leu	Thr	Thr	His	85	90	95	
His	Ser	Met	Thr	Pro	Glu	Glu	Tyr	Arg	Glu	Lys	Trp	Asp	Leu	Pro	Val				

100 105 110
 Asp Tyr Pro Met Val Ala Pro Ala Tyr Ala Glu Ala Arg Ser Arg Leu
 115 120 125
 Ala Lys Glu Met Gly Leu Gly Gln Arg Arg Lys Ala Asn Arg
 130 135 140

<210> 2

<211> 472

<212> DNA

<213> synthetic ROS

<400> 2
 gcggatcccc gggatatgact gagactgctt acggtaacgc tcaggatcctt cttgttgagc 60
 ttactgctga tatcggttgct gcttacgttt ctaaccacgt tgttcctggt actgagcttc 120
 ctggacttat ctctgatggt catactgcac tttctggaac atctgctcct gcttctgttg 180
 ctgttaacgt tgagaagcag aagcctgctg tttctgttcg taagtctggt caggatgac 240
 atatcgtttg tttggagtgt ggtgggttctt tcaagtctct caagcgtcac cttactactc 300
 atcactctat gactccagag gagtatagag agaagtggga tcttcctggt gattacccta 360
 tggttgctcc tgcttacgct gaggtcgtt ctcgtctcgc taaggagatg ggtctcggtc 420
 agcgtcgtaa ggctaaccgt ccaaaaaaga agcgttaagggt ctgagagctc gc 472

<210> 3

<211> 447

<212> DNA

<213> consensus

<220>

<221> misc_feature

<222> (1)..(447)

<223> where n is "a" or "c" or "t" or "g"

<220>

<221> misc_feature

<222> (1)..(447)

<223> where d is "a" or "t" or "g"

<220>

<221> misc_feature

<222> (1) .. (447)

<223> where v is "a" or "c" or "g"

<220>

<221> misc_feature

<222> (1) .. (447)

<223> where k is "t" or "g"

<220>

<221> misc_feature

<222> (1) .. (447)

<223> where s is "c" or "g"

<220>

<221> misc_feature

<222> (1) .. (447)

<223> where w is "a" or "t"

<220>

<221> misc_feature

<222> (1) .. (447)

<223> where h is "a" or "t" or "c"

<220>

<221> misc_feature

<222> (1) .. (447)

<223> where b is "t" or "c" or "g"

<220>

<221> misc_feature

<222> (1)..(447)

<223> where r is "a" or "g"

<220>

<221> misc_feature

<222> (1)..(447)

<223> where y is "c" or "t"

<220>

<221> misc_feature

<222> (1)..(447)

<223> where m is "a" or "c"

<400> 3	
atgacngara cngcntaygg naaygcncar gayytntyng tngarytnac ngcngayath	60
gtngcngcnt aygtnewsnaa ycaygtngtn ccngtnacng arytnccngg nytnathwsn	120
gaygtncaya cngcnytnws nggnacnwsn gcncncngcnw sngtngcngt naaygtngar	180
aarcaraarc cngcngtnws ngtnmgnaar wsngtncarg aygaycayat hgtntggytn	240
gartgyggng gnwsnttyaa rwsnytnaar mgncayytna cnacncayca ywsnatgacn	300
ccngargart aymngararaa rtgggayytn ccngtngayt ayccnatggt ngcncncngcn	360
taygcngarg cnmgnewsnmg nytngcnaar garatgggny tnggncarmg nmngnaargcn	420
aaymgncna araaraarmg naargtn	447

<210> 4

<211> 149

<212> PRT

<213> synthetic ROS

<400> 4

Met Thr Glu Thr Ala Tyr Gly Asn Ala Gln Asp Leu Leu Val Glu Leu

1 5 10 15

Thr Ala Asp Ile Val Ala Ala Tyr Val Ser Asn His Val Val Pro Val
20 25 30

Thr Glu Leu Pro Gly Leu Ile Ser Asp Val His Thr Ala Leu Ser Gly
35 40 45

Thr Ser Ala Pro Ala Ser Val Ala Val Asn Val Glu Lys Gln Lys Pro
50 55 60

Ala Val Ser Val Arg Lys Ser Val Gln Asp Asp His Ile Val Cys Leu
65 70 75 80

Glu Cys Gly Gly Ser Phe Lys Ser Leu Lys Arg His Leu Thr Thr His
85 90 95

His Ser Met Thr Pro Glu Glu Tyr Arg Glu Lys Trp Asp Leu Pro Val
100 105 110

Asp Tyr Pro Met Val Ala Pro Ala Tyr Ala Glu Ala Arg Ser Arg Leu
115 120 125

Ala Lys Glu Met Gly Leu Gly Gln Arg Arg Lys Ala Asn Arg Pro Lys
130 135 140

Lys Lys Arg Lys Val
145

<210> 5

<211> 10

<212> PRT

<213> ROS binding

<400> 5

Trp Ala Thr Asp His Trp Lys Met Ala Arg
1 5 10

<210> 6

<211> 7

<212> PRT

<213> NLS

<400> 6

Pro Lys Lys Lys Arg Lys Val
1 5

<210> 7

<211> 25

<212> DNA

<213> ROS operator

<400> 7
tatatttcaa ttttattgta atata

25

<210> 8

<211> 27

<212> DNA

<213> IPT gene operator

<400> 8
tataattaaa atattaactg tcgcatt

27

<210> 9

<211> 11

<212> DNA

<213> operator sequence binding to ERF

<400> 9
taagagccgc c

11

<210> 10

<211> 9

<212> DNA

<213> operator sequence binding to SEBF

<400> 10
gactgtcac

9

<210> 11

<211> 9

<212> DNA

<213> operator sequence binding to CBF

<400> 11
taccgacat

9

<210> 12

<211> 8

<212> DNA

<213> operator sequence binding to CBF

<400> 12
tggccgac

8

<210> 13

<211> 16

<212> PRT

<213> NLS of AGAMOUS protein

<400> 13

Arg Ile Glu Asn Thr Thr Asn Arg Gln Val Thr Phe Cys Lys Arg Arg
1 5 10 15

<210> 14

<211> 18

<212> PRT

<213> NLS of TGA-1A protein

<400> 14

Arg Arg Leu Ala Gln Asn Arg Glu Ala Ala Arg Lys Ser Arg Leu Arg
1 5 10 15

Lys Lys

<210> 15

<211> 21

<212> PRT

<213> NLS of TGA-1B protein

<400> 15

Lys Lys Arg Ala Arg Leu Val Arg Asn Arg Glu Ser Ala Gln Leu Ser
 1 5 10 15

Arg Gln Arg Lys Lys
 20

<210> 16

<211> 18

<212> PRT

<213> NLS of O2 NLS B protein

<400> 16

Arg Lys Arg Lys Glu Ser Asn Arg Glu Ser Ala Arg Arg Ser Arg Tyr
 1 5 10 15

Arg Lys

<210> 17

<211> 45

<212> PRT

<213> NLS of NIa protein

<220>

<221> LIPID

<222> (1)..(45)

<223> where "x" is any amino acid

<400> 17

Lys Lys Asn Gln Lys His Lys Leu Lys Met Xaa Xaa Xaa Xaa Xaa Xaa
 1 5 10 15

Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa
 20 25 30

Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Lys Arg Lys
 35 40 45

<210> 18

<211> 16

<212> PRT

<213> NLS nucleoplasmin protein

<400> 18

Lys Arg Pro Ala Ala Thr Lys Lys Ala Gly Gln Ala Lys Lys Lys Lys
 1 5 10 15

<210> 19

<211> 17

<212> PRT

<213> NLS of NO38 protein

<400> 19

Lys Arg Ile Ala Pro Asp Ser Ala Ser Lys Val Pro Arg Lys Lys Thr
 1 5 10 15

Arg

<210> 20

<211> 17

<212> PRT

<213> NLS of N1/N2 protein

<400> 20

Lys Arg Lys Thr Glu Glu Glu Ser Pro Leu Lys Asp Lys Asp Ala Lys
 1 5 10 15

Lys

<210> 21

<211> 17

<212> PRT

<213> NLS of Glucocorticoid receptor

<400> 21

Arg Lys Cys Leu Gln Ala Gly Met Asn Leu Glu Ala Arg Lys Thr Lys
 1 5 10 15

Lys

<210> 22

<211> 17

<212> PRT

<213> NLS of Glucocorticoid a receptor

<400> 22

Arg Lys Cys Leu Gln Ala Gly Met Asn Leu Glu Ala Arg Lys Thr Lys
1 5 10 15

Lys

<210> 23

<211> 17

<212> PRT

<213> NLS of Glucocorticoid b receptor

<400> 23

Arg Lys Cys Leu Gln Ala Gly Met Asn Leu Glu Ala Arg Lys Thr Lys
1 5 10 15

Lys

<210> 24

<211> 17

<212> PRT

<213> NLS of Progesterone receptor

<400> 24

Arg Lys Cys Cys Gln Ala Gly Met Val Leu Gly Gly Arg Lys Phe Lys
1 5 10 15

Lys

<210> 25

<211> 17

<212> PRT

<213> NLS of Androgen receptor

<400> 25

Arg Lys Cys Tyr Glu Ala Gly Met Thr Leu Gly Ala Arg Lys Leu Lys
 1 5 10 15

Lys

<210> 26

<211> 17

<212> PRT

<213> NLS of p53 protein

<400> 26

Arg Arg Cys Phe Glu Val Arg Val Cys Ala Cys Pro Gly Arg Asp Arg
 1 5 10 15

Lys

<210> 27

<211> 25

<212> DNA

<213> VirC/VirD operator sequence

<400> 27

tatatttcaa ttttattgta atata

25

<210> 28

<211> 108

<212> DNA

<213> ROS-OPDS

<400> 28

atctccactg acgtaagggga tgacgcacaa tcccactatc cttcgcaaga cccttcctct 60

atataatata tttcaatttt attgtaatat aacacggggg actctaga 108

<210> 29

<211> 113

<212> DNA

<213> ROS-OPDA

<400> 29
gatcctctag agtcccccggt gttatattac aataaaattg aaatatatta tatagaggaa 60
gggtcttgcg aaggatagtg ggattgtgcg tcatccctta cgtcagtgga gat 113

<210> 30

<211> 107

<212> DNA

<213> ROS-OPUS

<400> 30
atctccactg acgtaaggga tgacgcacaa tctatatttc aattttattg taatatacta 60
tataaggaag ttcatttcat ttggagagaa cacggggggac tctagag 107

<210> 31

<211> 111

<212> DNA

<213> ROS-OPUA

<400> 31
gatcctctag agtcccccggt gttctctcca aatgaaatga acttcottat atagtatatt 60
acaataaaat tgaaatatag attgtgcgtc atcccttacg tcagtggaga t 111

<210> 32

<211> 108

<212> DNA

<213> ROS-OPPS

<400> 32
atctccactg acgtaaggga tgacgcacaa tctatatttc aattttattg taatatacta 60
tataatatat ttcaatttta ttgtaatata acacggggga ctctagag 108

<210> 33

<211> 112

<212> DNA

<213> ROS-OPPA

<400> 33
gatcctctag agtcccccggt gttatattac aataaaattg aaatatatta tatagtatat 60
tacaataaaa ttgaaatata gattgtgcgt catcccttac gtcagtggag at 112

<210> 34

<211> 59

<212> DNA

<213> ROS-OP1

<400> 34
gacccctatat ttcaatttta ttgtaatatata gctatatttc aattttattg taatataat 59

<210> 35

<211> 57

<212> DNA

<213> ROS-OP2

<400> 35
cgatttatatt acaataaaaat tgaaatatag ctatattaca ataaaattga aatatag 57

<210> 36

<211> 36

<212> DNA

<213> tms2 promoter sense primer

<400> 36
tgcggatgca taagcttgct gacattgcta gaaaag 36

<210> 37

<211> 26

<212> DNA

<213> tms2 promoter anti-sense primer

<400> 37
cgggggtcct ttcagggcca tttcag

26

<210> 38

<211> 24

<212> DNA

<213> actin2 promoter sense primer

<400> 38
aagcttatgt atgcaagagt cagc

24

<210> 39

<211> 24

<212> DNA

<213> actin2 promoter anti-sense primer

<400> 39
ttgactagta tcagcctcag ccat

24

<210> 40

<211> 138

<212> DNA

<213> EcoRV to ATG of GUS

<400> 40
gatatctcca ctgacgtaag ggatgacgca caatcccact atccttcgca agacccttcc 60
tctatataat atatttcaat tttattgtaa tataacacgg gggactctag aggatccccg 120
ggtaggtcagt cccttatg 138

<210> 41

<211> 136

<212> DNA

<213> EcoRV to ATG of GUS

<400> 41

gatatctcca ctgacgtaag ggatgacgca caatctatat ttcaatttta ttgtaatata 60
 ctatataagg aagttcattt catttggaga gaacacgggg gactctagag gatccccggg 120
 tggtcagtc cttatg 136

<210> 42

<211> 137

<212> DNA

<213> EcoRV to ATG of GUS

<400> 42
 gatattctcca ctgacgtaag ggatgacgca caatctatat ttcaatttta ttgtaatata 60
 ctatataata tattttcaatt ttattgtaat ataacacggg ggactctaga ggatccccgg 120
 gtggtcagtc cttatg 137

<210> 43

<211> 237

<212> DNA

<213> EcoRV to ATG of GUS

<400> 43
 gatattctcca ctgacgtaag ggatgacgca caatcccact atccttcgca agacccttcc 60
 tctatataat atatttcaat ttattgttaa tataacacgg gggactctag aggatcctat 120
 atttcaattt tattgtaata tagctatatt tcaattttat tgtaatataa tcgatttcga 180
 acccggggta ccgaattcct cgagtctaga ggatccccgg gtggtcagtc cttatg 237

<210> 44

<211> 31

<212> DNA

<213> forward primer for HDA19 A. thaliana, pDBLeu-HDA19

<400> 44
 gcgtcgacga tggatactgg cggcaattcg c 31

<210> 45

<211> 32

<212> DNA

<213> reverse primer for HDA19 *A. thaliana*, pDBLeu-HDA19

<400> 45
aggcggccgc ttatgtttta ggaggaaacg cc

32

<210> 46

<211> 31

<212> DNA

<213> forward primer for Gen5 *Arabidopsis*, GST-Gen5

<400> 46
gcgtcgacga tggactctca ctcttccac c

31

<210> 47

<211> 31

<212> DNA

<213> reverse primer for Gen5 *Arabidopsis*, GST-Gen5

<400> 47
gcgcggccgc ctattgagat ttagcaccag a

31

<210> 48

<211> 31

<212> DNA

<213> reverse primer for HDA19, GST-HDA19

<400> 48
gcgcggccgc ttatgtttta ggaggaaacg c

31

<210> 49

<211> 29

<212> DNA

<213> forward primer for bnKCP1, 1-80, 1-160 (generation of mutants)

<400> 49
gcaagcttat ggcaggagga ggaccaact 29

<210> 50

<211> 29

<212> DNA

<213> reverse primer for bnKCP1 1-160 (generation of mutants)

<400> 50
cgctcgagct cctcctcatc attgtcttc 29

<210> 51

<211> 29

<212> DNA

<213> reverse primer for bnKCP1 1-80 (generation of mutants)

<400> 51
cgctcgagat gaacaggcaa aagaggcat 29

<210> 52

<211> 29

<212> DNA

<213> reverse primer for bnKCP1 (generation of mutants)

<400> 52
cgctcgagct catctttcttc ttctttcttc 29

<210> 53

<211> 30

<212> DNA

<213> forward primer for bnKCP1, 1-80 and 1-160 (in vivo assay and transactivation assay)

<400> 53
cgctcgacga tggcaggagg aggaccaact 30

<210> 54

<211> 31

<212> DNA

<213> reverse primer for bnKCP1

<400> 54

gcgcggccgc ctcattcttct tcttcttct c

31

<210> 55

<211> 31

<212> DNA

<213> reverse primer for bnKCP1

<400> 55

gcgcggccgc atgaacaggc aaaagaggca t

31

<210> 56

<211> 31

<212> DNA

<213> reverse primer for bnKCP1

<400> 56

gcgcggccgc ctctctctca tcattgtctt c

31

<210> 57

<211> 45

<212> DNA

<213> forward primer for bnKCP1G188

<400> 57

gatgttcttg cgaggagacc aggattcaag aacagagcat tgaag

45

<210> 58

<211> 45

<212> DNA

<213> reverse primer for bnKCP1G188

<400> 58
cttcaatgct ctgttcttga atcctggtct cctcgcaaga acatc 45

<210> 59

<211> 30

<212> DNA

<213> forward primer for bnKCP1 81-215

<400> 59
gcgtcgacgc tagggttggc ttcattgaga 30

<210> 60

<211> 29

<212> DNA

<213> forward primer for entire encoding region of bnKCP1

<400> 60
gcgaattcat ggcaggagga ggaccaact 29

<210> 61

<211> 29

<212> DNA

<213> reverse primer for entire coding region of bnKCP1

<400> 61
cggagtcct catcttcttc ttcttcttc 29

<210> 62

<211> 7

<212> PRT

<213> pat7 NLS (PLNKKRR)

<400> 62

Pro Leu Asn Lys Lys Arg Arg
1 5

<210> 63

<211> 143

<212> PRT

<213> aa seq of ROSR (ROS receptor)

<400> 63

Met Thr Asp Met Ala Thr Gly Asn Ala Pro Glu Leu Leu Val Glu Leu
 1 5 10 15
 Thr Ala Asp Ile Val Ala Ala Tyr Val Ser Asn His Val Val Pro Val
 20 25 30
 Ser Asp Leu Ala Asn Leu Ile Ser Asp Val His Ser Ala Leu Ser Asn
 35 40 45
 Thr Ser Val Pro Gln Pro Ala Ala Ala Val Val Glu Lys Gln Lys Pro
 50 55 60
 Ala Val Ser Val Arg Lys Ser Val Gln Asp Glu Gln Ile Thr Cys Leu
 65 70 75 80
 Glu Cys Gly Gly Asn Phe Lys Ser Leu Lys Arg His Leu Met Thr His
 85 90 95
 His Ser Leu Ser Pro Glu Glu Tyr Arg Glu Lys Trp Asp Leu Pro Thr
 100 105 110
 Asp Tyr Pro Met Val Ala Pro Ala Tyr Ala Glu Ala Arg Ser Arg Leu
 115 120 125
 Ala Lys Glu Met Gly Leu Gly Gln Arg Arg Lys Arg Gly Arg Gly
 130 135 140

<210> 64

<211> 142

<212> PRT

<213> aa seq of ROSAR (ROS receptor)

<400> 64

Met Thr Glu Thr Ala Tyr Gly Asn Ala Gln Asp Leu Leu Val Glu Leu
 1 5 10 15
 Thr Ala Asp Ile Val Ala Ala Tyr Val Ser Asn His Val Val Pro Val
 20 25 30
 Thr Glu Leu Pro Gly Leu Ile Ser Asp Val His Thr Ala Leu Ser Gly
 35 40 45
 Thr Ser Ala Pro Ala Ser Val Ala Val Asn Val Glu Lys Gln Lys Pro
 50 55 60
 Ala Val Ser Val Arg Lys Ser Val Gln Asp Asp His Ile Val Cys Leu

65

70

75

80

Glu Cys Gly Gly Ser Phe Lys Ser Leu Lys Arg His Leu Thr Thr His
85 90 95

His Ser Met Thr Pro Glu Glu Tyr Arg Glu Lys Trp Asp Leu Gln Val
100 105 110

Asp Tyr Pro Met Val Ala Pro Ala Tyr Ala Glu Ala Arg Ser Arg Leu
115 120 125

Ala Lys Glu Met Gly Leu Gly Gln Arg Arg Lys Ala Asn Arg
130 135 140

<210> 65

<211> 143

<212> . PRT

<213> aa seq of MucR (ROS receptor)

<400> 65

Met Thr Glu Thr Ser Leu Gly Thr Ser Asn Glu Leu Leu Val Glu Leu
1 5 10 15

Thr Ala Glu Ile Val Ala Ala Tyr Val Ser Asn His Val Val Pro Val
20 25 30

Ala Glu Leu Pro Thr Leu Ile Ala Asp Val His Ser Ala Leu Asn Asn
35 40 45

Thr Thr Ala Pro Ala Pro Val Val Val Pro Val Glu Lys Pro Lys Pro
50 55 60

Ala Val Ser Val Arg Lys Ser Val Gln Asp Asp Gln Ile Thr Cys Leu
65 70 75 80

Glu Cys Gly Gly Thr Phe Lys Ser Leu Lys Arg His Leu Met Thr His
85 90 95

His Asn Leu Ser Pro Glu Glu Tyr Arg Asp Lys Trp Asp Leu Pro Ala
100 105 110

Asp Tyr Pro Met Val Ala Pro Ala Tyr Ala Glu Ala Arg Ser Arg Leu
115 120 125

Ala Lys Glu Met Gly Leu Gly Gln Arg Arg Lys Arg Arg Gly Lys
130 135 140

<210> 66

<211> 10

<212> DNA

<213> VirC/VirD DNA binding site seq (1)

<400> 66
tatatttcaa

10

<210> 67

<211> 10

<212> DNA

<213> Virc/VirD DNA binding site seq (2)

<400> 67
tatattacaa

10

<210> 68

<211> 10

<212> DNA

<213> ipt DNA binding site seq (1)

<400> 68
tataattaaa

10

<210> 69

<211> 10

<212> DNA

<213> ipt DNA binding site seq (2)

<400> 69
aatgcgacag

10

<210> 70

<211> 10

<212> DNA

<213> consensus DNA binding site seq

<400> 70
tatahttcaa

10

<210> 71

<211> 215

<212> PRT

<213> bnKCP aa seq

<400> 71

```

Met Ala Gly Gly Gly Pro Thr Phe Ser Ile Glu Leu Ser Ala Tyr Gly
1          5          10          15
Ser Asp Leu Pro Thr Asp Lys Ala Ser Gly Asp Ile Pro Asn Glu Glu
20          25          30
Gly Ser Gly Leu Ser Arg Val Gly Ser Gly Ile Trp Ser Gly Arg Thr
35          40          45
Val Asp Tyr Ser Ser Glu Ser Ser Ser Ser Ile Gly Thr Pro Gly Asp
50          55          60
Ser Glu Glu Glu Asp Glu Glu Ser Glu Glu Asp Asn Asp Glu Glu Glu
65          70          75          80
Leu Gly Leu Ala Ser Leu Arg Ser Leu Glu Asp Ser Leu Pro Ser Lys
85          90          95
Gly Leu Ser Ser His Tyr Lys Gly Lys Ser Lys Ser Phe Gly Asn Leu
100         105         110
Gly Glu Ile Gly Ser Val Lys Glu Val Pro Lys Gln Glu Asn Pro Leu
115         120         125
Asn Lys Lys Arg Arg Leu Gln Ile Tyr Asn Lys Leu Ala Arg Lys Ser
130         135         140
Phe Tyr Ser Trp Gln Asn Pro Lys Ser Met Pro Leu Leu Pro Val His
145         150         155         160
Glu Asp Asn Asp Asp Glu Glu Gly Asp Asp Gly Asp Leu Ser Asp Glu
165         170         175
Glu Arg Gly Gly Asp Val Leu Ala Arg Arg Pro Ser Phe Lys Asn Arg
180         185         190
Ala Leu Lys Ser Met Ser Cys Phe Ala Leu Ser Asp Leu Gln Glu Glu
195         200         205
Glu Glu Glu Glu Glu Asp Glu
210         215

```

<210> 72

<211> 240

<212> PRT

<213> atKCP aa seq

<400> 72

Met Glu Leu Met Ala Lys Pro Thr Phe Ser Ile Glu Val Ser Gln Tyr
 1 5 10 15
 Gly Thr Thr Asp Leu Pro Ala Thr Glu Lys Ala Ser Ser Ser Ser Ser
 20 25 30
 Ser Phe Glu Thr Thr Asn Glu Glu Gly Val Glu Glu Ser Gly Leu Ser
 35 40 45
 Arg Ile Trp Ser Gly Gln Thr Ala Asp Tyr Ser Ser Asp Ser Ser Ser
 50 55 60
 Ile Gly Thr Pro Gly Asp Ser Glu Glu Asp Glu Glu Glu Ser Glu Asn
 65 70 75 80
 Glu Asn Asp Asp Val Ser Ser Lys Glu Leu Gly Leu Arg Gly Leu Ala
 85 90 95
 Ser Met Ser Ser Leu Glu Asp Ser Leu Pro Ser Lys Arg Gly Leu Ser
 100 105 110
 Asn His Tyr Lys Gly Lys Ser Lys Ser Phe Gly Asn Leu Gly Glu Ile
 115 120 125
 Gly Ser Val Lys Glu Val Ala Lys Gln Glu Asn Pro Leu Asn Lys Arg
 130 135 140
 Arg Arg Leu Gln Ile Cys Asn Lys Leu Ala Arg Lys Ser Phe Tyr Ser
 145 150 155 160
 Trp Gln Asn Pro Lys Ser Met Pro Leu Leu Pro Val Asn Glu Asp Glu
 165 170 175
 Asp Asp Asp Asp Glu Asp Asp Asp Glu Glu Asp Leu Lys Ser Gly Phe
 180 185 190
 Asp Glu Asn Lys Ser Ser Ser Asp Glu Glu Gly Val Lys Lys Val Val
 195 200 205
 Val Arg Lys Gly Ser Phe Lys Asn Arg Ala Tyr Lys Ser Arg Ser Cys
 210 215 220
 Phe Ala Leu Ser Asp Leu Ile Glu Glu Glu Asp Asp Asp Asp Asp Gln
 225 230 235 240

<210> 73

<211> 214

<212> PRT

<213> atKCL1 aa seq -

<400> 73

Met Glu Val Leu Val Gly Ser Thr Phe Arg Asp Arg Ser Ser Val Thr
 1 5 10 15

Thr His Asp Gln Ala Val Pro Ala Ser Leu Ser Ser Arg Ile Gly Leu
 20 25 30
 Arg Arg Cys Gly Arg Ser Pro Pro Pro Glu Ser Ser Ser Ser Val Gly
 35 40 45
 Glu Thr Ser Glu Asn Glu Glu Asp Glu Asp Asp Ala Val Ser Ser Ser
 50 55 60
 Gln Gly Arg Trp Leu Asn Ser Phe Ser Ser Ser Leu Glu Asp Ser Leu
 65 70 75 80
 Pro Ile Lys Arg Gly Leu Ser Asn His Tyr Ile Gly Lys Ser Lys Ser
 85 90 95
 Phe Gly Asn Leu Met Glu Ala Ser Asn Thr Asn Asp Leu Val Lys Val
 100 105 110
 Glu Ser Pro Leu Asn Lys Arg Arg Arg Leu Leu Ile Ala Asn Lys Leu
 115 120 125
 Arg Arg Arg Ser Ser Leu Ser Ser Phe Ser Ile Tyr Thr Lys Ile Asn
 130 135 140
 Pro Asn Ser Met Pro Leu Leu Ala Leu Gln Glu Ser Asp Asn Glu Asp
 145 150 155 160
 His Lys Leu Asn Asp Asp Asp Asp Asp Asp Ser Ser Ser Asp Asp
 165 170 175
 Glu Thr Ser Lys Leu Lys Glu Lys Arg Met Lys Met Thr Asn His Arg
 180 185 190
 Asp Phe Met Val Pro Gln Thr Lys Ser Cys Phe Ser Leu Thr Ser Phe
 195 200 205
 Gln Asp Asp Asp Asp Arg
 210

<210> 74

<211> 221

<212> PRT

<213> atKCL2 aa seq

<400> 74

Met Val Gly Ser Ser Phe Gly Ile Gly Met Ala Ala Tyr Val Arg Asp
 1 5 10 15
 His Arg Gly Val Ser Ala Gln Asp Lys Ala Val Gln Thr Ala Leu Phe
 20 25 30
 Leu Ala Asp Glu Ser Gly Arg Gly Gly Ser Gln Ile Gly Ile Gly Leu
 35 40 45
 Arg Met Ser Asn Asn Asn Asn Lys Ser Pro Glu Glu Ser Ser Asp Ser
 50 55 60

Ser Ala Asp Ser Glu Val Ile Asp Ser His Lys Arg Arg Glu Ile Leu
 1 5 10 15

Ser Arg Arg Pro Ser Tyr Arg Lys Ile Leu Asn Glu Leu Ser Ser Asp
 20 25 30

Val Pro Gly Ile Pro Lys Ile Glu Glu Glu
 35 40

<210> 80

<211> 42

<212> PRT

<213> cCREM aa seq.

<400> 80

Ala Glu Ser Glu Gly Val Ile Asp Ser His Lys Arg Arg Glu Ile Leu
 1 5 10 15

Ser Arg Arg Pro Ser Tyr Arg Lys Ile Leu Asn Glu Leu Ser Ser Asp
 20 25 30

Val Pro Gly Val Pro Lys Ile Glu Glu Glu
 35 40

<210> 81

<211> 461

<212> PRT

<213> aa seq of BNSCL1

<400> 81

Met Lys Leu Gln Ala Ser Ser Pro Gln Asp Asn Gln Pro Ser Asn Thr
 1 5 10 15

Thr Asn Asn Ser Thr Asp Ser Asn His Leu Ser Met Asp Glu His Ala
 20 25 30

Met Arg Ser Met Asp Trp Asp Ser Ile Met Lys Glu Leu Glu Val Asp
 35 40 45

Asp Asp Ser Ala Pro Tyr Gln Leu Gln Pro Ser Ser Phe Asn Leu Pro
 50 55 60

Val Phe Pro Asp Ile Asp Ser Ser Asp Val Tyr Pro Gly Pro Asn Gln
 65 70 75 80

Ile Thr Gly Tyr Gly Phe Asn Ser Leu Asp Ser Val Asp Asn Gly Gly
 85 90 95

Phe Asp Tyr Ile Glu Asp Leu Ile Arg Val Val Asp Cys Ile Glu Ser
 100 105 110

Asp Glu Leu His Leu Ala His Val Val Leu Ser Gln Leu Asn Gln Arg
 115 120 125
 Leu Gln Thr Ser Ala Gly Arg Pro Leu Gln Arg Ala Ala Phe Tyr Phe
 130 135 140
 Lys Glu Ala Leu Gly Ser Leu Leu Thr Gly Thr Asn Arg Asn Gln Leu
 145 150 155 160
 Phe Ser Trp Ser Asp Ile Val Gln Lys Ile Arg Ala Ile Lys Glu Phe
 165 170 175
 Ser Gly Ile Ser Pro Ile Pro Leu Phe Ser His Phe Thr Ala Asn Gln
 180 185 190
 Ala Ile Leu Asp Ser Leu Ser Ser Gln Ser Ser Ser Pro Phe Val His
 195 200 205
 Val Val Asp Phe Glu Ile Gly Phe Gly Gly Gln Tyr Ala Ser Leu Met
 210 215 220
 Arg Glu Ile Ala Glu Lys Ser Ala Asn Gly Gly Phe Leu Arg Val Thr
 225 230 235 240
 Ala Val Val Ala Glu Asp Cys Ala Val Glu Thr Arg Leu Val Lys Glu
 245 250 255
 Asn Leu Thr Gln Phe Ala Ala Glu Met Lys Ile Arg Phe Gln Ile Glu
 260 265 270
 Phe Val Leu Met Lys Thr Phe Glu Ile Leu Ser Phe Lys Ala Ile Arg
 275 280 285
 Phe Val Asp Gly Glu Arg Thr Val Val Leu Ile Ser Pro Ala Ile Phe
 290 295 300
 Arg Arg Val Ile Gly Ile Ala Glu Phe Val Asn Asn Leu Gly Arg Val
 305 310 315 320
 Ser Pro Asn Val Val Val Phe Val Asp Ser Glu Gly Cys Thr Glu Thr
 325 330 335
 Ala Gly Ser Gly Ser Phe Arg Arg Glu Phe Val Ser Ala Phe Glu Phe
 340 345 350
 Tyr Thr Met Val Leu Glu Ser Leu Asp Ala Ala Ala Pro Pro Gly Asp
 355 360 365
 Leu Val Lys Lys Ile Val Glu Thr Phe Leu Leu Arg Pro Lys Ile Ser
 370 375 380
 Ala Ala Val Glu Thr Ala Ala Asn Arg Arg Ser Ala Gly Gln Met Thr
 385 390 395 400
 Trp Arg Glu Met Leu Cys Ala Ala Gly Met Arg Pro Val Gln Leu Ser
 405 410 415
 Gln Phe Ala Asp Phe Gln Ala Glu Cys Leu Leu Glu Lys Ala Gln Val
 420 425 430
 Arg Gly Phe His Val Ala Lys Arg Gln Gly Glu Leu Val Leu Cys Trp
 435 440 445

His Gly Arg Ala Leu Val Ala Thr Ser Ala Trp Arg Phe
 450 455 460

<210> 82

<211> 486

<212> PRT

<213> aa seq of atSCL15

<400> 82

Met Lys Ile Pro Ala Ser Ser Pro Gln Asp Thr Thr Asn Asn Asn Asn
 1 5 10 15
 Asn Thr Asn Ser Thr Asp Ser Asn His Leu Ser Met Asp Glu His Val
 20 25 30
 Met Arg Ser Met Asp Trp Asp Ser Ile Met Lys Glu Leu Glu Leu Asp
 35 40 45
 Asp Asp Ser Ala Pro Asn Ser Leu Lys Thr Gly Phe Thr Thr Thr Thr
 50 55 60
 Thr Asp Ser Thr Ile Leu Pro Leu Tyr Ala Val Asp Ser Asn Leu Pro
 65 70 75 80
 Gly Phe Pro Asp Gln Ile Gln Pro Ser Asp Phe Glu Ser Ser Ser Asp
 85 90 95
 Val Tyr Pro Gly Gln Asn Gln Thr Thr Gly Tyr Gly Phe Asn Ser Leu
 100 105 110
 Asp Ser Val Asp Asn Gly Gly Phe Asp Phe Ile Glu Asp Leu Ile Arg
 115 120 125
 Val Val Asp Cys Val Glu Ser Asp Glu Leu Gln Leu Ala Gln Val Val
 130 135 140
 Leu Ser Arg Leu Asn Gln Arg Leu Arg Ser Pro Ala Gly Arg Pro Leu
 145 150 155 160
 Gln Arg Ala Ala Phe Tyr Phe Lys Glu Ala Leu Gly Ser Phe Leu Thr
 165 170 175
 Gly Ser Asn Arg Asn Pro Ile Arg Leu Ser Ser Trp Ser Glu Ile Val
 180 185 190
 Gln Arg Ile Arg Ala Ile Lys Glu Tyr Ser Gly Ile Ser Pro Ile Pro
 195 200 205
 Leu Phe Ser His Phe Thr Ala Asn Gln Ala Ile Leu Asp Ser Leu Ser
 210 215 220
 Ser Gln Ser Ser Ser Pro Phe Val His Val Val Asp Phe Glu Ile Gly
 225 230 235 240
 Phe Gly Gly Gln Tyr Ala Ser Leu Met Arg Glu Ile Thr Glu Lys Ser
 245 250 255

Val Ser Gly Gly Phe Leu Arg Val Thr Ala Val Val Ala Glu Glu Cys
 260 265 270
 Ala Val Glu Thr Arg Leu Val Lys Glu Asn Leu Thr Gln Phe Ala Ala
 275 280 285
 Glu Met Lys Ile Arg Phe Gln Ile Glu Phe Val Leu Met Lys Thr Phe
 290 295 300
 Glu Met Leu Ser Phe Lys Ala Ile Arg Phe Val Glu Gly Glu Arg Thr
 305 310 315 320
 Val Val Leu Ile Ser Pro Ala Ile Phe Arg Arg Leu Ser Gly Ile Thr
 325 330 335
 Asp Phe Val Asn Asn Leu Arg Arg Val Ser Pro Lys Val Val Val Phe
 340 345 350
 Val Asp Ser Glu Gly Trp Thr Glu Ile Ala Gly Ser Gly Ser Phe Arg
 355 360 365
 Arg Glu Phe Val Ser Ala Leu Glu Phe Tyr Thr Met Val Leu Glu Ser
 370 375 380
 Leu Asp Ala Ala Ala Pro Pro Gly Asp Leu Val Lys Lys Ile Val Glu
 385 390 395 400
 Ala Phe Val Leu Arg Pro Lys Ile Ser Ala Ala Val Glu Thr Ala Ala
 405 410 415
 Asp Arg Arg His Thr Gly Glu Met Thr Trp Arg Glu Ala Phe Cys Ala
 420 425 430
 Ala Gly Met Arg Pro Ile Gln Gln Ser Gln Phe Ala Asp Phe Gln Ala
 435 440 445
 Glu Cys Leu Leu Glu Lys Ala Gln Val Arg Gly Phe His Val Ala Lys
 450 455 460
 Arg Gln Gly Glu Leu Val Leu Cys Trp His Gly Arg Ala Leu Val Ala
 465 470 475 480
 Thr Ser Ala Trp Arg Phe
 485

<210> 83

<211> 536

<212> PRT

<213> aa seq lsSCR

<400> 83

Met Lys Val Pro Phe Ser Thr Asn Asp Asn Val Ser Ser Lys Pro Leu
 1 5 10 15
 Val Asn Ser Asn Asn Ser Phe Thr Phe Pro Ala Ala Thr Asn Gly Ser
 20 25 30

Asn Leu Cys Tyr Glu Pro Lys Ser Val Leu Glu Leu Arg Arg Ser Pro
 35 40 45
 Ser Pro Ile Val Asp Lys Gln Ile Ile Thr Thr Asn Pro Asp Leu Ser
 50 55 60
 Ala Leu Cys Gly Gly Glu Asp Pro Leu Gln Leu Gly Asp His Val Leu
 65 70 75 80
 Ser Asn Phe Glu Asp Trp Asp Ser Leu Met Arg Glu Leu Gly Leu His
 85 90 95
 Asp Asp Ser Ala Ser Leu Ser Lys Thr Asn Pro Leu Thr His Ser Glu
 100 105 110
 Ser Leu Thr Gln Phe His Asn Leu Ser Glu Phe Ser Ala Glu Ser Asn
 115 120 125
 Gln Phe Pro Ser Pro Asp Phe Ser Phe Ser Asp Thr Asn Phe Pro Gln
 130 135 140
 Gln Phe Pro Thr Val Asn Gln Ala Ser Phe Ile Asn Ala Leu Asp Leu
 145 150 155 160
 Ser Gly Asp Ile His Gln Asn Trp Ser Val Gly Phe Asp Tyr Val Asp
 165 170 175
 Glu Leu Ile Arg Phe Ala Glu Cys Phe Glu Thr Asn Ala Phe Gln Leu
 180 185 190
 Ala His Val Ile Leu Ala Arg Leu Asn Gln Arg Leu Arg Ser Ala Ala
 195 200 205
 Gly Lys Pro Leu Gln Arg Ala Ala Phe Tyr Phe Lys Glu Ala Leu Gln
 210 215 220
 Ala Gln Leu Ala Gly Ser Ala Arg Gln Thr Arg Ser Ser Ser Ser Ser
 225 230 235 240
 Asp Val Ile Gln Thr Ile Lys Ser Tyr Lys Ile Leu Ser Asn Ile Ser
 245 250 255
 Pro Ile Pro Met Phe Ser Ser Phe Thr Ala Asn Gln Ala Val Leu Glu
 260 265 270
 Ala Val Asp Gly Ser Met Leu Val His Val Ile Asp Phe Asp Ile Gly
 275 280 285
 Leu Gly Gly His Trp Ala Ser Phe Met Lys Glu Leu Ala Asp Lys Ala
 290 295 300
 Glu Cys Arg Lys Ala Asn Ala Pro Ile Leu Arg Ile Thr Ala Leu Val
 305 310 315 320
 Pro Glu Glu Tyr Ala Val Glu Ser Arg Leu Ile Arg Glu Asn Leu Thr
 325 330 335
 Gln Phe Ala Arg Glu Leu Asn Ile Gly Phe Glu Ile Asp Phe Val Leu
 340 345 350
 Ile Arg Thr Phe Glu Leu Leu Ser Phe Lys Ala Ile Lys Phe Met Glu
 355 360 365

Gly Glu Lys Thr Ala Val Leu Leu Ser Pro Ala Ile Phe Arg Arg Val
 370 375 380
 Gly Ser Gly Phe Val Asn Glu Leu Arg Arg Ile Ser Pro Asn Val Val
 385 390 395 400
 Val His Val Asp Ser Glu Gly Leu Met Gly Tyr Gly Ala Met Ser Phe
 405 410 415
 Arg Gln Thr Val Ile Asp Gly Leu Glu Phe Tyr Ser Thr Leu Leu Glu
 420 425 430
 Ser Leu Glu Ala Ala Asn Ile Gly Gly Gly Asn Cys Gly Asp Trp Met
 435 440 445
 Arg Lys Ile Glu Asn Phe Val Leu Phe Pro Lys Ile Val Asp Met Ile
 450 455 460
 Gly Ala Val Gly Arg Arg Gly Gly Gly Gly Ser Trp Arg Asp Ala Met
 465 470 475 480
 Val Asp Ala Gly Phe Arg Pro Val Gly Leu Ser Gln Phe Ala Asp Phe
 485 490 495
 Gln Ala Asp Cys Leu Leu Gly Arg Val Gln Val Arg Gly Phe His Val
 500 505 510
 Ala Lys Arg Gln Ala Glu Met Leu Leu Cys Trp His Asp Arg Ala Leu
 515 520 525
 Val Ala Thr Ser Ala Trp Arg Cys
 530 535

<210> 84

<211> 26

<212> DNA

<213> BnSCL1 sense primer

<400> 84
 gatggacgaa catgccatgc gttcca

26

<210> 85

<211> 21

<212> DNA

<213> BnSCL1 anti-sense primer

<400> 85
 cgctcggatc ttctgaacaa t

21

<210> 86

<211> 21

<212> DNA

<213> BnIAA1 sense primer

<400> 86

ccacgcgtcc ggtacgatga t

21

<210> 87

<211> 22

<212> DNA

<213> BnIAA1 anti-sense primer

<400> 87

gaagttgaga aatggtttat ga

22

<210> 88

<211> 21

<212> DNA

<213> BnIAA12 sense primer

<400> 88

acgctgggtgc ttctcctcct c

21

<210> 89

<211> 24

<212> DNA

<213> BNIAA12 anti-sense primer

<400> 89

aaaacccatt agaagaacca agaa

24

<210> 90

<211> 33

<212> DNA

<213> forward primer for BnSCL1, BnSCL1 1-358, BnSCL1 1-261, BnSCL1 1-217
and BnSCL1 1-145 for pET-28b vector

<400> 90
gcaagcttat ggacgaacat gccatgcggtt cca 33

<210> 91

<211> 29

<212> DNA

<213> reverse primer for BnSCL1 for pET-28b vector

<400> 91
cgctcgagaa agcgccacgc tgacgtggc 29

<210> 92

<211> 29

<212> DNA

<213> reverse primer for BnSCL1 1-358 for pET-28b vector

<400> 92
cgctcgagcg cggagatctt cggacgtaa 29

<210> 93

<211> 29

<212> DNA

<213> reverse primer for BnSCL1 1-261 for pET-28b vector

<400> 93
cgctcgagcc taatcgctt gaaagataa 29

<210> 94

<211> 29

<212> DNA

<213> reverse primer for BnSCL1 1-217 for pET-28b vector

<400> 94
cgctcgagcg ccacaaccgc cgtgactct 29

<210> 104

<211> 5

<212> PRT

<213> aa seq of LXXLL motif (148LGSL152)

<400> 104

Leu Gly Ser Leu Leu
1 5

**This Page is Inserted by IFW Indexing and Scanning
Operations and is not part of the Official Record**

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- ☐ BLACK BORDERS
- ☐ IMAGE CUT OFF AT TOP, BOTTOM OR SIDES
- ☐ FADED TEXT OR DRAWING
- ☒ BLURRED OR ILLEGIBLE TEXT OR DRAWING
- ☐ SKEWED/SLANTED IMAGES
- ☐ COLOR OR BLACK AND WHITE PHOTOGRAPHS
- ☐ GRAY SCALE DOCUMENTS
- ☐ LINES OR MARKS ON ORIGINAL DOCUMENT
- ☐ REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY
- ☐ OTHER: _____

IMAGES ARE BEST AVAILABLE COPY.

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.